0	Nonreplicating	O
1	vaccinia	O
2	vector	O
3	efficiently	O
4	expresses	O
5	recombinant	O
6	genes	O
7	.	O

0	Wherever	O
1	the	O
2	site	O
3	of	O
4	the	O
5	conditioning	O
6	stimulation	O
7	,	O
8	these	O
9	modifications	O
10	disappeared	O
11	after	O
12	ischaemia	O
13	of	O
14	the	O
15	leg	O
16	.	O

0	Necrosis	O
1	appears	O
2	6	O
3	h	O
4	after	O
5	TA	O
6	infusion	O
7	,	O
8	being	O
9	5	O
10	.	O
11	77	O
12	%	O
13	in	O
14	extent	O
15	after	O
16	12	O
17	h	O
18	,	O
19	14	O
20	.	O
21	9	O
22	%	O
23	after	O
24	24	O
25	h	O
26	and	O
27	animals	O
28	die	O
29	with	O
30	an	O
31	area	O
32	of	O
33	29	O
34	.	O
35	5	O
36	%	O
37	necrosis	O
38	.	O

0	It	O
1	also	O
2	suggests	O
3	that	O
4	there	O
5	is	O
6	another	O
7	pathway	O
8	which	O
9	can	O
10	activate	O
11	SWI4	B
12	transcription	O
13	in	O
14	the	O
15	absence	O
16	of	O
17	SWI6	B
18	.	O

0	An	O
1	evolutionary	O
2	conserved	O
3	element	O
4	is	O
5	essential	O
6	for	O
7	somite	O
8	and	O
9	adjacent	O
10	mesenchymal	O
11	expression	O
12	of	O
13	the	O
14	Hoxa1	B
15	gene	I
16	.	O

0	Mitochondria	O
1	-	O
2	lytic	O
3	action	O
4	of	O
5	warfarin	O
6	in	O
7	lymphocytes	O
8	.	O

0	Substitution	O
1	of	O
2	either	O
3	Val33	O
4	(	O
5	by	O
6	Gly	O
7	)	O
8	or	O
9	Gly28	O
10	(	O
11	by	O
12	Ser	O
13	),	O
14	two	O
15	of	O
16	the	O
17	most	O
18	conserved	O
19	residues	O
20	in	O
21	all	O
22	protein	O
23	kinases	O
24	,	O
25	resulted	O
26	in	O
27	enzyme	O
28	with	O
29	marginally	O
30	detectable	O
31	activity	O
32	.	O

0	Computer	O
1	assisted	O
2	mapping	O
3	in	O
4	quantitative	O
5	analysis	O
6	of	O
7	cerebral	O
8	positron	O
9	emission	O
10	tomograms	O
11	.	O

0	Pathogens	O
1	(	O
2	Staphylococcus	O
3	aureus	O
4	or	O
5	Gram	O
6	-	O
7	negative	O
8	bacilli	O
9	)	O
10	were	O
11	isolated	O
12	from	O
13	only	O
14	one	O
15	member	O
16	of	O
17	staff	O
18	in	O
19	small	O
20	numbers	O
21	and	O
22	irregularly	O
23	and	O
24	rarely	O
25	in	O
26	large	O
27	numbers	O
28	from	O
29	patients	O
30	.	O

0	In	O
1	a	O
2	Hoosier	O
3	Oncology	O
4	Group	O
5	randomized	O
6	study	O
7	involving	O
8	extensive	O
9	-	O
10	disease	O
11	SCLC	O
12	patients	O
13	,	O
14	VIP	O
15	was	O
16	superior	O
17	to	O
18	etoposide	O
19	/	O
20	cisplatin	O
21	with	O
22	regard	O
23	to	O
24	median	O
25	time	O
26	to	O
27	progression	O
28	(	O
29	6	O
30	.	O
31	6	O
32	v	O
33	5	O
34	.	O
35	8	O
36	months	O
37	),	O
38	median	O
39	survival	O
40	times	O
41	(	O
42	9	O
43	.	O
44	1	O
45	v	O
46	7	O
47	.	O
48	3	O
49	months	O
50	),	O
51	and	O
52	2	O
53	-	O
54	and	O
55	3	O
56	-	O
57	year	O
58	survival	O
59	rates	O
60	(	O
61	13	O
62	%	O
63	v	O
64	5	O
65	%	O
66	and	O
67	5	O
68	%	O
69	v	O
70	0	O
71	%,	O
72	respectively	O
73	).	O

0	Neural	O
1	-	O
2	specific	O
3	expression	O
4	,	O
5	genomic	O
6	structure	O
7	,	O
8	and	O
9	chromosomal	O
10	localization	O
11	of	O
12	the	O
13	gene	O
14	encoding	O
15	the	O
16	zinc	B
17	-	I
18	finger	I
19	transcription	I
20	factor	I
21	NGFI	I
22	-	I
23	C	I
24	.	O

0	Sleep	O
1	was	O
2	determined	O
3	again	O
4	for	O
5	an	O
6	additional	O
7	3	O
8	days	O
9	and	O
10	6	O
11	hours	O
12	.	O

0	The	O
1	5	O
2	'-	O
3	terminus	O
4	of	O
5	the	O
6	p	B
7	-	I
8	gvpF	I
9	-	I
10	M	I
11	mRNA	I
12	was	O
13	located	O
14	169	O
15	nucleotides	O
16	upstream	O
17	of	O
18	p	B
19	-	I
20	gvpF	I
21	within	O
22	p	B
23	-	I
24	gvpE	I
25	.	O

0	Two	O
1	episodes	O
2	of	O
3	peritonitis	O
4	occurred	O
5	while	O
6	the	O
7	patient	O
8	received	O
9	CAPD	O
10	(	O
11	1	O
12	episode	O
13	/	O
14	3	O
15	.	O
16	5	O
17	patient	O
18	-	O
19	months	O
20	).	O

0	NMR	O
1	of	O
2	diffusing	O
3	atoms	O
4	in	O
5	a	O
6	periodic	O
7	porous	O
8	medium	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	a	O
14	nonuniform	O
15	magnetic	O
16	field	O
17	.	O

0	These	O
1	findings	O
2	suggest	O
3	that	O
4	the	O
5	increase	O
6	in	O
7	V	O
8	O2	O
9	may	O
10	have	O
11	been	O
12	a	O
13	consequence	O
14	of	O
15	the	O
16	increase	O
17	in	O
18	Q	O
19	O2	O
20	rather	O
21	than	O
22	a	O
23	response	O
24	to	O
25	the	O
26	procedure	O
27	itself	O
28	.	O

0	A	O
1	brief	O
2	discussion	O
3	of	O
4	color	O
5	deficiencies	O
6	.	O

0	MCh	O
1	infusion	O
2	caused	O
3	a	O
4	concentration	O
5	-	O
6	dependent	O
7	increase	O
8	in	O
9	airway	O
10	resistance	O
11	at	O
12	constant	O
13	QBA	O
14	.	O

0	When	O
1	vascular	O
2	pressure	O
3	(	O
4	Pvas	O
5	)	O
6	was	O
7	raised	O
8	abruptly	O
9	from	O
10	-	O
11	5	O
12	to	O
13	+	O
14	25	O
15	cmH2O	O
16	by	O
17	air	O
18	inflation	O
19	for	O
20	60	O
21	min	O
22	,	O
23	Px	O
24	(	O
25	f	O
26	)	O
27	became	O
28	abruptly	O
29	less	O
30	negative	O
31	,	O
32	then	O
33	remained	O
34	stable	O
35	.	O

0	The	O
1	effects	O
2	of	O
3	contrast	O
4	media	O
5	on	O
6	coagulation	B
7	factor	I
8	XII	I
9	.	O

0	Symposium	O
1	on	O
2	presenile	O
3	spongy	O
4	encephalopathies	O
5	.	O

0	Assembly	O
1	of	O
2	a	O
3	complex	O
4	between	O
5	FAK	B
6	and	O
7	Src	B
8	kinases	I
9	may	O
10	serve	O
11	to	O
12	regulate	O
13	the	O
14	subcellular	O
15	localization	O
16	and	O
17	the	O
18	enzymatic	O
19	activity	O
20	of	O
21	members	O
22	of	O
23	the	O
24	Src	B
25	family	I
26	of	O
27	kinases	O
28	.	O

0	We	O
1	characterized	O
2	three	O
3	Arabidopsis	O
4	thaliana	O
5	cDNA	O
6	clones	O
7	that	O
8	could	O
9	rescue	O
10	the	O
11	sterile	O
12	phenotype	O
13	of	O
14	the	O
15	Schizosaccharomyces	B
16	pombe	I
17	pde1	I
18	mutant	I
19	,	O
20	which	O
21	is	O
22	defective	O
23	in	O
24	cAMP	B
25	phosphodiesterase	I
26	.	O

0	Evidence	O
1	that	O
2	therapeutic	O
3	alterations	O
4	of	O
5	a	O
6	circadian	O
7	rhythm	O
8	for	O
9	gastric	O
10	emptying	O
11	response	O
12	may	O
13	be	O
14	possible	O
15	.	O

0	Moreover	O
1	,	O
2	the	O
3	mass	O
4	estimated	O
5	with	O
6	the	O
7	QCM	O
8	response	O
9	through	O
10	the	O
11	Sauerbrey	O
12	equation	O
13	and	O
14	the	O
15	mass	O
16	which	O
17	can	O
18	be	O
19	measured	O
20	thanks	O
21	to	O
22	other	O
23	analytical	O
24	techniques	O
25	,	O
26	in	O
27	our	O
28	case	O
29	an	O
30	enzymatic	O
31	assay	O
32	,	O
33	are	O
34	different	O
35	:	O
36	the	O
37	deposited	O
38	mass	O
39	is	O
40	generally	O
41	overestimated	O
42	by	O
43	the	O
44	QCM	O
45	.	O

0	Plasma	B
1	histaminase	I
2	in	O
3	patients	O
4	of	O
5	bronchial	O
6	asthma	O
7	and	O
8	the	O
9	effect	O
10	of	O
11	prednisolone	O
12	administration	O
13	on	O
14	it	O
15	.	O

0	It	O
1	has	O
2	been	O
3	previously	O
4	shown	O
5	that	O
6	genes	O
7	transcribed	O
8	by	O
9	RNA	B
10	polymerase	I
11	II	I
12	(	O
13	RNAP	B
14	II	I
15	)	O
16	are	O
17	subject	O
18	to	O
19	position	O
20	effect	O
21	variegation	O
22	when	O
23	located	O
24	near	O
25	yeast	O
26	telomeres	O
27	.	O

0	M	B
1	.	O
2	leprae	O
3	OxyR	B
4	was	O
5	overproduced	O
6	and	O
7	purified	O
8	,	O
9	and	O
10	its	O
11	binding	O
12	to	O
13	the	O
14	oxyR	B
15	-	O
16	ahpC	B
17	intergenic	O
18	region	O
19	of	O
20	M	O
21	.	O
22	leprae	O
23	was	O
24	demonstrated	O
25	.	O

0	Discrepant	O
1	results	O
2	with	O
3	a	O
4	latex	O
5	agglutination	O
6	test	O
7	in	O
8	the	O
9	assessment	O
10	of	O
11	cytomegalovirus	O
12	antibody	O
13	status	O
14	of	O
15	cardiac	O
16	transplant	O
17	donors	O
18	.	O

0	Because	O
1	the	O
2	number	O
3	of	O
4	parameters	O
5	required	O
6	by	O
7	a	O
8	Volterra	O
9	series	O
10	grows	O
11	rapidly	O
12	with	O
13	both	O
14	the	O
15	length	O
16	of	O
17	its	O
18	memory	O
19	and	O
20	the	O
21	order	O
22	of	O
23	its	O
24	nonlinearity	O
25	,	O
26	methods	O
27	for	O
28	identifying	O
29	these	O
30	models	O
31	from	O
32	measurements	O
33	of	O
34	input	O
35	/	O
36	output	O
37	data	O
38	are	O
39	limited	O
40	to	O
41	low	O
42	-	O
43	order	O
44	systems	O
45	with	O
46	relatively	O
47	short	O
48	memories	O
49	.	O

0	Beyond	O
1	the	O
2	Tower	O
3	of	O
4	Babel	O
5	:	O
6	a	O
7	nomenclature	O
8	for	O
9	suicidology	O
10	.	O

0	In	O
1	addition	O
2	,	O
3	mapping	O
4	of	O
5	the	O
6	promoter	O
7	region	O
8	and	O
9	the	O
10	identification	O
11	of	O
12	putative	O
13	promoter	O
14	regulatory	O
15	sequences	O
16	should	O
17	give	O
18	insight	O
19	into	O
20	the	O
21	transcriptional	O
22	regulation	O
23	of	O
24	UCP2	B
25	expression	O
26	--	O
27	in	O
28	particular	O
29	by	O
30	anyone	O
31	of	O
32	the	O
33	above	O
34	mentioned	O
35	factors	O
36	--	O
37	in	O
38	vitro	O
39	and	O
40	in	O
41	vivo	O
42	.	O

0	The	O
1	observation	O
2	that	O
3	beta	B
4	2m	I
5	with	O
6	covalently	O
7	attached	O
8	peptide	O
9	can	O
10	effectively	O
11	create	O
12	CTL	O
13	target	O
14	structures	O
15	in	O
16	vitro	O
17	offers	O
18	new	O
19	possibilities	O
20	for	O
21	the	O
22	in	O
23	vivo	O
24	induction	O
25	of	O
26	epitope	O
27	-	O
28	specific	O
29	CTL	O
30	responses	O
31	by	O
32	either	O
33	DNA	O
34	immunization	O
35	or	O
36	injection	O
37	of	O
38	the	O
39	purified	O
40	epitope	O
41	-	O
42	linked	O
43	beta	B
44	2m	I
45	.	O

0	Conservative	O
1	treatment	O
2	of	O
3	central	O
4	nervous	O
5	system	O
6	injuries	O

0	This	O
1	lack	O
2	of	O
3	correlation	O
4	may	O
5	be	O
6	due	O
7	to	O
8	variations	O
9	in	O
10	the	O
11	metabolic	O
12	activity	O
13	of	O
14	the	O
15	endometriotic	O
16	implants	O
17	present	O
18	at	O
19	different	O
20	stages	O
21	of	O
22	the	O
23	disease	O
24	.	O

0	When	O
1	the	O
2	entire	O
3	diet	O
4	consisted	O
5	of	O
6	SBF	O
7	,	O
8	voluntary	O
9	feed	O
10	intake	O
11	was	O
12	reduced	O
13	,	O
14	indicating	O
15	that	O
16	SBF	O
17	should	O
18	not	O
19	be	O
20	fed	O
21	to	O
22	ponies	O
23	as	O
24	the	O
25	sole	O
26	dietary	O
27	ingredient	O
28	.	O

0	We	O
1	conclude	O
2	from	O
3	this	O
4	study	O
5	that	O
6	Arix	B
7	and	O
8	NBPhox	B
9	exhibit	O
10	indistinguishable	O
11	and	O
12	independent	O
13	transcriptional	O
14	regulatory	O
15	properties	O
16	on	O
17	the	O
18	DBH	B
19	promoter	I
20	.	O

0	Mastocytosis	O
1	.	O

0	Given	O
1	its	O
2	relative	O
3	longevity	O
4	on	O
5	the	O
6	Web	O
7	,	O
8	TIE	O
9	researchers	O
10	have	O
11	been	O
12	in	O
13	a	O
14	unique	O
15	position	O
16	to	O
17	observe	O
18	trends	O
19	in	O
20	telemedicine	O
21	.	O

0	Environmental	O
1	factors	O
2	were	O
3	more	O
4	important	O
5	in	O
6	the	O
7	older	O
8	cohorts	O
9	(	O
10	perhaps	O
11	because	O
12	of	O
13	less	O
14	reliable	O
15	recall	O
16	).	O

0	Genomic	O
1	and	O
2	cDNA	O
3	clones	O
4	homologous	O
5	to	O
6	the	O
7	yeast	B
8	GCN2	I
9	eIF	I
10	-	I
11	2alpha	I
12	kinase	I
13	(	O
14	yGCN2	B
15	)	O
16	were	O
17	isolated	O
18	from	O
19	Drosophila	O
20	melanogaster	O
21	.	O

0	The	O
1	latter	O
2	method	O
3	adds	O
4	clamping	O
5	of	O
6	the	O
7	inferior	O
8	vena	O
9	cava	O
10	,	O
11	which	O
12	results	O
13	in	O
14	hypotension	O
15	,	O
16	requiring	O
17	invasive	O
18	anesthetic	O
19	management	O
20	.	O

0	Ectopic	O
1	expression	O
2	of	O
3	Apo	B
4	-	I
5	3	I
6	in	O
7	HEK293	O
8	or	O
9	HeLa	O
10	cells	O
11	induced	O
12	marked	O
13	apoptosis	O
14	.	O

0	The	O
1	27	O
2	-	O
3	base	O
4	element	O
5	interacts	O
6	with	O
7	a	O
8	PDGF	B
9	-	I
10	activated	I
11	serine	I
12	/	I
13	threonine	I
14	phosphoprotein	I
15	that	O
16	is	O
17	detected	O
18	only	O
19	within	O
20	the	O
21	nucleus	O
22	of	O
23	PDGF	B
24	-	O
25	treated	O
26	3T3	O
27	cells	O
28	.	O

0	In	O
1	a	O
2	randomized	O
3	study	O
4	on	O
5	150	O
6	patients	O
7	(	O
8	ASA	O
9	1	O
10	)	O
11	undergoing	O
12	induction	O
13	of	O
14	anaesthesia	O
15	,	O
16	the	O
17	effects	O
18	of	O
19	Fentanyl	O
20	(	O
21	0	O
22	.	O
23	1	O
24	mg	O
25	),	O
26	the	O
27	combination	O
28	of	O
29	Fentanyl	O
30	(	O
31	0	O
32	.	O
33	1	O
34	mg	O
35	)	O
36	and	O
37	Droperidol	O
38	(	O
39	5	O
40	mg	O
41	)	O
42	(	O
43	Innovar	O
44	,	O
45	Thalamonal	O
46	)	O
47	and	O
48	Atropine	O
49	(	O
50	0	O
51	.	O
52	01	O
53	mg	O
54	/	O
55	kg	O
56	b	O
57	.	O
58	w	O
59	.)	O
60	alone	O
61	on	O
62	cardiocirculatory	O
63	parameters	O
64	were	O
65	studied	O
66	.	O

0	OBJECTIVE	O
1	:	O
2	To	O
3	investigate	O
4	the	O
5	incidence	O
6	and	O
7	presentation	O
8	of	O
9	acute	O
10	pernicious	O
11	or	O
12	fulminating	O
13	beriberi	O
14	in	O
15	a	O
16	general	O
17	district	O
18	hospital	O
19	.	O

0	The	O
1	3	O
2	'	O
3	stem	O
4	-	O
5	loop	O
6	is	O
7	highly	O
8	divergent	O
9	in	O
10	structure	O
11	among	O
12	species	O
13	and	O
14	lies	O
15	immediately	O
16	upstream	O
17	of	O
18	the	O
19	binding	O
20	site	O
21	for	O
22	Sm	B
23	proteins	I
24	.	O

0	In	O
1	all	O
2	eight	O
3	cases	O
4	,	O
5	neither	O
6	FL	O
7	nor	O
8	DLL	O
9	cells	O
10	showed	O
11	alterations	O
12	of	O
13	bcl	B
14	-	I
15	2	I
16	gene	I
17	sequences	I
18	in	O
19	the	O
20	breakpoint	O
21	region	O
22	,	O
23	suggesting	O
24	high	O
25	conservation	O
26	of	O
27	the	O
28	bcl	B
29	-	I
30	2	I
31	gene	I
32	during	O
33	both	O
34	t	O
35	(	O
36	14	O
37	;	O
38	18	O
39	)	O
40	translocation	O
41	and	O
42	morphologic	O
43	transformation	O
44	of	O
45	the	O
46	FL	O
47	cells	O
48	.	O

0	All	O
1	of	O
2	the	O
3	indigo	O
4	-	O
5	producing	O
6	bacteria	O
7	had	O
8	an	O
9	indoxyl	B
10	phosphatase	I
11	with	O
12	a	O
13	pI	O
14	of	O
15	6	O
16	.	O
17	4	O
18	.	O

0	Sequencing	O
1	of	O
2	the	O
3	three	O
4	pag	B
5	-	I
6	3	I
7	alleles	I
8	showed	O
9	that	O
10	two	O
11	apparent	O
12	null	O
13	alleles	O
14	encode	O
15	a	O
16	nonsense	O
17	mutation	O
18	before	O
19	the	O
20	zinc	O
21	fingers	O
22	and	O
23	a	O
24	missense	O
25	mutation	O
26	in	O
27	the	O
28	fourth	O
29	zinc	O
30	finger	O
31	that	O
32	changes	O
33	a	O
34	coordinating	O
35	histidine	O
36	to	O
37	a	O
38	tyrosine	O
39	.	O

0	A	O
1	phylogenetic	O
2	analysis	O
3	of	O
4	the	O
5	reverse	B
6	transcriptase	I
7	domain	I
8	confirms	O
9	our	O
10	differential	O
11	genetic	O
12	assessment	O
13	that	O
14	Cyclops	O
15	from	O
16	pea	O
17	is	O
18	a	O
19	novel	O
20	element	O
21	with	O
22	no	O
23	specific	O
24	relationship	O
25	to	O
26	the	O
27	previously	O
28	described	O
29	Gypsy	O
30	-	O
31	like	O
32	elements	O
33	from	O
34	plants	O
35	.	O

0	The	O
1	GEF	B
2	and	O
3	GAP	B
4	activities	O
5	for	O
6	Ypt1p	B
7	localize	O
8	to	O
9	particulate	O
10	cellular	O
11	fractions	O
12	.	O

0	The	O
1	two	O
2	main	O
3	experimental	O
4	variables	O
5	were	O
6	the	O
7	attended	O
8	hemifield	O
9	(	O
10	left	O
11	or	O
12	right	O
13	)	O
14	and	O
15	the	O
16	proportion	O
17	of	O
18	trials	O
19	requiring	O
20	a	O
21	shift	O
22	within	O
23	that	O
24	hemifield	O
25	(	O
26	20	O
27	%	O
28	or	O
29	80	O
30	%).	O

0	For	O
1	symptomatic	O
2	relief	O
3	and	O
4	inhibition	O
5	of	O
6	the	O
7	growth	O
8	of	O
9	the	O
10	metastases	O
11	interferon	B
12	-	I
13	a	I
14	and	O
15	somatostatin	B
16	analogues	O
17	can	O
18	be	O
19	employed	O
20	.	O

0	Characterization	O
1	of	O
2	an	O
3	EcR	B
4	/	O
5	USP	B
6	heterodimer	O
7	target	O
8	site	O
9	that	O
10	mediates	O
11	ecdysone	O
12	responsiveness	O
13	of	O
14	the	O
15	Drosophila	B
16	Lsp	I
17	-	I
18	2	I
19	gene	I
20	.	O

0	In	O
1	addition	O
2	,	O
3	a	O
4	21	O
5	-	O
6	mer	O
7	subrepeat	O
8	structure	O
9	is	O
10	also	O
11	present	O
12	in	O
13	each	O
14	unit	O
15	.	O

0	Epigenetic	O
1	switching	O
2	of	O
3	transcriptional	O
4	states	O
5	:	O
6	cis	O
7	-	O
8	and	O
9	trans	O
10	-	O
11	acting	O
12	factors	O
13	affecting	O
14	establishment	O
15	of	O
16	silencing	O
17	at	O
18	the	O
19	HMR	B
20	locus	I
21	in	O
22	Saccharomyces	O
23	cerevisiae	O
24	.	O

0	These	O
1	and	O
2	other	O
3	data	O
4	presented	O
5	suggest	O
6	that	O
7	TAg	B
8	'	O
9	re	O
10	-	O
11	models	O
12	'	O
13	host	O
14	cell	O
15	transcription	O
16	factors	O
17	that	O
18	are	O
19	used	O
20	early	O
21	in	O
22	viral	O
23	infection	O
24	,	O
25	and	O
26	thereby	O
27	mimics	O
28	an	O
29	event	O
30	that	O
31	naturally	O
32	occurs	O
33	during	O
34	transformation	O
35	.	O

0	A	O
1	larger	O
2	region	O
3	upstream	O
4	of	O
5	human	O
6	CMV	O
7	dbp	O
8	also	O
9	mediated	O
10	replication	O
11	in	O
12	transient	O
13	assays	O
14	.	O

0	A	O
1	distinct	O
2	staining	O
3	pattern	O
4	for	O
5	the	O
6	N	B
7	-	I
8	utrophin	I
9	was	O
10	not	O
11	detectable	O
12	,	O
13	although	O
14	it	O
15	was	O
16	expected	O
17	to	O
18	localise	O
19	at	O
20	the	O
21	actin	B
22	stress	O
23	fibers	O
24	.	O

0	Organisms	O
1	were	O
2	recovered	O
3	from	O
4	the	O
5	conjunctiva	O
6	for	O
7	several	O
8	weeks	O
9	,	O
10	and	O
11	persistent	O
12	genital	O
13	and	O
14	gastrointestinal	O
15	infection	O
16	also	O
17	resulted	O
18	from	O
19	the	O
20	ocular	O
21	infection	O
22	in	O
23	some	O
24	cats	O
25	.	O

0	The	O
1	predominant	O
2	sensitizing	O
3	allergens	O
4	in	O
5	Swedish	O
6	asthmatic	O
7	children	O
8	are	O
9	furred	O
10	pet	O
11	animals	O
12	.	O

0	Thioredoxin	B
1	(	O
2	TR	B
3	)	O
4	is	O
5	a	O
6	small	O
7	ubiquitous	O
8	dithiol	B
9	-	I
10	reductase	I
11	enzyme	I
12	first	O
13	identified	O
14	in	O
15	bacteria	O
16	and	O
17	plants	O
18	.	O

0	Furthermore	O
1	,	O
2	a	O
3	pTyr317	O
4	Shc	O
5	phosphopeptide	O
6	selectively	O
7	recognized	O
8	Grb2	B
9	,	O
10	Sos1	B
11	,	O
12	SHIP	B
13	,	O
14	and	O
15	the	O
16	p85	B
17	subunit	I
18	of	O
19	phosphatidylinositol	B
20	3	I
21	'	I
22	kinase	I
23	from	O
24	mast	O
25	cells	O
26	,	O
27	as	O
28	characterized	O
29	by	O
30	mass	O
31	spectrometry	O
32	.	O

0	Slap	B
1	negatively	O
2	regulates	O
3	Src	B
4	mitogenic	O
5	function	O
6	but	O
7	does	O
8	not	O
9	revert	O
10	Src	B
11	-	O
12	induced	O
13	cell	O
14	morphology	O
15	changes	O
16	.	O

0	Primer	O
1	extension	O
2	and	O
3	mung	B
4	bean	B
5	and	O
6	S1	B
7	nuclease	I
8	mapping	O
9	indicated	O
10	multiple	O
11	transcription	O
12	initiation	O
13	sites	O
14	and	O
15	were	O
16	consistent	O
17	with	O
18	Northern	O
19	analyses	O
20	.	O

0	Droperidol	O
1	-	O
2	induced	O
3	extrapyramidal	O
4	symptoms	O
5	in	O
6	an	O
7	adolescent	O
8	following	O
9	strabismus	O
10	surgery	O
11	.	O

0	The	O
1	distribution	O
2	of	O
3	cryptosporidia	O
4	in	O
5	the	O
6	intestine	O
7	and	O
8	number	O
9	of	O
10	cryptosporidia	O
11	per	O
12	ileal	O
13	villus	O
14	on	O
15	different	O
16	DPI	O
17	were	O
18	also	O
19	estimated	O
20	for	O
21	detailed	O
22	characterization	O
23	of	O
24	the	O
25	infection	O
26	in	O
27	kids	O
28	as	O
29	a	O
30	model	O
31	for	O
32	experimental	O
33	cryptosporidiosis	O
34	.	O

0	We	O
1	compared	O
2	the	O
3	inhibitory	O
4	effect	O
5	of	O
6	naturally	O
7	occurring	O
8	mutant	B
9	hTR	I
10	beta	I
11	1	I
12	,	O
13	artificially	O
14	created	O
15	hTR	B
16	alpha	I
17	1	I
18	mutants	I
19	,	O
20	c	B
21	-	I
22	erbA	I
23	alpha	I
24	2	I
25	and	O
26	the	O
27	human	B
28	peroxisome	I
29	proliferator	I
30	-	I
31	activated	I
32	receptor	I
33	(	O
34	hPPAR	B
35	)	O
36	on	O
37	three	O
38	prototypic	O
39	T3	O
40	-	O
41	response	O
42	elements	O
43	(	O
44	TREs	O
45	),	O
46	TRE	O
47	-	O
48	PAL	O
49	,	O
50	DR	O
51	+	O
52	4	O
53	and	O
54	TRE	O
55	-	O
56	LAP	O
57	.	O

0	In	O
1	a	O
2	randomised	O
3	double	O
4	-	O
5	blind	O
6	study	O
7	,	O
8	46	O
9	first	O
10	episode	O
11	schizophrenics	O
12	were	O
13	given	O
14	pimozide	O
15	or	O
16	flupenthixol	O
17	for	O
18	up	O
19	to	O
20	5	O
21	weeks	O
22	;	O
23	the	O
24	mean	O
25	daily	O
26	dose	O
27	at	O
28	the	O
29	end	O
30	was	O
31	18	O
32	.	O
33	8	O
34	mg	O
35	pimozide	O
36	and	O
37	20	O
38	mg	O
39	flupenthixol	O
40	.	O

0	Both	O
1	functional	O
2	analyses	O
3	in	O
4	undifferentiated	O
5	and	O
6	differentiated	O
7	F9	O
8	cells	O
9	and	O
10	characterization	O
11	of	O
12	DNA	O
13	-	O
14	protein	O
15	complexes	O
16	in	O
17	vitro	O
18	have	O
19	identified	O
20	the	O
21	sequence	O
22	motifs	O
23	GTGACT	O
24	(	O
25	C	O
26	),	O
27	ATTGT	O
28	,	O
29	and	O
30	GATA	B
31	as	O
32	the	O
33	key	O
34	transcription	O
35	factor	O
36	binding	O
37	sites	O
38	.	O

0	Apart	O
1	from	O
2	iron	O
3	regulation	O
4	,	O
5	sodA	B
6	expression	O
7	was	O
8	affected	O
9	by	O
10	changes	O
11	in	O
12	DNA	O
13	topology	O
14	induced	O
15	by	O
16	coumermycin	O
17	A	O
18	but	O
19	not	O
20	by	O
21	the	O
22	global	O
23	virulence	O
24	regulatory	O
25	Bvg	O
26	system	O
27	.	O

0	Simple	O
1	reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	to	O
7	a	O
8	peripheral	O
9	visual	O
10	target	O
11	(	O
12	S2	O
13	)	O
14	is	O
15	shortened	O
16	when	O
17	a	O
18	non	O
19	-	O
20	informative	O
21	cue	O
22	(	O
23	S1	O
24	)	O
25	is	O
26	flashed	O
27	at	O
28	the	O
29	S2	O
30	location	O
31	100	O
32	-	O
33	150	O
34	ms	O
35	before	O
36	target	O
37	onset	O
38	(	O
39	early	O
40	facilitation	O
41	).	O

0	The	O
1	Oct	B
2	-	I
3	3	I
4	/	I
5	4	I
6	gene	I
7	product	I
8	,	O
9	which	O
10	belongs	O
11	to	O
12	the	O
13	POU	B
14	family	I
15	of	O
16	transcription	O
17	factors	O
18	,	O
19	is	O
20	a	O
21	good	O
22	candidate	O
23	for	O
24	regulating	O
25	initial	O
26	differentiation	O
27	decisions	O
28	.	O

0	Feed	O
1	intake	O
2	and	O
3	BW	O
4	gains	O
5	were	O
6	decreased	O
7	(	O
8	P	O
9	<	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	dietary	O
16	treatments	O
17	containing	O
18	M	O
19	.	O

0	Cerebral	O
1	flow	O
2	and	O
3	resistance	O
4	showed	O
5	minor	O
6	reductions	O
7	with	O
8	HD	O
9	.	O

0	A	O
1	dose	O
2	-	O
3	dependent	O
4	fall	O
5	in	O
6	GABA	O
7	content	O
8	was	O
9	observed	O
10	;	O
11	GABA	O
12	decrease	O
13	was	O
14	evident	O
15	15	O
16	min	O
17	after	O
18	the	O
19	administration	O
20	,	O
21	reached	O
22	its	O
23	nadir	O
24	at	O
25	60	O
26	min	O
27	and	O
28	disappeared	O
29	at	O
30	120	O
31	minutes	O
32	.	O

0	(	O
1	1988	O
2	)	O
3	J	O
4	.	O

0	Engagement	O
1	of	O
2	human	B
3	CD2	I
4	by	O
5	mitogenic	O
6	pairs	O
7	of	O
8	anti	B
9	-	I
10	CD2	I
11	mAb	I
12	induces	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	a	O
17	number	O
18	of	O
19	intracellular	O
20	proteins	O
21	including	O
22	a	O
23	120	O
24	kDa	O
25	phosphoprotein	O
26	that	O
27	we	O
28	identify	O
29	as	O
30	the	O
31	proto	O
32	-	O
33	oncogene	O
34	c	B
35	-	I
36	Cbl	I
37	.	O

0	Under	O
1	these	O
2	schedules	O
3	,	O
4	a	O
5	reinforced	O
6	response	O
7	run	O
8	consisted	O
9	of	O
10	responding	O
11	between	O
12	eight	O
13	and	O
14	12	O
15	times	O
16	on	O
17	one	O
18	response	O
19	key	O
20	(	O
21	work	O
22	key	O
23	)	O
24	and	O
25	then	O
26	responding	O
27	once	O
28	on	O
29	a	O
30	second	O
31	response	O
32	key	O
33	(	O
34	reinforced	O
35	key	O
36	).	O

0	BIAcore	O
1	analysis	O
2	gave	O
3	a	O
4	Kaff	O
5	of	O
6	4	O
7	.	O
8	4	O
9	x	O
10	10	O
11	(	O
12	10	O
13	)	O
14	M	O
15	-	O
16	1	O
17	for	O
18	the	O
19	binding	O
20	of	O
21	N	O
22	-	O
23	A3	O
24	to	O
25	T84	O
26	.	O
27	1	O
28	and	O
29	2	O
30	.	O
31	2	O
32	x	O
33	10	O
34	(	O
35	10	O
36	)	O
37	M	O
38	-	O
39	1	O
40	for	O
41	the	O
42	binding	O
43	of	O
44	N	O
45	-	O
46	A3	O
47	to	O
48	T84	O
49	.	O
50	66	O
51	.	O

0	Rhesus	O
1	macaques	O
2	and	O
3	BALB	O
4	/	O
5	c	O
6	mice	O
7	inoculated	O
8	with	O
9	the	O
10	Mengo	O
11	virus	O
12	SIV	I
13	recombinants	I
14	failed	O
15	to	O
16	develop	O
17	CTL	O
18	responses	O
19	against	O
20	the	O
21	SIV	B
22	gene	I
23	products	I
24	,	O
25	while	O
26	one	O
27	of	O
28	the	O
29	HIV	B
30	-	I
31	Nef	I
32	recombinants	I
33	induced	O
34	a	O
35	weak	O
36	CTL	O
37	response	O
38	in	O
39	mice	O
40	directed	O
41	to	O
42	an	O
43	HIV1	B
44	Nef	I
45	peptide	I
46	spanning	O
47	positions	O
48	182	O
49	-	O
50	198	O
51	.	O

0	Therefore	O
1	,	O
2	the	O
3	results	O
4	indicate	O
5	that	O
6	repeated	O
7	exposure	O
8	to	O
9	amphetamine	O
10	or	O
11	apomorphine	O
12	overcomes	O
13	the	O
14	context	O
15	-	O
16	dependent	O
17	component	O
18	of	O
19	sensitization	O
20	of	O
21	amphetamine	O
22	-	O
23	or	O
24	apomorphine	O
25	-	O
26	induced	O
27	stereotyped	O
28	behavior	O
29	.	O

0	Malonate	O
1	decarboxylation	O
2	in	O
3	Malonomonas	O
4	rubra	O
5	involves	O
6	the	O
7	formation	O
8	of	O
9	malonyl	O
10	-	O
11	S	O
12	-[	O
13	acyl	O
14	-	O
15	carrier	O
16	protein	O
17	]	O
18	from	O
19	acetyl	O
20	-	O
21	S	O
22	-[	O
23	acyl	O
24	-	O
25	carrier	O
26	protein	O
27	]	O
28	and	O
29	malonate	O
30	,	O
31	carboxyltransfer	O
32	to	O
33	a	O
34	biotin	B
35	protein	I
36	and	O
37	its	O
38	decarboxylation	O
39	that	O
40	is	O
41	coupled	O
42	to	O
43	delta	O
44	mu	O
45	Na	O
46	+	O
47	generation	O
48	.	O

0	No	O
1	TATA	O
2	box	O
3	was	O
4	found	O
5	in	O
6	the	O
7	putative	O
8	promoter	O
9	region	O
10	,	O
11	but	O
12	multiple	O
13	GC	O
14	boxes	O
15	were	O
16	found	O
17	around	O
18	the	O
19	cap	O
20	sites	O
21	,	O
22	supporting	O
23	the	O
24	previously	O
25	inferred	O
26	housekeeping	O
27	nature	O
28	of	O
29	CYP51	B
30	gene	I
31	and	O
32	the	O
33	existence	O
34	of	O
35	the	O
36	multiple	O
37	transcription	O
38	initiation	O
39	sites	O
40	.	O

0	Blood	O
1	pressure	O
2	also	O
3	was	O
4	increased	O
5	by	O
6	lidocaine	O
7	(	O
8	6	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	).	O

0	Clinical	O
1	use	O
2	of	O
3	absorbable	O
4	polyglycolic	O
5	acid	O
6	suture	O
7	in	O
8	Blalock	O
9	-	O
10	Taussig	O
11	'	O
12	s	O
13	operation	O

0	All	O
1	of	O
2	the	O
3	newly	O
4	acquired	O
5	proviruses	O
6	identified	O
7	in	O
8	mosaic	O
9	founder	O
10	SWR	O
11	/	O
12	J	O
13	-	O
14	RF	O
15	/	O
16	J	O
17	mice	O
18	that	O
19	could	O
20	be	O
21	transmitted	O
22	through	O
23	the	O
24	germ	O
25	line	O
26	were	O
27	also	O
28	present	O
29	in	O
30	somatic	O
31	tissues	O
32	,	O
33	demonstrating	O
34	that	O
35	viral	O
36	integration	O
37	occurred	O
38	before	O
39	the	O
40	germ	O
41	line	O
42	was	O
43	set	O
44	aside	O
45	from	O
46	the	O
47	somatic	O
48	lineages	O
49	.	O

0	The	O
1	DNA	O
2	binding	O
3	activities	O
4	of	O
5	the	O
6	three	O
7	repressor	O
8	preparations	O
9	were	O
10	studied	O
11	using	O
12	fragments	O
13	containing	O
14	CIRs	O
15	(	O
16	CIR3	O
17	-	O
18	CIR6	B
19	)	O
20	from	O
21	the	O
22	essential	O
23	early	O
24	region	O
25	as	O
26	templates	O
27	for	O
28	DNase	B
29	I	I
30	footprinting	O
31	.	O

0	In	O
1	the	O
2	same	O
3	period	O
4	we	O
5	pointed	O
6	out	O
7	an	O
8	increase	O
9	of	O
10	hematocrit	O
11	(	O
12	from	O
13	29	O
14	%	O
15	to	O
16	35	O
17	%)	O
18	and	O
19	of	O
20	the	O
21	Hb	O
22	(	O
23	from	O
24	9	O
25	.	O
26	3	O
27	to	O
28	11	O
29	.	O
30	2	O
31	g	O
32	/	O
33	dl	O
34	).	O

0	In	O
1	this	O
2	study	O
3	,	O
4	a	O
5	common	O
6	mechanism	O
7	has	O
8	been	O
9	identified	O
10	to	O
11	coordinate	O
12	the	O
13	growth	O
14	-	O
15	and	O
16	FC	O
17	-	O
18	dependent	O
19	expression	O
20	of	O
21	caveolin	B
22	.	O

0	The	O
1	minimal	O
2	promoter	O
3	of	O
4	the	O
5	RII	B
6	beta	I
7	gene	I
8	was	O
9	composed	O
10	of	O
11	two	O
12	adjacent	O
13	functional	O
14	elements	O
15	.	O

0	IL	B
1	-	I
2	12	I
3	production	O
4	was	O
5	correlated	O
6	with	O
7	C3a	B
8	concentration	O
9	measured	O
10	at	O
11	the	O
12	outlet	O
13	of	O
14	hemodialyzer	O
15	after	O
16	15	O
17	min	O
18	of	O
19	dialysis	O
20	(	O
21	r	O
22	=	O
23	0	O
24	.	O
25	69	O
26	,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	01	O
32	).	O

0	Cyclic	B
1	AMP	I
2	-	I
3	dependent	I
4	protein	I
5	kinase	I
6	binding	O
7	to	O
8	A	B
9	-	I
10	kinase	I
11	anchoring	O
12	proteins	O
13	in	O
14	living	O
15	cells	O
16	by	O
17	fluorescence	O
18	resonance	O
19	energy	O
20	transfer	O
21	of	O
22	green	B
23	fluorescent	I
24	protein	I
25	fusion	I
26	proteins	I
27	.	O

0	55	O
1	+/-	O
2	11	O
3	%),	O
4	all	O
5	other	O
6	parameters	O
7	showed	O
8	a	O
9	significant	O
10	increase	O
11	:	O
12	RS	O
13	index	O
14	5	O
15	.	O
16	4	O
17	+/-	O
18	1	O
19	.	O
20	4	O
21	mVolt	O
22	to	O
23	6	O
24	.	O
25	0	O
26	+/-	O
27	1	O
28	.	O
29	7	O
30	mVolt	O
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	01	O
38	);	O
39	EDD	O
40	6	O
41	.	O
42	3	O
43	+/-	O
44	0	O
45	.	O
46	7	O
47	to	O
48	6	O
49	.	O
50	8	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	cm	O
56	(	O
57	p	O
58	less	O
59	than	O
60	0	O
61	.	O
62	001	O
63	);	O
64	HV	O
65	1017	O
66	+/-	O
67	151	O
68	ml	O
69	to	O
70	1099	O
71	+/-	O
72	261	O
73	ml	O
74	(	O
75	p	O
76	less	O
77	than	O
78	0	O
79	.	O
80	01	O
81	);	O
82	EDV	O
83	371	O
84	+/-	O
85	131	O
86	ml	O
87	to	O
88	441	O
89	+/-	O
90	175	O
91	ml	O
92	(	O
93	p	O
94	less	O
95	than	O
96	0	O
97	.	O
98	001	O
99	);	O
100	RBV	O
101	117	O
102	+/-	O
103	57	O
104	ml	O
105	to	O
106	151	O
107	+/-	O
108	77	O
109	ml	O
110	(	O
111	p	O
112	less	O
113	than	O
114	0	O
115	.	O
116	001	O
117	).	O

0	An	O
1	automated	O
2	method	O
3	for	O
4	the	O
5	quantitative	O
6	analysis	O
7	of	O
8	the	O
9	polyamines	O
10	putrescine	O
11	,	O
12	spermidine	O
13	and	O
14	spermine	O
15	in	O
16	cerebrospinal	O
17	fluid	O
18	(	O
19	CSF	O
20	)	O
21	was	O
22	used	O
23	to	O
24	analyze	O
25	CSF	O
26	samples	O
27	from	O
28	37	O
29	patients	O
30	with	O
31	central	O
32	nervous	O
33	system	O
34	(	O
35	CNS	O
36	)	O
37	tumors	O
38	and	O
39	from	O
40	13	O
41	patients	O
42	without	O
43	tumors	O
44	.	O

0	To	O
1	understand	O
2	the	O
3	basis	O
4	for	O
5	the	O
6	increased	O
7	cell	O
8	surface	O
9	stability	O
10	compared	O
11	with	O
12	wild	O
13	-	O
14	type	O
15	peptide	O
16	and	O
17	to	O
18	understand	O
19	the	O
20	differences	O
21	in	O
22	T	O
23	cell	O
24	recognition	O
25	between	O
26	I1Y	B
27	and	O
28	I1F	B
29	,	O
30	we	O
31	determined	O
32	the	O
33	x	O
34	-	O
35	ray	O
36	crystal	O
37	structures	O
38	of	O
39	the	O
40	two	O
41	class	B
42	I	I
43	MHC	I
44	-	I
45	peptide	I
46	complexes	I
47	.	O

0	In	O
1	1993	O
2	and	O
3	1994	O
4	and	O
5	infection	O
6	with	O
7	body	O
8	lice	O
9	was	O
10	registered	O
11	41	O
12	times	O
13	in	O
14	31	O
15	patients	O
16	at	O
17	the	O
18	clinic	O
19	for	O
20	homeless	O
21	of	O
22	the	O
23	Community	O
24	Health	O
25	Service	O
26	of	O
27	Utrecht	O
28	.	O

0	Mutational	O
1	analysis	O
2	of	O
3	mRNA	O
4	capping	O
5	enzyme	O
6	identifies	O
7	amino	O
8	acids	O
9	involved	O
10	in	O
11	GTP	O
12	binding	O
13	,	O
14	enzyme	O
15	-	O
16	guanylate	O
17	formation	O
18	,	O
19	and	O
20	GMP	O
21	transfer	O
22	to	O
23	RNA	O
24	.	O

0	The	O
1	present	O
2	research	O
3	evaluated	O
4	the	O
5	possibility	O
6	that	O
7	polyethylene	O
8	glycol	O
9	400	O
10	(	O
11	PEG	O
12	400	O
13	)	O
14	might	O
15	be	O
16	efficacious	O
17	,	O
18	toxic	O
19	,	O
20	or	O
21	both	O
22	.	O

0	Sequence	O
1	comparison	O
2	of	O
3	the	O
4	0	O
5	.	O
6	38	O
7	kb	O
8	promoter	O
9	sequence	O
10	with	O
11	the	O
12	promoters	O
13	of	O
14	the	O
15	Sm	B
16	-	I
17	E	I
18	gene	I
19	and	O
20	U1	B
21	snRNA	I
22	genes	I
23	revealed	O
24	several	O
25	homologous	O
26	motifs	O
27	,	O
28	suggesting	O
29	that	O
30	genes	O
31	encoding	O
32	the	O
33	snRNP	O
34	components	O
35	may	O
36	be	O
37	coordinately	O
38	regulated	O
39	.	O

0	Both	O
1	can	O
2	be	O
3	elevated	O
4	on	O
5	a	O
6	single	O
7	vascular	O
8	pedicle	O
9	based	O
10	on	O
11	the	O
12	superficial	O
13	temporal	O
14	artery	O
15	,	O
16	the	O
17	double	O
18	-	O
19	layered	O
20	temporal	O
21	fascia	O
22	flap	O
23	.	O

0	LCBF	O
1	in	O
2	normal	O
3	and	O
4	hypoxic	O
5	puppies	O
6	was	O
7	correlated	O
8	with	O
9	local	O
10	cerebral	O
11	glucose	O
12	utilization	O
13	(	O
14	LCGU	O
15	)	O
16	obtained	O
17	under	O
18	the	O
19	same	O
20	experimental	O
21	conditions	O
22	(	O
23	Duffy	O
24	et	O
25	al	O
26	,	O
27	1982	O
28	).	O

0	The	O
1	C	O
2	-	O
3	terminal	O
4	end	O
5	of	O
6	this	O
7	polypeptide	O
8	harbors	O
9	three	O
10	types	O
11	of	O
12	repeated	O
13	sequences	O
14	.	O

0	A	O
1	cDNA	O
2	library	O
3	of	O
4	tumour	O
5	cells	O
6	was	O
7	screened	O
8	with	O
9	an	O
10	interleukin	B
11	2	I
12	gene	I
13	-	O
14	specific	O
15	probe	O
16	.	O

0	This	O
1	E	O
2	box	O
3	sequence	O
4	(	O
5	CACGTG	O
6	)	O
7	is	O
8	identical	O
9	to	O
10	the	O
11	binding	O
12	element	O
13	for	O
14	USF	B
15	(	O
16	upstream	B
17	stimulatory	I
18	factor	I
19	),	O
20	a	O
21	member	O
22	of	O
23	the	O
24	helix	B
25	-	I
26	loop	I
27	-	I
28	helix	I
29	family	I
30	of	O
31	transcription	O
32	factors	O
33	.	O

0	When	O
1	a	O
2	tumour	O
3	is	O
4	present	O
5	nipple	O
6	discharge	O
7	is	O
8	of	O
9	little	O
10	importance	O
11	for	O
12	the	O
13	diagnosis	O
14	and	O
15	treatment	O
16	.	O

0	Clinical	O
1	and	O
2	haematological	O
3	signs	O
4	are	O
5	not	O
6	specific	O
7	in	O
8	this	O
9	setting	O
10	,	O
11	and	O
12	the	O
13	diagnosis	O
14	relies	O
15	on	O
16	histological	O
17	features	O
18	,	O
19	mainly	O
20	bone	O
21	marrow	O
22	examination	O
23	.	O

0	Electronic	O
1	data	O
2	processing	O
3	(	O
4	EDP	O
5	)	O
6	latex	O
7	immunoassay	O
8	using	O
9	anti	B
10	-	I
11	human	I
12	seminal	I
13	acid	I
14	phosphatase	I
15	(	O
16	anti	B
17	-	I
18	HSAP	I
19	)	O
20	immune	O
21	serum	O
22	was	O
23	applied	O
24	for	O
25	the	O
26	species	O
27	and	O
28	organ	O
29	identification	O
30	of	O
31	human	O
32	seminal	O
33	stains	O
34	.	O

0	Zebrafish	B
1	cyclops	I
2	(	O
3	cyc	B
4	)	O
5	encodes	O
6	a	O
7	Transforming	B
8	Growth	I
9	Factor	I
10	beta	I
11	(	O
12	TGFbeta	B
13	)	O
14	signaling	O
15	factor	O
16	closely	O
17	related	O
18	to	O
19	mouse	B
20	Nodal	I
21	.	O

0	Furthermore	O
1	,	O
2	Zelen	O
3	'	O
4	s	O
5	method	O
6	is	O
7	used	O
8	to	O
9	balance	O
10	the	O
11	number	O
12	of	O
13	patients	O
14	allocated	O
15	to	O
16	the	O
17	two	O
18	groups	O
19	within	O
20	each	O
21	institution	O
22	(	O
23	M	O
24	.	O

0	Congruent	O
1	with	O
2	empirical	O
3	predictions	O
4	,	O
5	the	O
6	most	O
7	homesick	O
8	children	O
9	perceived	O
10	low	O
11	control	O
12	over	O
13	homesickness	O
14	and	O
15	separation	O
16	,	O
17	and	O
18	coped	O
19	by	O
20	relinquishing	O
21	control	O
22	.	O

0	We	O
1	studied	O
2	the	O
3	role	O
4	of	O
5	prostaglandins	O
6	in	O
7	acid	O
8	-	O
9	induced	O
10	esophagitis	O
11	and	O
12	the	O
13	associated	O
14	LES	O
15	hypotension	O
16	by	O
17	simultaneous	O
18	treatment	O
19	of	O
20	some	O
21	animals	O
22	with	O
23	indomethacin	O
24	(	O
25	150	O
26	micrograms	O
27	/	O
28	kg	O
29	intravenous	O
30	),	O
31	a	O
32	specific	O
33	inhibitor	O
34	of	O
35	prostaglandin	O
36	synthesis	O
37	,	O
38	either	O
39	during	O
40	production	O
41	of	O
42	esophagitis	O
43	or	O
44	during	O
45	recovery	O
46	.	O

0	Asymptomatic	O
1	bacteriospermia	O
2	and	O
3	fertility	O

0	This	O
1	suggests	O
2	that	O
3	mechanisms	O
4	other	O
5	than	O
6	an	O
7	excessive	O
8	increase	O
9	in	O
10	myocardial	O
11	oxygen	O
12	demand	O
13	may	O
14	be	O
15	responsible	O
16	for	O
17	the	O
18	many	O
19	episodes	O
20	occurring	O
21	outside	O
22	the	O
23	hospital	O
24	.	O

0	Deaths	O
1	stopped	O
2	11	O
3	hours	O
4	after	O
5	copper	O
6	concentrations	O
7	decreased	O
8	below	O
9	0	O
10	.	O
11	2	O
12	ppm	O
13	and	O
14	signs	O
15	of	O
16	distress	O
17	stopped	O
18	in	O
19	surviving	O
20	pinfish	O
21	by	O
22	approximately	O
23	6	O
24	hours	O
25	after	O
26	the	O
27	last	O
28	death	O
29	.	O

0	The	O
1	pyrR	B
2	and	O
3	pyrP	B
4	genes	I
5	encoded	O
6	polypeptides	O
7	with	O
8	calculated	O
9	molecular	O
10	masses	O
11	of	O
12	19	O
13	.	O
14	9	O
15	and	O
16	45	O
17	.	O
18	2	O
19	kDa	O
20	,	O
21	respectively	O
22	.	O

0	Interleukin	B
1	-	I
2	12	I
3	(	O
4	IL	B
5	-	I
6	12	I
7	)	O
8	is	O
9	a	O
10	cytokine	O
11	produced	O
12	by	O
13	peripheral	O
14	blood	O
15	mononuclear	O
16	cells	O
17	(	O
18	PBMC	O
19	)	O
20	that	O
21	causes	O
22	interferon	B
23	-	I
24	gamma	I
25	(	O
26	IFN	B
27	-	I
28	gamma	I
29	)	O
30	production	O
31	and	O
32	enhancement	O
33	of	O
34	cell	O
35	-	O
36	mediated	O
37	cytotoxicity	O
38	.	O

0	When	O
1	introduced	O
2	into	O
3	recJ	B
4	+	O
5	strains	O
6	,	O
7	srjA	B
8	mutations	I
9	conferred	O
10	hyperrecombinational	O
11	and	O
12	hyper	O
13	-	O
14	UVr	O
15	phenotypes	O
16	.	O

0	Human	O
1	antitetanus	O
2	serum	O
3	:	O
4	an	O
5	unused	O
6	wealth	O

0	In	O
1	sixteen	O
2	patients	O
3	with	O
4	moderate	O
5	essential	O
6	hypertension	O
7	the	O
8	effects	O
9	of	O
10	10	O
11	-	O
12	day	O
13	nifedipine	O
14	treatment	O
15	on	O
16	serum	O
17	uric	O
18	acid	O
19	and	O
20	renal	O
21	excretion	O
22	of	O
23	uric	O
24	acid	O
25	were	O
26	evaluated	O
27	.	O

0	The	O
1	mRNAs	O
2	of	O
3	these	O
4	genes	O
5	contain	O
6	respectively	O
7	one	O
8	(	O
9	YAP1	B
10	uORF	O
11	)	O
12	and	O
13	two	O
14	(	O
15	YAP2	B
16	uORF1	I
17	and	O
18	uORF2	B
19	)	O
20	upstream	O
21	open	O
22	reading	O
23	frames	O
24	.	O
25	uORF	B
26	-	O
27	mediated	O
28	modulation	O
29	of	O
30	post	O
31	-	O
32	termination	O
33	events	O
34	on	O
35	the	O
36	5	O
37	'-	O
38	untranslated	O
39	region	O
40	(	O
41	5	O
42	'-	O
43	UTR	O
44	)	O
45	directs	O
46	differential	O
47	control	O
48	not	O
49	only	O
50	of	O
51	translation	O
52	but	O
53	also	O
54	of	O
55	mRNA	O
56	decay	O
57	.	O

0	In	O
1	11	O
2	patients	O
3	with	O
4	Horton	O
5	'	O
6	s	O
7	headache	O
8	morphological	O
9	investigations	O
10	(	O
11	differential	O
12	white	O
13	blood	O
14	cell	O
15	count	O
16	),	O
17	cytoenzymatic	O
18	determinations	O
19	(	O
20	alkaline	B
21	and	I
22	acid	I
23	phosphatase	I
24	,	O
25	non	B
26	-	I
27	specific	I
28	esterase	I
29	)	O
30	and	O
31	cytoimmunological	O
32	tests	O
33	(	O
34	IgM	B
35	and	O
36	IgG	B
37	binding	O
38	)	O
39	were	O
40	carried	O
41	out	O
42	on	O
43	capillary	O
44	blood	O
45	neutrophils	O
46	obtained	O
47	from	O
48	the	O
49	area	O
50	of	O
51	pain	O
52	,	O
53	non	O
54	-	O
55	painful	O
56	area	O
57	of	O
58	the	O
59	skin	O
60	on	O
61	the	O
62	head	O
63	on	O
64	the	O
65	contralateral	O
66	side	O
67	,	O
68	and	O
69	from	O
70	the	O
71	finger	O
72	.	O

0	They	O
1	also	O
2	negatively	O
3	modulate	O
4	the	O
5	PI	B
6	3	I
7	-	I
8	kinase	I
9	catalytic	O
10	activity	O
11	but	O
12	to	O
13	different	O
14	extents	O
15	,	O
16	dependent	O
17	on	O
18	the	O
19	unique	O
20	N	O
21	-	O
22	terminal	O
23	structure	O
24	of	O
25	each	O
26	isoform	O
27	.	O

0	Our	O
1	results	O
2	concluded	O
3	that	O
4	1	O
5	)	O
6	the	O
7	two	O
8	inhibin	B
9	/	O
10	activin	B
11	beta	I
12	B	I
13	-	I
14	subunit	I
15	mRNAs	I
16	were	O
17	transcribed	O
18	from	O
19	different	O
20	initiation	O
21	sites	O
22	;	O
23	2	O
24	)	O
25	both	O
26	promoters	O
27	may	O
28	be	O
29	controlled	O
30	by	O
31	up	O
32	-	O
33	stream	O
34	negative	O
35	regulatory	O
36	elements	O
37	;	O
38	and	O
39	3	O
40	)	O
41	neither	O
42	of	O
43	these	O
44	promoters	O
45	is	O
46	responsive	O
47	to	O
48	cAMP	O
49	and	O
50	/	O
51	or	O
52	phorbol	O
53	esters	O
54	under	O
55	the	O
56	conditions	O
57	employed	O
58	.	O

0	Protein	O
1	splicing	O
2	:	O
3	evidence	O
4	for	O
5	an	O
6	N	O
7	-	O
8	O	O
9	acyl	O
10	rearrangement	O
11	as	O
12	the	O
13	initial	O
14	step	O
15	in	O
16	the	O
17	splicing	O
18	process	O
19	.	O

0	This	O
1	report	O
2	describes	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	gene	O
8	of	O
9	related	O
10	function	O
11	,	O
12	SMD1	B
13	,	O
14	located	O
15	immediately	O
16	3	O
17	'	O
18	to	O
19	PRP38	B
20	.	O

0	The	O
1	PAC	B
2	clone	O
3	with	O
4	an	O
5	insert	O
6	size	O
7	of	O
8	120kb	O
9	was	O
10	isolated	O
11	and	O
12	mapped	O
13	by	O
14	restriction	O
15	analysis	O
16	.	O

0	Lysine	B
1	-	I
2	ketoglutarate	I
3	reductase	I
4	and	O
5	saccharopine	B
6	dehydrogenase	I
7	from	I
8	Arabidopsis	I
9	thaliana	I
10	:	O
11	nucleotide	O
12	sequence	O
13	and	O
14	characterization	O
15	.	O

0	The	O
1	5	O
2	'	O
3	end	O
4	of	O
5	the	O
6	coding	O
7	region	O
8	was	O
9	located	O
10	precisely	O
11	by	O
12	comparing	O
13	the	O
14	deduced	O
15	amino	O
16	acid	O
17	sequence	O
18	to	O
19	the	O
20	actual	O
21	N	O
22	-	O
23	terminal	O
24	amino	O
25	acid	O
26	sequence	O
27	of	O
28	IHF	B
29	.	O

0	A	O
1	cause	O
2	of	O
3	increase	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	in	O
8	children	O

0	Twelve	O
1	genomic	O
2	fragments	O
3	containing	O
4	novel	O
5	response	O
6	elements	O
7	are	O
8	described	O
9	,	O
10	and	O
11	the	O
12	transcription	O
13	unit	O
14	associated	O
15	with	O
16	one	O
17	of	O
18	them	O
19	,	O
20	NN	B
21	-	I
22	84AG	I
23	,	O
24	was	O
25	characterized	O
26	in	O
27	detail	O
28	.	O

0	Cloning	O
1	by	O
2	complementation	O
3	and	O
4	subsequent	O
5	physical	O
6	and	O
7	genetic	O
8	analysis	O
9	revealed	O
10	that	O
11	it	O
12	maps	O
13	to	O
14	RAF1	B
15	.	O

0	Location	O
1	and	O
2	orientation	O
3	of	O
4	an	O
5	activating	O
6	region	O
7	in	O
8	the	O
9	Escherichia	B
10	coli	I
11	transcription	I
12	factor	I
13	,	O
14	FNR	B
15	.	O

0	The	O
1	sequences	O
2	following	O
3	the	O
4	X	O
5	.	O
6	borealis	O
7	oocyte	O
8	and	O
9	somatic	B
10	5S	I
11	genes	I
12	are	O
13	identical	O
14	in	O
15	12	O
16	of	O
17	the	O
18	first	O
19	14	O
20	residues	O
21	and	O
22	contain	O
23	two	O
24	or	O
25	more	O
26	T	O
27	clusters	O
28	,	O
29	as	O
30	does	O
31	the	O
32	corresponding	O
33	region	O
34	of	O
35	X	O
36	.	O
37	laevis	O
38	oocyte	I
39	5S	I
40	DNA	O
41	.	O

0	These	O
1	data	O
2	strongly	O
3	implicate	O
4	the	O
5	normal	O
6	product	O
7	of	O
8	the	O
9	int	B
10	-	I
11	2	I
12	gene	I
13	,	O
14	which	O
15	is	O
16	related	O
17	to	O
18	the	O
19	fibroblast	B
20	growth	I
21	factor	I
22	family	I
23	,	O
24	as	O
25	a	O
26	contributory	O
27	factor	O
28	in	O
29	virally	O
30	induced	O
31	mammary	O
32	tumors	O
33	.	O

0	The	O
1	MCA	O
2	and	O
3	UA	O
4	PI	O
5	values	O
6	showed	O
7	the	O
8	greatest	O
9	deviation	O
10	for	O
11	any	O
12	single	O
13	-	O
14	vessel	O
15	parameter	O
16	.	O

0	Ste18p	B
1	was	O
2	targeted	O
3	to	O
4	the	O
5	plasma	O
6	membrane	O
7	even	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	prenylation	O
13	or	O
14	thioacylation	O
15	.	O

0	Regarding	O
1	"	O
2	the	O
3	relation	O
4	between	O
5	sexual	O
6	orientation	O
7	and	O
8	penile	O
9	size	O
10	,"	O
11	by	O
12	A	O
13	.	O

0	The	O
1	potency	O
2	of	O
3	the	O
4	effect	O
5	of	O
6	Nim	O
7	(	O
8	0	O
9	.	O
10	5	O
11	mg	O
12	.	O
13	kg	O
14	-	O
15	1	O
16	i	O
17	.	O
18	p	O
19	.)	O
20	was	O
21	similar	O
22	to	O
23	that	O
24	of	O
25	NBP	O
26	(	O
27	10	O
28	mg	O
29	.	O
30	kg	O
31	-	O
32	1	O
33	i	O
34	.	O
35	p	O
36	.).	O

0	Abundant	O
1	infiltration	O
2	of	O
3	lymphocytes	O
4	and	O
5	plasma	O
6	cells	O
7	was	O
8	also	O
9	wide	O
10	-	O
11	spread	O
12	beneath	O
13	the	O
14	carcinoma	O
15	in	O
16	situ	O
17	,	O
18	together	O
19	with	O
20	the	O
21	lymphoid	O
22	follicles	O
23	.	O

0	Further	O
1	investigation	O
2	on	O
3	the	O
4	chemotactic	O
5	influence	O
6	of	O
7	thymic	B
8	hormone	I
9	on	O
10	lymphocytes	O

0	1	O
1	.	O

0	However	O
1	,	O
2	the	O
3	BCH	O
4	group	O
5	showed	O
6	inferior	O
7	gross	O
8	motor	O
9	performance	O
10	on	O
11	the	O
12	Bruininks	O
13	-	O
14	Oseretsky	O
15	Test	O
16	of	O
17	Motor	O
18	Proficiency	O
19	(	O
20	Bruininks	O
21	1978	O
22	).	O

0	PATIENTS	O
1	AND	O
2	METHODS	O
3	:	O
4	In	O
5	807	O
6	consecutive	O
7	patients	O
8	from	O
9	the	O
10	Chilean	O
11	National	O
12	Registry	O
13	of	O
14	Acute	O
15	Myocardial	O
16	Infarction	O
17	we	O
18	analyzed	O
19	the	O
20	resolution	O
21	of	O
22	chest	O
23	pain	O
24	and	O
25	ST	O
26	segment	O
27	elevation	O
28	over	O
29	50	O
30	%	O
31	within	O
32	the	O
33	first	O
34	90	O
35	min	O
36	,	O
37	abrupt	O
38	CK	O
39	rise	O
40	within	O
41	8	O
42	h	O
43	and	O
44	T	O
45	wave	O
46	inversion	O
47	in	O
48	infarct	O
49	related	O
50	EKG	O
51	leads	O
52	within	O
53	the	O
54	first	O
55	24	O
56	h	O
57	after	O
58	thrombolysis	O
59	.	O

0	However	O
1	,	O
2	it	O
3	is	O
4	not	O
5	known	O
6	whether	O
7	the	O
8	recently	O
9	identified	O
10	isoforms	O
11	Vav2	B
12	and	O
13	Vav3	B
14	,	O
15	which	O
16	are	O
17	broadly	O
18	expressed	O
19	,	O
20	can	O
21	couple	O
22	with	O
23	similar	O
24	classes	O
25	of	O
26	receptors	O
27	,	O
28	nor	O
29	is	O
30	it	O
31	known	O
32	whether	O
33	all	O
34	Vav	B
35	isoforms	I
36	possess	O
37	identical	O
38	functional	O
39	activities	O
40	.	O

0	The	O
1	gene	O
2	encodes	O
3	an	O
4	ATP	O
5	-	O
6	binding	O
7	cassette	O
8	,	O
9	ABC	B
10	transporter	I
11	.	O

0	Furthermore	O
1	,	O
2	45Ca	O
3	-	O
4	binding	O
5	assays	O
6	revealed	O
7	that	O
8	CCaMK	B
9	directly	O
10	binds	O
11	Ca2	O
12	+.	O

0	Patients	O
1	with	O
2	lesions	O
3	affecting	O
4	the	O
5	PRC	O
6	but	O
7	sparing	O
8	the	O
9	PHC	O
10	,	O
11	and	O
12	patients	O
13	with	O
14	lesions	O
15	affecting	O
16	both	O
17	PRC	O
18	and	O
19	PHC	O
20	,	O
21	performed	O
22	an	O
23	oculomotor	O
24	delayed	O
25	response	O
26	task	O
27	with	O
28	unpredictably	O
29	varied	O
30	memory	O
31	delays	O
32	of	O
33	up	O
34	to	O
35	30	O
36	s	O
37	.	O

0	Thus	O
1	,	O
2	Fis	B
3	acts	O
4	as	O
5	an	O
6	accessory	O
7	transcriptional	O
8	activator	O
9	at	O
10	the	O
11	mar	B
12	promoter	I
13	.	O

0	One	O
1	cDNA	O
2	clone	O
3	designated	O
4	NCoA	B
5	-	I
6	62	I
7	,	O
8	encoded	O
9	a	O
10	62	O
11	,	O
12	000	O
13	-	O
14	Da	O
15	protein	O
16	that	O
17	is	O
18	highly	O
19	related	O
20	to	O
21	BX42	B
22	,	O
23	a	O
24	Drosophila	B
25	melanogaster	O
26	nuclear	O
27	protein	O
28	involved	O
29	in	O
30	ecdysone	O
31	-	O
32	stimulated	O
33	gene	O
34	expression	O
35	.	O

0	50	O
1	kDa	O
2	and	O
3	130	O
4	-	O
5	170	O
6	kDa	O
7	were	O
8	detected	O
9	.	O

0	The	O
1	ARG	B
2	SH2	I
3	domain	I
4	exhibited	O
5	relatively	O
6	weak	O
7	affinity	O
8	for	O
9	BCR	B
10	and	O
11	was	O
12	determined	O
13	to	O
14	bind	O
15	about	O
16	10	O
17	-	O
18	fold	O
19	less	O
20	strongly	O
21	than	O
22	the	O
23	ABL	B
24	SH2	I
25	domain	I
26	.	O

0	The	O
1	article	O
2	deals	O
3	with	O
4	the	O
5	diagnosing	O
6	and	O
7	correction	O
8	of	O
9	reversible	O
10	ischemia	O
11	of	O
12	the	O
13	intestine	O
14	.	O

0	Nutritional	O
1	cataracts	O
2	in	O
3	timber	O
4	wolves	O
5	.	O

0	Molecular	O
1	analysis	O
2	of	O
3	a	O
4	novel	O
5	schizosaccharomyces	O
6	pombe	O
7	gene	O
8	containing	O
9	two	O
10	RNP	B
11	consensus	I
12	-	I
13	sequence	I
14	RNA	I
15	-	I
16	binding	I
17	domains	I
18	.	O

0	Whole	O
1	blood	O
2	serotonin	O
3	levels	O
4	were	O
5	investigated	O
6	in	O
7	a	O
8	control	O
9	group	O
10	(	O
11	n	O
12	=	O
13	35	O
14	)	O
15	and	O
16	in	O
17	a	O
18	group	O
19	of	O
20	chronic	O
21	renal	O
22	failure	O
23	patients	O
24	(	O
25	n	O
26	=	O
27	127	O
28	)	O
29	on	O
30	various	O
31	treatment	O
32	regimen	O
33	i	O
34	.	O
35	e	O
36	.	O
37	conservative	O
38	treatment	O
39	(	O
40	n	O
41	=	O
42	39	O
43	),	O
44	maintenance	O
45	haemodialysis	O
46	(	O
47	n	O
48	=	O
49	35	O
50	)	O
51	and	O
52	after	O
53	renal	O
54	transplantation	O
55	(	O
56	n	O
57	=	O
58	53	O
59	).	O

0	Sequence	O
1	analysis	O
2	of	O
3	a	O
4	6	O
5	.	O
6	3	O
7	-	O
8	kbp	O
9	genomic	O
10	EcoRI	O
11	-	O
12	fragment	O
13	of	O
14	Alcaligenes	O
15	eutrophus	O
16	,	O
17	which	O
18	was	O
19	recently	O
20	identified	O
21	by	O
22	using	O
23	a	O
24	dihydrolipoamide	B
25	dehydrogenase	I
26	-	O
27	specific	O
28	DNA	O
29	probe	O
30	(	O
31	A	O
32	.	O

0	PCR	O
1	-	O
2	derived	O
3	fragments	O
4	were	O
5	used	O
6	as	O
7	probes	O
8	for	O
9	the	O
10	isolation	O
11	of	O
12	the	O
13	U3	B
14	snRNA	I
15	genes	I
16	from	O
17	a	O
18	genomic	O
19	library	O
20	of	O
21	Arabidopsis	O
22	.	O

0	In	O
1	Saccharomyces	O
2	cerevisiae	O
3	the	O
4	cAMP	B
5	-	I
6	dependent	I
7	kinases	I
8	(	O
9	PKAs	B
10	)	O
11	promote	O
12	cytoplasmic	O
13	growth	O
14	and	O
15	modulate	O
16	the	O
17	growth	O
18	-	O
19	regulated	O
20	mechanism	O
21	triggering	O
22	the	O
23	begin	O
24	of	O
25	DNA	O
26	synthesis	O
27	.	O

0	He	O
1	visited	O
2	our	O
3	hospital	O
4	and	O
5	left	O
6	solitary	O
7	renal	O
8	cyst	O
9	was	O
10	suspected	O
11	.	O

0	Each	O
1	half	O
2	molecule	O
3	contains	O
4	four	O
5	disulfide	O
6	linkages	O
7	and	O
8	four	O
9	cis	O
10	peptides	O
11	.	O

0	Identification	O
1	of	O
2	Ste4	B
3	as	O
4	a	O
5	potential	O
6	regulator	O
7	of	O
8	Byr2	B
9	in	O
10	the	O
11	sexual	O
12	response	O
13	pathway	O
14	of	O
15	Schizosaccharomyces	O
16	pombe	O
17	.	O

0	S1	B
1	nuclease	I
2	analysis	O
3	of	O
4	RNA	O
5	from	O
6	chemically	O
7	induced	O
8	B95	O
9	-	O
10	8	O
11	cells	O
12	and	O
13	from	O
14	Vero	O
15	cells	O
16	cotransfected	O
17	with	O
18	NotI	B
19	repeat	O
20	promoter	O
21	-	O
22	CAT	O
23	and	O
24	Z	B
25	showed	O
26	that	O
27	Z	B
28	transactivation	O
29	increased	O
30	the	O
31	level	O
32	of	O
33	correctly	O
34	initiated	O
35	,	O
36	stable	O
37	RNA	O
38	transcripts	O
39	.	O

0	Abrogation	O
1	of	O
2	p53	B
3	function	O
4	by	O
5	E6	B
6	resulted	O
7	in	O
8	an	O
9	increase	O
10	in	O
11	the	O
12	spontaneous	O
13	mutation	O
14	frequencies	O
15	at	O
16	the	O
17	heterozygous	O
18	thymidine	B
19	kinase	I
20	(	O
21	TK	B
22	)	O
23	locus	O
24	but	O
25	not	O
26	at	O
27	the	O
28	hemizygous	O
29	hypoxanthine	B
30	phosphoribosyl	I
31	transferase	I
32	(	O
33	HPRT	B
34	)	O
35	locus	O
36	.	O

0	Intron	O
1	K1	O
2	cox1	I
3	.	I
4	2	I
5	is	O
6	not	O
7	found	O
8	in	O
9	S	O
10	.	O
11	cerevisiae	O
12	and	O
13	appears	O
14	at	O
15	an	O
16	unique	O
17	location	O
18	in	O
19	K	O
20	.	O
21	lactis	O
22	.	O

0	Clinical	O
1	aspects	O
2	of	O
3	early	O
4	increase	O
5	in	O
6	serum	B
7	gamma	B
8	-	I
9	glutamyl	I
10	transferase	I
11	in	O
12	cerebral	O
13	infarction	O
14	.	O

0	This	O
1	site	O
2	is	O
3	upstream	O
4	from	O
5	the	O
6	TATA	O
7	box	O
8	used	O
9	in	O
10	somatic	O
11	cells	O
12	.	O

0	Auditory	O
1	threshold	O
2	shifts	O
3	,	O
4	as	O
5	measured	O
6	by	O
7	the	O
8	auditory	O
9	evoked	O
10	brainstem	O
11	response	O
12	,	O
13	were	O
14	measured	O
15	at	O
16	2	O
17	,	O
18	4	O
19	,	O
20	8	O
21	,	O
22	12	O
23	,	O
24	16	O
25	,	O
26	20	O
27	and	O
28	24	O
29	kHz	O
30	.	O

0	Biol	O
1	.	O

0	After	O
1	nitric	O
2	oxide	O
3	inhalation	O
4	,	O
5	the	O
6	results	O
7	showed	O
8	moderate	O
9	increases	O
10	in	O
11	PaO2	O
12	and	O
13	SaO2	O
14	(	O
15	P	O
16	>	O
17	0	O
18	.	O
19	05	O
20	)	O
21	and	O
22	a	O
23	significant	O
24	decrease	O
25	in	O
26	Qs	O
27	/	O
28	Q	O
29	tau	O
30	ratio	O
31	(	O
32	P	O
33	<	O
34	0	O
35	.	O
36	01	O
37	).	O

0	Oleate	O
1	induced	O
2	steady	O
3	-	O
4	state	O
5	levels	O
6	of	O
7	M	B
8	-	I
9	CPT	I
10	I	I
11	mRNA	I
12	4	O
13	.	O
14	5	O
15	-	O
16	fold	O
17	.	O

0	A	O
1	newly	O
2	developed	O
3	broad	O
4	-	O
5	spectrum	O
6	fluoroquinolone	O
7	,	O
8	levofloxacin	O
9	(	O
10	LVFX	O
11	,	O
12	DR	O
13	-	O
14	3355	O
15	),	O
16	was	O
17	evaluated	O
18	in	O
19	vitro	O
20	and	O
21	in	O
22	vivo	O
23	in	O
24	comparison	O
25	with	O
26	ciprofloxacin	O
27	(	O
28	CPFX	O
29	),	O
30	ofloxacin	O
31	(	O
32	OFLX	O
33	)	O
34	and	O
35	norfloxacin	O
36	(	O
37	NFLX	O
38	).	O

0	Also	O
1	,	O
2	samples	O
3	of	O
4	serum	O
5	were	O
6	absorbed	O
7	with	O
8	the	O
9	various	O
10	solid	O
11	-	O
12	phase	O
13	allergens	O
14	and	O
15	the	O
16	reactivity	O
17	of	O
18	the	O
19	remaining	O
20	IgE	B
21	antibodies	I
22	was	O
23	determined	O
24	.	O

0	We	O
1	describe	O
2	a	O
3	case	O
4	of	O
5	a	O
6	perinephric	O
7	abscess	O
8	treated	O
9	with	O
10	amphotericin	O
11	B	O
12	and	O
13	nephrectomy	O
14	.	O

0	Thus	O
1	,	O
2	SPECT	O
3	was	O
4	not	O
5	as	O
6	sensitive	O
7	as	O
8	PET	O
9	in	O
10	this	O
11	activation	O
12	task	O
13	.	O

0	The	O
1	inhibition	O
2	by	O
3	the	O
4	RIalpha	B
5	subunit	I
6	is	O
7	reversed	O
8	by	O
9	addition	O
10	of	O
11	nanomolar	O
12	concentrations	O
13	of	O
14	cAMP	O
15	(	O
16	Ka	O
17	=	O
18	40	O
19	nM	O
20	),	O
21	thus	O
22	demonstrating	O
23	that	O
24	PrKX	B
25	is	O
26	a	O
27	novel	O
28	,	O
29	type	B
30	I	I
31	cAMP	I
32	-	I
33	dependent	I
34	protein	I
35	kinase	I
36	that	O
37	is	O
38	activated	O
39	at	O
40	lower	O
41	cAMP	O
42	concentrations	O
43	than	O
44	the	O
45	holoenzyme	O
46	with	O
47	the	O
48	Calpha	B
49	subunit	I
50	of	O
51	cAMP	B
52	-	I
53	dependent	I
54	protein	I
55	kinase	I
56	.	O

0	The	O
1	induced	O
2	respiratory	O
3	burst	O
4	was	O
5	investigated	O
6	by	O
7	the	O
8	intracellular	O
9	oxidative	O
10	transformation	O
11	of	O
12	dihydrorhodamine	O
13	123	O
14	to	O
15	the	O
16	fluorescent	O
17	dye	O
18	rhodamine	O
19	123	O
20	via	O
21	flow	O
22	cytometry	O
23	.	O

0	The	O
1	c	B
2	-	I
3	Ets	I
4	-	I
5	1	I
6	oncoprotein	I
7	is	O
8	a	O
9	transcription	O
10	activator	O
11	that	O
12	specifically	O
13	binds	O
14	to	O
15	DNA	O
16	.	O

0	Senior	O
1	systems	O
2	--	O
3	45	O
4	;	O
5	Mental	O
6	health	O
7	and	O
8	illness	O
9	in	O
10	old	O
11	age	O
12	--	O
13	3	O
14	.	O

0	Regulation	O
1	at	O
2	37	O
3	degrees	O
4	C	O
5	,	O
6	therefore	O
7	,	O
8	involves	O
9	the	O
10	action	O
11	of	O
12	three	O
13	protein	O
14	kinase	O
15	cascades	O
16	that	O
17	repress	O
18	HSF1	B
19	through	O
20	phosphorylation	O
21	of	O
22	serine	O
23	residues	O
24	303	O
25	,	O
26	307	O
27	,	O
28	and	O
29	363	O
30	and	O
31	may	O
32	promote	O
33	growth	O
34	by	O
35	suppressing	O
36	the	O
37	heat	O
38	shock	O
39	response	O
40	.	O

0	Human	B
1	acid	I
2	ceramidase	I
3	((	I
4	AC	I
5	)	I
6	N	I
7	-	I
8	acylsphingosine	I
9	amidohydrolase	I
10	,	O
11	EC	B
12	3	I
13	.	I
14	5	I
15	.	O

0	The	O
1	construction	O
2	of	O
3	a	O
4	small	O
5	library	O
6	of	O
7	mouse	O
8	repetitive	O
9	DNA	O
10	has	O
11	been	O
12	previously	O
13	reported	O
14	(	O
15	Pietras	O
16	et	O
17	al	O
18	.,	O
19	Nucleic	B
20	Acids	O
21	Res	O
22	.	O

0	Interestingly	O
1	,	O
2	an	O
3	increase	O
4	of	O
5	distance	O
6	per	O
7	se	O
8	did	O
9	not	O
10	have	O
11	a	O
12	deleterious	O
13	effect	O
14	on	O
15	translation	O
16	efficiency	O
17	.	O

0	The	O
1	addition	O
2	of	O
3	an	O
4	equimolar	O
5	complex	O
6	of	O
7	the	O
8	fourth	O
9	and	O
10	seventh	O
11	largest	O
12	subunits	O
13	,	O
14	purified	O
15	from	O
16	pol	B
17	II	I
18	holoenzyme	I
19	by	O
20	ion	O
21	-	O
22	exchange	O
23	chromatography	O
24	in	O
25	the	O
26	presence	O
27	of	O
28	urea	O
29	,	O
30	restored	O
31	promoter	O
32	-	O
33	directed	O
34	initiation	O
35	activity	O
36	to	O
37	pol	B
38	II	I
39	delta	I
40	4	I
41	/	I
42	7	I
43	.	O

0	From	O
1	an	O
2	RNK	B
3	-	I
4	16	I
5	lambda	I
6	-	I
7	gt11	I
8	library	O
9	,	O
10	we	O
11	have	O
12	isolated	O
13	and	O
14	sequenced	O
15	a	O
16	novel	O
17	cDNA	O
18	rat	I
19	NK	I
20	cell	I
21	protease	I
22	1	I
23	(	O
24	RNKP	B
25	-	I
26	1	I
27	)	O
28	that	O
29	has	O
30	characteristics	O
31	unique	O
32	to	O
33	serine	B
34	proteases	I
35	.	O

0	Localization	O
1	of	O
2	the	O
3	intronless	O
4	gene	O
5	coding	O
6	for	O
7	calmodulin	B
8	-	I
9	like	I
10	protein	I
11	CLP	I
12	to	O
13	human	O
14	chromosome	O
15	10p13	O
16	-	O
17	ter	O
18	.	O

0	One	O
1	hundred	O
2	twenty	O
3	units	O
4	of	O
5	deglycerolized	O
6	red	O
7	blood	O
8	cells	O
9	,	O
10	some	O
11	with	O
12	glycerol	O
13	added	O
14	so	O
15	as	O
16	to	O
17	exceed	O
18	an	O
19	acceptable	O
20	1	O
21	%	O
22	glycerol	O
23	content	O
24	,	O
25	had	O
26	measurements	O
27	made	O
28	of	O
29	the	O
30	post	O
31	-	O
32	wash	O
33	supernatant	O
34	fluid	O
35	by	O
36	refractive	O
37	index	O
38	and	O
39	osmometry	O
40	.	O

0	When	O
1	pollen	O
2	allergen	O
3	from	O
4	three	O
5	grass	O
6	species	O
7	were	O
8	used	O
9	,	O
10	The	O
11	RAST	O
12	-	O
13	test	O
14	results	O
15	did	O
16	not	O
17	differ	O
18	from	O
19	duplicate	O
20	values	O
21	either	O
22	.	O

0	The	O
1	topography	O
2	and	O
3	trajectories	O
4	of	O
5	the	O
6	commissural	O
7	fibers	O
8	of	O
9	the	O
10	superior	O
11	temporal	O
12	region	O
13	(	O
14	STR	O
15	)	O
16	are	O
17	studied	O
18	using	O
19	the	O
20	autoradiographic	O
21	technique	O
22	.	O

0	However	O
1	,	O
2	we	O
3	did	O
4	detect	O
5	lot	O
6	-	O
7	to	O
8	-	O
9	lot	O
10	variation	O
11	and	O
12	differences	O
13	in	O
14	performance	O
15	between	O
16	narrow	O
17	bandpass	O
18	and	O
19	wide	O
20	bandpass	O
21	spectrophotometers	O
22	.	O

0	Induction	O
1	of	O
2	B	O
3	cell	O
4	apoptosis	O
5	by	O
6	co	O
7	-	O
8	cross	O
9	-	O
10	linking	O
11	CD23	B
12	and	O
13	sIg	B
14	involves	O
15	aberrant	O
16	regulation	O
17	of	O
18	c	B
19	-	I
20	myc	I
21	and	O
22	is	O
23	inhibited	O
24	by	O
25	bcl	B
26	-	I
27	2	I
28	.	O

0	CPAP	O
1	reduced	O
2	isotime	O
3	(	O
4	defined	O
5	as	O
6	the	O
7	last	O
8	common	O
9	minute	O
10	of	O
11	exercise	O
12	)	O
13	VO2	O
14	and	O
15	dyspnea	O
16	in	O
17	those	O
18	patients	O
19	with	O
20	more	O
21	severe	O
22	lung	O
23	disease	O
24	,	O
25	but	O
26	these	O
27	values	O
28	tended	O
29	to	O
30	increase	O
31	slightly	O
32	in	O
33	the	O
34	patients	O
35	with	O
36	only	O
37	mild	O
38	lung	O
39	disease	O
40	.	O

0	We	O
1	cloned	O
2	a	O
3	DNA	O
4	fragment	O
5	encoding	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	part	O
11	of	O
12	a	O
13	protein	O
14	with	O
15	significant	O
16	similarity	O
17	to	O
18	members	O
19	of	O
20	the	O
21	LysR	B
22	family	O
23	of	O
24	transcriptional	O
25	regulators	O
26	(	O
27	LTTRs	B
28	).	O

0	Once	O
1	HIT	O
2	II	O
3	is	O
4	suspected	O
5	,	O
6	heparin	O
7	(	O
8	and	O
9	low	O
10	-	O
11	molecular	O
12	-	O
13	weight	O
14	heparins	O
15	)	O
16	should	O
17	be	O
18	stopped	O
19	immediately	O
20	.	O

0	NiCl	B
1	(	I
2	2	I
3	)-	O
4	induced	O
5	MCP	B
6	-	I
7	1	I
8	synthesis	O
9	required	O
10	activation	O
11	of	O
12	NF	B
13	-	I
14	kappaB	I
15	since	O
16	mutation	O
17	of	O
18	NF	B
19	-	I
20	kappaB	I
21	-	I
22	binding	I
23	sites	I
24	in	O
25	the	O
26	promoter	O
27	resulted	O
28	in	O
29	complete	O
30	loss	O
31	of	O
32	inducible	O
33	promoter	O
34	activity	O
35	.	O

0	Our	O
1	results	O
2	indicate	O
3	that	O
4	interaction	O
5	between	O
6	Jak2	B
7	and	O
8	PRLR	B
9	requires	O
10	a	O
11	proline	O
12	-	O
13	rich	O
14	sequence	O
15	in	O
16	the	O
17	membrane	O
18	proximal	O
19	region	O
20	of	O
21	the	O
22	receptor	O
23	,	O
24	which	O
25	is	O
26	conserved	O
27	among	O
28	the	O
29	different	O
30	members	O
31	of	O
32	the	O
33	cytokine	B
34	receptor	I
35	superfamily	I
36	.	O

0	The	O
1	use	O
2	of	O
3	CRF	B
4	-	I
5	41	I
6	in	O
7	the	O
8	differential	O
9	diagnosis	O
10	of	O
11	Cushing	O
12	'	O
13	s	O
14	syndrome	O
15	and	O
16	obesity	O
17	.	O

0	The	O
1	inhibition	O
2	of	O
3	StAR	B
4	gene	I
5	transcription	O
6	by	O
7	DAX	B
8	-	I
9	1	I
10	was	O
11	dose	O
12	-	O
13	dependent	O
14	reducing	O
15	transcription	O
16	to	O
17	6	O
18	%	O
19	of	O
20	control	O
21	levels	O
22	.	O

0	For	O
1	higher	O
2	expression	O
3	of	O
4	lipA	B
5	in	O
6	S	O
7	.	O
8	lividans	O
9	,	O
10	the	O
11	gene	O
12	was	O
13	cloned	O
14	next	O
15	to	O
16	the	O
17	strong	O
18	aphII	B
19	promoter	I
20	.	O

0	Female	O
1	mice	O
2	were	O
3	significantly	O
4	more	O
5	resistant	O
6	to	O
7	infection	O
8	than	O
9	males	O
10	.	O

0	Picture	O
1	the	O
2	smell	O
3	.	O

0	We	O
1	describe	O
2	a	O
3	novel	O
4	zinc	B
5	finger	I
6	protein	I
7	,	O
8	dsRBP	B
9	-	O
10	ZFa	B
11	,	O
12	isolated	O
13	by	O
14	screening	O
15	an	O
16	expression	O
17	library	O
18	with	O
19	dsRNA	O
20	.	O

0	According	O
1	to	O
2	symptoms	O
3	,	O
4	signs	O
5	,	O
6	imaging	O
7	features	O
8	,	O
9	operation	O
10	findings	O
11	,	O
12	the	O
13	original	O
14	places	O
15	and	O
16	the	O
17	expansive	O
18	directions	O
19	of	O
20	the	O
21	tumor	O
22	,	O
23	they	O
24	were	O
25	divided	O
26	into	O
27	four	O
28	clinical	O
29	types	O
30	:	O
31	sellar	O
32	,	O
33	clival	O
34	,	O
35	occipito	O
36	-	O
37	temporal	O
38	and	O
39	extent	O
40	.	O

0	The	O
1	mutation	O
2	within	O
3	the	O
4	asgB480	B
5	allele	I
6	was	O
7	identified	O
8	as	O
9	an	O
10	A	O
11	-	O
12	to	O
13	-	O
14	G	O
15	transition	O
16	that	O
17	results	O
18	in	O
19	a	O
20	threonine	O
21	-	O
22	to	O
23	-	O
24	alanine	O
25	substitution	O
26	in	O
27	the	O
28	predicted	O
29	protein	O
30	product	O
31	.	O

0	TB	O
1	bone	O
2	area	O
3	(	O
4	p	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	height	O
11	(	O
12	p	O
13	<	O
14	0	O
15	.	O
16	01	O
17	),	O
18	years	O
19	in	O
20	present	O
21	colony	O
22	(	O
23	p	O
24	=	O
25	0	O
26	.	O
27	03	O
28	),	O
29	and	O
30	menses	O
31	(	O
32	p	O
33	<	O
34	0	O
35	.	O
36	01	O
37	)	O
38	predicted	O
39	TB	O
40	BMC	O
41	.	O

0	Polysorbate	O
1	80	O
2	did	O
3	not	O
4	have	O
5	a	O
6	direct	O
7	stimulant	O
8	or	O
9	relaxant	O
10	effect	O
11	on	O
12	either	O
13	guinea	O
14	pig	O
15	ileum	O
16	or	O
17	rat	O
18	uterus	O
19	,	O
20	however	O
21	,	O
22	it	O
23	antagonised	O
24	the	O
25	contractions	O
26	induced	O
27	by	O
28	acetylcholine	O
29	,	O
30	histamine	O
31	,	O
32	barium	O
33	,	O
34	5	O
35	-	O
36	hydroxytryptamine	O
37	and	O
38	carbachol	O
39	in	O
40	a	O
41	dose	O
42	-	O
43	dependent	O
44	manner	O
45	.	O

0	The	O
1	frequency	O
2	of	O
3	lactase	B
4	phenotypes	O
5	in	O
6	Aymara	O
7	children	O
8	.	O

0	To	O
1	identify	O
2	these	O
3	sites	O
4	,	O
5	Cdk2	B
6	-	O
7	phosphorylated	O
8	MARCKS	B
9	was	O
10	digested	O
11	with	O
12	lysyl	B
13	endoprotease	I
14	and	O
15	analysed	O
16	by	O
17	electrospray	O
18	MS	O
19	.	O

0	Among	O
1	mucus	O
2	-	O
3	secreting	O
4	cells	O
5	,	O
6	the	O
7	gastric	O
8	gland	O
9	mucous	O
10	cells	O
11	,	O
12	Brunner	O
13	'	O
14	s	O
15	glands	O
16	,	O
17	accessory	O
18	glands	O
19	of	O
20	pancreaticobiliary	O
21	tract	O
22	,	O
23	and	O
24	pancreatic	O
25	ducts	O
26	exhibiting	O
27	gastric	O
28	metaplasia	O
29	are	O
30	unique	O
31	in	O
32	that	O
33	they	O
34	express	O
35	class	O
36	III	O
37	mucin	B
38	identified	O
39	by	O
40	paradoxical	O
41	Con	O
42	A	O
43	staining	O
44	composed	O
45	of	O
46	periodate	O
47	oxidation	O
48	,	O
49	sodium	O
50	borohydride	O
51	reduction	O
52	,	O
53	Con	O
54	A	O
55	,	O
56	and	O
57	horseradish	B
58	peroxidase	I
59	reaction	O
60	.	O

0	According	O
1	to	O
2	the	O
3	biochemical	O
4	tests	O
5	,	O
6	high	O
7	activity	O
8	(	O
9	over	O
10	200	O
11	U	O
12	/	O
13	l	O
14	)	O
15	of	O
16	alkaline	B
17	phosphatase	I
18	was	O
19	recorded	O
20	exclusively	O
21	in	O
22	patients	O
23	with	O
24	the	O
25	lymphogranulomatosis	O
26	-	O
27	induced	O
28	liver	O
29	damage	O
30	.	O

0	XYL1	B
1	was	O
2	isolated	O
3	as	O
4	a	O
5	highly	O
6	expressed	O
7	fusion	O
8	clone	O
9	from	O
10	a	O
11	'	O
12	lacZ	O
13	translational	O
14	fusion	O
15	library	O
16	.	O

0	None	O
1	had	O
2	a	O
3	past	O
4	history	O
5	of	O
6	opportunistic	O
7	infections	O
8	;	O
9	neither	O
10	did	O
11	any	O
12	have	O
13	lymphopenia	O
14	.	O

0	General	O
1	formulae	O
2	for	O
3	estimating	O
4	heritability	O
5	in	O
6	a	O
7	population	O
8	with	O
9	related	O
10	parents	O
11	.	O

0	These	O
1	data	O
2	indicate	O
3	that	O
4	although	O
5	218leu	B
6	retains	O
7	normal	O
8	transactivation	O
9	activity	O
10	on	O
11	a	O
12	p53	B
13	promoter	I
14	in	O
15	yeast	O
16	at	O
17	physiological	O
18	temperatures	O
19	,	O
20	it	O
21	is	O
22	not	O
23	capable	O
24	of	O
25	normal	O
26	p53	B
27	function	O
28	in	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	248trp	B
34	allele	I
35	in	O
36	SNU	B
37	-	I
38	C5	I
39	cells	O
40	.	O

0	We	O
1	examined	O
2	the	O
3	hypothesis	O
4	that	O
5	the	O
6	coronary	O
7	vasomotor	O
8	responses	O
9	to	O
10	etomidate	O
11	(	O
12	ETO	O
13	),	O
14	propofol	O
15	(	O
16	PRO	O
17	),	O
18	and	O
19	sodium	O
20	thiopental	O
21	(	O
22	STP	O
23	)	O
24	are	O
25	mediated	O
26	through	O
27	contrasting	O
28	effects	O
29	on	O
30	the	O
31	resting	O
32	nitric	O
33	oxide	O
34	(	O
35	NO	O
36	)-	O
37	dependent	O
38	vasodilator	O
39	tone	O
40	that	O
41	opposes	O
42	adrenergic	O
43	vasoconstrictor	O
44	activity	O
45	in	O
46	the	O
47	intact	O
48	dog	O
49	.	O

0	Antiviral	O
1	agents	O
2	.	O

0	Elimination	O
1	of	O
2	ETH1	B
3	in	O
4	apn1	B
5	strains	O
6	also	O
7	increased	O
8	spontaneous	O
9	mutation	O
10	rates	O
11	9	O
12	-	O
13	or	O
14	31	O
15	-	O
16	fold	O
17	compared	O
18	to	O
19	the	O
20	wild	O
21	type	O
22	as	O
23	determined	O
24	by	O
25	reversion	O
26	to	O
27	adenine	O
28	or	O
29	lysine	O
30	prototrophy	O
31	,	O
32	respectively	O
33	.	O

0	We	O
1	reviewed	O
2	the	O
3	records	O
4	of	O
5	151	O
6	patients	O
7	with	O
8	optic	O
9	neuritis	O
10	examined	O
11	over	O
12	an	O
13	eight	O
14	-	O
15	year	O
16	period	O
17	.	O

0	The	O
1	disease	O
2	ran	O
3	an	O
4	atypical	O
5	course	O
6	;	O
7	with	O
8	early	O
9	jaundice	O
10	syndrome	O
11	,	O
12	severe	O
13	enterorrhagia	O
14	and	O
15	late	O
16	appearance	O
17	of	O
18	roseola	O
19	.	O

0	BACKGROUND	O
1	:	O
2	Studies	O
3	in	O
4	lean	O
5	men	O
6	show	O
7	poor	O
8	regulation	O
9	of	O
10	energy	O
11	(	O
12	EB	O
13	)	O
14	and	O
15	fat	O
16	balance	O
17	(	O
18	FB	O
19	)	O
20	during	O
21	manipulation	O
22	of	O
23	dietary	O
24	ratios	O
25	of	O
26	fat	O
27	to	O
28	carbohydrate	O
29	.	O

0	Amisulpride	O
1	400	O
2	mg	O
3	had	O
4	several	O
5	adverse	O
6	effects	O
7	on	O
8	psychomotor	O
9	and	O
10	,	O
11	although	O
12	less	O
13	severe	O
14	,	O
15	on	O
16	cognitive	O
17	performance	O
18	on	O
19	the	O
20	fifth	O
21	day	O
22	only	O
23	.	O

0	Surprisingly	O
1	,	O
2	TFIIIC	B
3	alpha	I
4	has	O
5	no	O
6	homology	O
7	to	O
8	any	O
9	of	O
10	the	O
11	yeast	B
12	TFIIIC	I
13	subunits	I
14	already	O
15	cloned	O
16	,	O
17	suggesting	O
18	a	O
19	significant	O
20	degree	O
21	of	O
22	evolutionary	O
23	divergence	O
24	for	O
25	RNA	B
26	polymerase	I
27	III	I
28	factors	I
29	.	O

0	Dissolution	O
1	of	O
2	the	O
3	Pt	O
4	-	O
5	30	O
6	%	O
7	Ir	O
8	microelectrode	O
9	tip	O
10	was	O
11	observed	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	at	O
17	charge	O
18	densities	O
19	as	O
20	low	O
21	as	O
22	200	O
23	microC	O
24	/	O
25	cm2	O
26	X	O
27	ph	O
28	(	O
29	1	O
30	A	O
31	/	O
32	cm2	O
33	),	O
34	whereas	O
35	erosion	O
36	of	O
37	activated	O
38	iridium	O
39	microelectrodes	O
40	occurred	O
41	only	O
42	at	O
43	the	O
44	highest	O
45	charge	O
46	and	O
47	current	O
48	densities	O
49	(	O
50	3200	O
51	microC	O
52	/	O
53	cm2	O
54	X	O
55	ph	O
56	,	O
57	16	O
58	A	O
59	/	O
60	cm2	O
61	).	O

0	Crohn	O
1	'	O
2	s	O
3	disease	O
4	in	O
5	prolonged	O
6	remission	O
7	:	O
8	should	O
9	one	O
10	augment	O
11	protein	O
12	-	O
13	calorie	O
14	intake	O
15	as	O
16	compared	O
17	to	O
18	healthy	O
19	subjects	O
20	?]	O
21	The	O
22	aim	O
23	of	O
24	our	O
25	two	O
26	year	O
27	prospective	O
28	study	O
29	was	O
30	to	O
31	evaluate	O
32	whether	O
33	adult	O
34	Crohn	O
35	'	O
36	s	O
37	disease	O
38	patients	O
39	in	O
40	prolonged	O
41	remission	O
42	(	O
43	CDAI	O
44	<	O
45	150	O
46	),	O
47	in	O
48	order	O
49	to	O
50	maintain	O
51	their	O
52	body	O
53	weight	O
54	as	O
55	close	O
56	as	O
57	possible	O
58	to	O
59	the	O
60	ideal	O
61	one	O
62	,	O
63	need	O
64	a	O
65	protein	O
66	-	O
67	calorie	O
68	intake	O
69	higher	O
70	than	O
71	the	O
72	predicted	O
73	one	O
74	and	O
75	that	O
76	of	O
77	healthy	O
78	controls	O
79	.	O

0	These	O
1	results	O
2	are	O
3	consistent	O
4	with	O
5	the	O
6	well	O
7	established	O
8	polarity	O
9	of	O
10	RXR	B
11	heterodimer	I
12	binding	O
13	to	O
14	bipartite	O
15	hormone	O
16	response	O
17	elements	O
18	,	O
19	with	O
20	the	O
21	VDR	O
22	recognizing	O
23	the	O
24	3	O
25	'-	O
26	half	O
27	-	O
28	element	O
29	.	O

0	However	O
1	,	O
2	the	O
3	inability	O
4	to	O
5	export	O
6	RNA	O
7	from	O
8	the	O
9	nucleus	O
10	to	O
11	the	O
12	cytoplasm	O
13	was	O
14	not	O
15	limited	O
16	to	O
17	a	O
18	particular	O
19	phase	O
20	of	O
21	the	O
22	cell	O
23	division	O
24	cycle	O
25	.	O

0	Polypeptide	B
1	growth	I
2	factors	I
3	and	O
4	cytokines	O
5	mediate	O
6	their	O
7	biochemical	O
8	functions	O
9	through	O
10	their	O
11	responsive	O
12	receptors	O
13	.	O

0	Interspecific	O
1	mouse	O
2	back	O
3	-	O
4	cross	O
5	analysis	O
6	identified	O
7	the	O
8	loci	O
9	for	O
10	mouse	B
11	3Ost	I
12	genes	I
13	and	O
14	syntenic	O
15	assignments	O
16	of	O
17	corresponding	O
18	human	O
19	isologs	O
20	were	O
21	confirmed	O
22	by	O
23	the	O
24	identification	O
25	of	O
26	mapped	O
27	sequence	O
28	-	O
29	tagged	O
30	site	O
31	markers	O
32	.	O

0	Thus	O
1	,	O
2	blocks	O
3	in	O
4	the	O
5	RARalpha	O
6	-	O
7	specific	O
8	pathway	O
9	of	O
10	retinoid	O
11	-	O
12	induced	O
13	differentiation	O
14	may	O
15	be	O
16	bypassed	O
17	during	O
18	retinoid	O
19	induction	O
20	of	O
21	FR	B
22	-	I
23	beta	I
24	expression	O
25	.	O

0	Kinetics	O
1	of	O
2	the	O
3	inhibition	O
4	indicated	O
5	that	O
6	this	O
7	polymerase	O
8	domain	O
9	can	O
10	inhibit	O
11	viral	O
12	replication	O
13	only	O
14	during	O
15	the	O
16	preinitiation	O
17	stage	O
18	.	O

0	An	O
1	intact	O
2	neurovascular	O
3	supply	O
4	is	O
5	essential	O
6	for	O
7	the	O
8	viability	O
9	of	O
10	a	O
11	muscle	O
12	flap	O
13	.	O

0	The	O
1	rat	O
2	incisor	O
3	is	O
4	an	O
5	excellent	O
6	model	O
7	system	O
8	in	O
9	which	O
10	to	O
11	study	O
12	amelgenesis	O
13	.	O

0	Use	O
1	of	O
2	Selenastrum	O
3	capricornutum	O
4	and	O
5	Microfeast	O
6	as	O
7	food	O
8	for	O
9	Daphnia	O
10	pulex	O
11	.	O

0	The	O
1	combination	O
2	of	O
3	Pitx2	B
4	and	O
5	another	O
6	homeodomain	B
7	protein	I
8	,	O
9	Pit	B
10	-	I
11	1	I
12	,	O
13	yielded	O
14	a	O
15	synergistic	O
16	55	O
17	-	O
18	fold	O
19	activation	O
20	of	O
21	the	O
22	prolactin	B
23	promoter	I
24	in	O
25	transfection	O
26	assays	O
27	.	O

0	Respiratory	O
1	chain	O
2	enzyme	O
3	activity	O
4	was	O
5	normal	O
6	.	O

0	Northern	O
1	blotting	O
2	analysis	O
3	indicates	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	genes	O
9	corresponding	O
10	to	O
11	these	O
12	clones	O
13	is	O
14	confined	O
15	to	O
16	pollen	O
17	tissue	O
18	.	O

0	If	O
1	NCR	O
2	-	O
3	sensitive	O
4	gene	O
5	expression	O
6	occurs	O
7	exclusively	O
8	by	O
9	this	O
10	pathway	O
11	,	O
12	as	O
13	has	O
14	been	O
15	thought	O
16	to	O
17	be	O
18	the	O
19	case	O
20	,	O
21	then	O
22	the	O
23	NCR	O
24	sensitivity	O
25	of	O
26	a	O
27	gene	O
28	'	O
29	s	O
30	expression	O
31	should	O
32	be	O
33	abolished	O
34	by	O
35	a	O
36	ure2	B
37	delta	I
38	mutation	I
39	.	O

0	The	O
1	predicted	O
2	domain	O
3	structures	O
4	of	O
5	FkbB	B
6	and	O
7	FkbC	B
8	are	O
9	analogous	O
10	to	O
11	that	O
12	of	O
13	FkbA	B
14	and	O
15	comprise	O
16	30	O
17	fatty	B
18	-	I
19	acid	I
20	-	I
21	synthase	I
22	(	O
23	FAS	B
24	)-	O
25	like	O
26	domains	O
27	arranged	O
28	in	O
29	6	O
30	modules	O
31	.	O

0	However	O
1	,	O
2	the	O
3	signaling	O
4	cascade	O
5	utilized	O
6	by	O
7	the	O
8	urokinase	B
9	receptor	I
10	is	O
11	only	O
12	incompletely	O
13	understood	O
14	.	O

0	Pathogenetic	O
1	relationships	O
2	between	O
3	renal	O
4	tubular	O
5	acidosis	O
6	and	O
7	sodium	O
8	metabolism	O
9	alterations	O
10	in	O
11	liver	O
12	cirrhosis	O
13	.	O

0	Fifty	O
1	-	O
2	seven	O
3	patients	O
4	aged	O
5	<	O
6	55	O
7	years	O
8	with	O
9	acute	O
10	lymphoblastic	O
11	leukemia	O
12	(	O
13	ALL	O
14	)	O
15	in	O
16	second	O
17	or	O
18	third	O
19	bone	O
20	marrow	O
21	(	O
22	BM	O
23	)	O
24	relapse	O
25	or	O
26	refractory	O
27	to	O
28	first	O
29	-	O
30	line	O
31	therapy	O
32	were	O
33	enrolled	O
34	in	O
35	an	O
36	Italian	O
37	cooperative	O
38	study	O
39	.	O

0	Results	O
1	demonstrated	O
2	that	O
3	the	O
4	presence	O
5	of	O
6	myofibroblasts	O
7	varied	O
8	considerably	O
9	from	O
10	case	O
11	to	O
12	case	O
13	and	O
14	was	O
15	always	O
16	related	O
17	to	O
18	smooth	O
19	muscle	O
20	cell	O
21	dispersion	O
22	,	O
23	which	O
24	occurred	O
25	around	O
26	medium	O
27	-	O
28	sized	O
29	damaged	O
30	portal	O
31	vein	O
32	branches	O
33	.	O

0	The	O
1	paramyxovirus	B
2	fusion	I
3	(	I
4	F	I
5	)	O
6	protein	O
7	mediates	O
8	membrane	O
9	fusion	O
10	.	O

0	A	O
1	32P	O
2	-	O
3	labeled	O
4	LAP	O
5	DNA	O
6	-	O
7	binding	O
8	and	O
9	dimerization	O
10	domain	O
11	"	O
12	zipper	O
13	probe	O
14	"	O
15	was	O
16	used	O
17	to	O
18	isolate	O
19	a	O
20	clone	O
21	that	O
22	encodes	O
23	a	O
24	new	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	homologous	I
30	protein	I
31	:	O
32	CHOP	B
33	-	I
34	10	I
35	.	O

0	A	O
1	lambda	O
2	gt10	O
3	cDNA	O
4	library	O
5	was	O
6	constructed	O
7	from	O
8	poly	O
9	(	O
10	A	O
11	)+	O
12	RNA	O
13	of	O
14	young	O
15	green	O
16	leaves	O
17	of	O
18	spinach	O
19	.	O

0	These	O
1	results	O
2	demonstrate	O
3	a	O
4	specific	O
5	association	O
6	of	O
7	SIV	O
8	and	O
9	HIV	O
10	-	O
11	2	O
12	nef	O
13	,	O
14	but	O
15	not	O
16	HIV	O
17	-	O
18	1	O
19	nef	O
20	,	O
21	with	O
22	TCRzeta	O
23	.	O

0	Evidence	O
1	for	O
2	such	O
3	peak	O
4	shifts	O
5	has	O
6	been	O
7	found	O
8	in	O
9	the	O
10	responses	O
11	of	O
12	auditory	O
13	nerve	O
14	fibers	O
15	,	O
16	cochlear	O
17	microphonics	O
18	,	O
19	and	O
20	the	O
21	responses	O
22	of	O
23	outer	O
24	hair	O
25	cells	O
26	and	O
27	supporting	O
28	cells	O
29	in	O
30	the	O
31	cochlea	O
32	,	O
33	as	O
34	well	O
35	as	O
36	in	O
37	basilar	O
38	membrane	O
39	vibration	O
40	measurements	O
41	,	O
42	and	O
43	indirectly	O
44	,	O
45	in	O
46	psychophysical	O
47	data	O
48	.	O

0	We	O
1	have	O
2	determined	O
3	the	O
4	molecular	O
5	lesions	O
6	of	O
7	nine	O
8	Scm	B
9	mutant	I
10	alleles	I
11	,	O
12	which	O
13	identify	O
14	functional	O
15	requirements	O
16	for	O
17	specific	O
18	domains	O
19	.	O

0	In	O
1	controls	O
2	,	O
3	only	O
4	modest	O
5	differences	O
6	were	O
7	observed	O
8	.	O

0	To	O
1	our	O
2	knowledge	O
3	,	O
4	type	O
5	IV	O
6	renal	O
7	tubular	O
8	acidosis	O
9	has	O
10	not	O
11	been	O
12	reported	O
13	previously	O
14	in	O
15	association	O
16	with	O
17	Alport	O
18	'	O
19	s	O
20	syndrome	O
21	in	O
22	an	O
23	adult	O
24	patient	O
25	.	O

0	Five	O
1	patients	O
2	developed	O
3	metastatic	O
4	spread	O
5	,	O
6	and	O
7	all	O
8	of	O
9	them	O
10	died	O
11	of	O
12	tumor	O
13	.	O

0	When	O
1	the	O
2	cervical	O
3	Pap	O
4	smear	O
5	is	O
6	positive	O
7	.	O

0	Studies	O
1	on	O
2	Coxsackie	O
3	B	O
4	Type	O
5	5	O
6	virus	O
7	infections	O
8	.	O

0	The	O
1	proposed	O
2	algorithm	O
3	consists	O
4	of	O
5	several	O
6	steps	O
7	.	O

0	Relief	O
1	from	O
2	autoinhibition	O
3	and	O
4	a	O
5	subsequent	O
6	10	O
7	-	O
8	60	O
9	-	O
10	fold	O
11	increase	O
12	in	O
13	V	O
14	(	O
15	max	O
16	)	O
17	have	O
18	been	O
19	observed	O
20	upon	O
21	N	B
22	-	I
23	SH2	I
24	domain	O
25	engagement	O
26	by	O
27	a	O
28	specific	O
29	phosphotyrosyl	O
30	ligand	O
31	or	O
32	upon	O
33	deletion	O
34	of	O
35	the	O
36	SH2	B
37	domains	I
38	to	O
39	yield	O
40	the	O
41	catalytic	O
42	PTPase	B
43	domain	I
44	.	O

0	These	O
1	are	O
2	two	O
3	regions	O
4	of	O
5	known	O
6	conserved	O
7	synteny	O
8	,	O
9	providing	O
10	further	O
11	evidence	O
12	that	O
13	the	O
14	human	B
15	STEP	I
16	is	O
17	a	O
18	true	O
19	homolog	O
20	of	O
21	the	O
22	murine	B
23	STEP	I
24	gene	I
25	.	O

0	To	O
1	identify	O
2	structural	O
3	features	O
4	of	O
5	residues	O
6	flanking	O
7	the	O
8	c	O
9	-	O
10	region	O
11	that	O
12	influence	O
13	the	O
14	fidelity	O
15	and	O
16	efficiency	O
17	of	O
18	signal	B
19	peptidase	I
20	cleavage	O
21	as	O
22	well	O
23	as	O
24	co	O
25	-	O
26	translational	O
27	translocation	O
28	,	O
29	we	O
30	introduced	O
31	six	O
32	amino	O
33	acid	O
34	substitutions	O
35	into	O
36	the	O
37	COOH	O
38	terminus	O
39	of	O
40	the	O
41	hydrophobic	O
42	core	O
43	and	O
44	seven	O
45	substitutions	O
46	at	O
47	the	O
48	NH2	O
49	terminus	O
50	of	O
51	the	O
52	mature	O
53	region	O
54	(	O
55	the	O
56	+	O
57	1	O
58	position	O
59	)	O
60	of	O
61	a	O
62	model	O
63	eukaryotic	O
64	preprotein	O
65	-	O
66	human	B
67	pre	I
68	(	I
69	delta	I
70	pro	I
71	)	I
72	apoA	I
73	-	I
74	II	I
75	.	O

0	The	O
1	rate	O
2	of	O
3	decrement	O
4	in	O
5	DPOAE	O
6	amplitude	O
7	over	O
8	a	O
9	prescribed	O
10	time	O
11	period	O
12	was	O
13	utilized	O
14	as	O
15	a	O
16	measure	O
17	of	O
18	susceptibility	O
19	to	O
20	the	O
21	acoustic	O
22	trauma	O
23	.	O

0	The	O
1	high	O
2	sequence	O
3	homology	O
4	,	O
5	similar	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	identical	O
11	chromosomal	O
12	loci	O
13	of	O
14	hKID	B
15	,	O
16	MIP	B
17	,	O
18	and	O
19	AQP	B
20	-	I
21	2	I
22	suggest	O
23	a	O
24	MIP	B
25	family	I
26	gene	I
27	cluster	O
28	at	O
29	chromosome	O
30	locus	O
31	12q13	O
32	.	O

0	Instead	O
1	,	O
2	it	O
3	contained	O
4	two	O
5	tandem	O
6	kappaB	O
7	elements	O
8	and	O
9	a	O
10	variant	B
11	activating	I
12	transcription	I
13	factor	I
14	/	O
15	cAMP	O
16	response	O
17	element	O
18	site	O
19	,	O
20	which	O
21	closely	O
22	resembled	O
23	sites	O
24	in	O
25	the	O
26	E	B
27	-	I
28	selectin	I
29	gene	I
30	that	O
31	are	O
32	required	O
33	for	O
34	TNF	B
35	-	I
36	alpha	I
37	-	O
38	or	O
39	LPS	B
40	-	O
41	inducible	O
42	expression	O
43	.	O

0	Because	O
1	ATF	B
2	-	I
3	1	I
4	and	O
5	CREM	B
6	are	O
7	known	O
8	to	O
9	bind	O
10	to	O
11	cAMP	O
12	response	O
13	elements	O
14	(	O
15	CRE	O
16	),	O
17	this	O
18	functional	O
19	sequence	O
20	was	O
21	named	O
22	the	O
23	kappa	O
24	E3	O
25	'-	O
26	CRE	O
27	.	O

0	In	O
1	patients	O
2	in	O
3	group	O
4	A	O
5	("	O
6	normal	O
7	"	O
8	CI	O
9	),	O
10	the	O
11	CI	O
12	,	O
13	heart	O
14	rate	O
15	and	O
16	the	O
17	mean	O
18	circumferential	O
19	fiber	O
20	shortening	O
21	velocity	O
22	(	O
23	mVCF	O
24	)	O
25	were	O
26	normal	O
27	,	O
28	but	O
29	the	O
30	TPR	O
31	was	O
32	increased	O
33	significantly	O
34	.	O

0	The	O
1	degree	O
2	of	O
3	hypoperfusion	O
4	was	O
5	slightly	O
6	related	O
7	to	O
8	decrease	O
9	in	O
10	FEV1	O
11	.	O
12	0	O
13	%,	O
14	V25	O
15	and	O
16	PaO2	O
17	and	O
18	increase	O
19	in	O
20	circulating	O
21	blood	O
22	volume	O
23	and	O
24	peripheral	O
25	red	O
26	blood	O
27	cell	O
28	counts	O
29	.	O

0	Thromboplastic	O
1	and	O
2	fibrynolytic	O
3	activity	O
4	of	O
5	the	O
6	blood	O
7	after	O
8	administration	O
9	of	O
10	intralipid	O
11	in	O
12	men	O
13	with	O
14	history	O
15	of	O
16	myocardial	O
17	infarction	O
18	up	O
19	to	O
20	45	O
21	year	O
22	of	O
23	life	O

0	Grade	O
1	3	O
2	mucositis	O
3	was	O
4	reported	O
5	in	O
6	1	O
7	patient	O
8	.	O

0	Preceptorship	O
1	of	O
2	CNS	O
3	students	O
4	:	O
5	an	O
6	exploratory	O
7	study	O
8	.	O

0	Myocardial	O
1	interstitial	O
2	edema	O
3	is	O
4	more	O
5	likely	O
6	a	O
7	potential	O
8	mechanism	O
9	of	O
10	diastolic	O
11	dysfunction	O
12	after	O
13	DC	O
14	shocks	O
15	.	O

0	A	O
1	38	O
2	-	O
3	bp	O
4	poly	O
5	(	O
6	dA	O
7	-	O
8	dT	O
9	)	O
10	region	O
11	was	O
12	found	O
13	to	O
14	be	O
15	a	O
16	positive	O
17	regulator	O
18	of	O
19	Act1	B
20	promoter	I
21	activity	O
22	.	O

0	Nor	O
1	is	O
2	such	O
3	adjustment	O
4	possible	O
5	unless	O
6	one	O
7	posits	O
8	a	O
9	model	O
10	that	O
11	relates	O
12	the	O
13	missing	O
14	observations	O
15	to	O
16	other	O
17	observed	O
18	information	O
19	for	O
20	each	O
21	subject	O
22	-	O
23	models	O
24	that	O
25	are	O
26	inherently	O
27	untestable	O
28	.	O

0	It	O
1	has	O
2	repeatedly	O
3	been	O
4	shown	O
5	that	O
6	HCMV	O
7	IE1	O
8	/	O
9	IE2	B
10	can	O
11	independently	O
12	transactivate	O
13	HIV	B
14	-	I
15	1	I
16	LTR	I
17	.	O

0	The	O
1	genome	O
2	organization	O
3	of	O
4	the	O
5	mite	O
6	-	O
7	transmitted	O
8	wheat	O
9	streak	O
10	mosaic	O
11	virus	O
12	(	O
13	WSMV	O
14	)	O
15	appears	O
16	to	O
17	parallel	O
18	that	O
19	of	O
20	members	O
21	of	O
22	the	O
23	Potyviridae	O
24	with	O
25	monopartite	O
26	genomes	O
27	,	O
28	but	O
29	there	O
30	are	O
31	substantial	O
32	amino	O
33	acid	O
34	dissimilarities	O
35	with	O
36	other	O
37	potyviral	O
38	polyproteins	O
39	.	O

0	Consistent	O
1	with	O
2	the	O
3	hepatic	O
4	and	O
5	epidermal	O
6	expression	O
7	of	O
8	histidase	B
9	,	O
10	this	O
11	finding	O
12	suggests	O
13	that	O
14	histidase	B
15	transcription	O
16	may	O
17	be	O
18	regulated	O
19	by	O
20	these	O
21	factors	O
22	.	O

0	The	O
1	genomic	O
2	and	O
3	transcriptional	O
4	complexity	O
5	of	O
6	the	O
7	Crry	B
8	and	O
9	Crry	B
10	-	I
11	ps	I
12	genes	I
13	.	O

0	Microvessels	O
1	were	O
2	counted	O
3	in	O
4	a	O
5	x200	O
6	field	O
7	(	O
8	0	O
9	.	O
10	754	O
11	mm2	O
12	)	O
13	in	O
14	the	O
15	area	O
16	of	O
17	maximal	O
18	angiogenesis	O
19	.	O

0	Moreover	O
1	,	O
2	the	O
3	reconstitution	O
4	of	O
5	eUSF	B
6	and	O
7	TFIID	B
8	-	O
9	depleted	O
10	transcription	O
11	complexes	O
12	with	O
13	purified	O
14	protein	O
15	fractions	O
16	demonstrate	O
17	that	O
18	not	O
19	only	O
20	TFIID	B
21	but	O
22	also	O
23	eUSF	B
24	essentially	O
25	participates	O
26	in	O
27	complex	O
28	formation	O
29	even	O
30	on	O
31	H5	B
32	promoter	I
33	mutations	O
34	lacking	O
35	the	O
36	TATA	O
37	-	O
38	box	O
39	.	O

0	Rainbow	O
1	trout	O
2	were	O
3	obtained	O
4	from	O
5	a	O
6	commercial	O
7	trout	O
8	farm	O
9	,	O
10	kept	O
11	in	O
12	running	O
13	water	O
14	and	O
15	feeding	O
16	in	O
17	experimental	O
18	pellets	O
19	for	O
20	4	O
21	to	O
22	8	O
23	weeks	O
24	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	time	O
5	to	O
6	engraftment	O
7	was	O
8	significantly	O
9	shorter	O
10	in	O
11	the	O
12	amifostine	O
13	arm	O
14	in	O
15	both	O
16	cohorts	O
17	.	O

0	To	O
1	identify	O
2	the	O
3	DNA	O
4	sequences	O
5	that	O
6	cis	O
7	-	O
8	regulate	O
9	the	O
10	expression	O
11	of	O
12	the	O
13	rat	B
14	liver	I
15	pyruvate	I
16	kinase	I
17	(	O
18	L	B
19	-	I
20	PK	I
21	)	O
22	genes	O
23	,	O
24	a	O
25	series	O
26	of	O
27	constructs	O
28	in	O
29	which	O
30	the	O
31	chloramphenicol	B
32	acetyltransferase	I
33	reporter	I
34	genes	I
35	is	O
36	driven	O
37	by	O
38	various	O
39	deleted	O
40	fragments	O
41	of	O
42	the	O
43	3200	O
44	base	O
45	pairs	O
46	(	O
47	bp	O
48	)	O
49	upstream	O
50	of	O
51	the	O
52	L	B
53	-	I
54	PK	I
55	gene	I
56	cap	I
57	site	I
58	have	O
59	been	O
60	assayed	O
61	for	O
62	transient	O
63	expression	O
64	after	O
65	introduction	O
66	into	O
67	hepatoma	O
68	HepG2	O
69	cells	O
70	,	O
71	rat	O
72	hepatocytes	O
73	in	O
74	primary	O
75	culture	O
76	,	O
77	fibroblast	O
78	LTK	B
79	-	O
80	cells	O
81	,	O
82	myogenic	O
83	C2C12	O
84	cells	O
85	,	O
86	and	O
87	CHO	O
88	cells	O
89	.	O

0	In	O
1	another	O
2	study	O
3	,	O
4	intravenous	O
5	administration	O
6	of	O
7	devazepide	O
8	,	O
9	a	O
10	specific	O
11	cholecystokinin	B
12	-	I
13	A	I
14	receptor	I
15	antagonist	O
16	,	O
17	at	O
18	a	O
19	dose	O
20	of	O
21	0	O
22	.	O
23	1	O
24	mg	O
25	/	O
26	kg	O
27	/	O
28	hr	O
29	was	O
30	begun	O
31	15	O
32	min	O
33	before	O
34	postprandial	O
35	saline	O
36	intake	O
37	and	O
38	continued	O
39	for	O
40	1	O
41	hr	O
42	.	O

0	Taurine	O
1	deficiency	O
2	significantly	O
3	depressed	O
4	the	O
5	amplitude	O
6	of	O
7	OP1	O
8	and	O
9	OP4	O
10	.	O

0	A	O
1	database	O
2	search	O
3	has	O
4	revealed	O
5	as	O
6	the	O
7	most	O
8	significative	O
9	homology	O
10	a	O
11	match	O
12	with	O
13	the	O
14	human	B
15	mitochondrial	I
16	transcription	I
17	termination	I
18	factor	I
19	(	O
20	mTERF	B
21	),	O
22	a	O
23	protein	O
24	that	O
25	also	O
26	binds	O
27	DNA	O
28	as	O
29	a	O
30	monomer	O
31	and	O
32	contains	O
33	three	O
34	leucine	O
35	zippers	O
36	forming	O
37	intramolecular	O
38	interactions	O
39	.	O

0	The	O
1	localization	O
2	of	O
3	ZAP	B
4	-	I
5	70	I
6	to	O
7	the	O
8	cell	O
9	cortex	O
10	is	O
11	,	O
12	therefore	O
13	,	O
14	regulated	O
15	by	O
16	the	O
17	activity	O
18	of	O
19	SRC	B
20	-	I
21	family	I
22	kinases	I
23	,	O
24	independently	O
25	of	O
26	their	O
27	ability	O
28	to	O
29	phosphorylate	O
30	immunoreceptor	O
31	tyrosine	O
32	-	O
33	based	O
34	activation	O
35	motifs	O
36	of	O
37	the	O
38	TCR	B
39	.	O

0	Guinea	O
1	pigs	O
2	weighing	O
3	300	O
4	approximately	O
5	350	O
6	g	O
7	were	O
8	used	O
9	.	O

0	Subcutaneous	O
1	administration	O
2	of	O
3	the	O
4	somatostatin	B
5	analogue	O
6	,	O
7	octreotide	O
8	,	O
9	100	O
10	micrograms	O
11	thrice	O
12	daily	O
13	,	O
14	resulted	O
15	in	O
16	a	O
17	sustained	O
18	improvement	O
19	in	O
20	diarrhoea	O
21	and	O
22	disappearance	O
23	of	O
24	faecal	O
25	incontinence	O
26	without	O
27	reducing	O
28	calcitonin	B
29	levels	O
30	.	O

0	With	O
1	steady	O
2	illumination	O
3	,	O
4	outer	O
5	retinal	O
6	(	O
7	photoreceptor	O
8	)	O
9	QO2	O
10	decreased	O
11	to	O
12	1	O
13	.	O
14	4	O
15	+/-	O
16	0	O
17	.	O
18	9	O
19	ml	O
20	O2	O
21	/(	O
22	100	O
23	g	O
24	.	O
25	min	O
26	),	O
27	but	O
28	inner	O
29	retinal	O
30	QO2	O
31	remained	O
32	unchanged	O
33	at	O
34	3	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	5	O
41	ml	O
42	O2	O
43	/(	O
44	100	O
45	g	O
46	.	O
47	min	O
48	)	O
49	(	O
50	5	O
51	cats	O
52	).	O

0	This	O
1	indicates	O
2	that	O
3	under	O
4	certain	O
5	experimental	O
6	conditions	O
7	cdc2	B
8	/	O
9	p58	B
10	and	O
11	cdc2	B
12	/	O
13	p62	B
14	may	O
15	express	O
16	some	O
17	differences	O
18	in	O
19	their	O
20	catalytic	O
21	activity	O
22	.	O

0	Sibling	O
1	aggregation	O
2	of	O
3	low	B
4	-	I
5	and	I
6	high	I
7	-	I
8	density	I
9	lipoprotein	I
10	cholesterol	I
11	and	O
12	apolipoproteins	B
13	B	I
14	and	O
15	A	B
16	-	I
17	I	I
18	levels	O
19	in	O
20	black	O
21	and	O
22	white	O
23	children	O
24	:	O
25	the	O
26	Bogalusa	O
27	Heart	O
28	Study	O
29	.	O

0	The	O
1	revertant	O
2	TATA	O
3	boxes	O
4	accelerated	O
5	the	O
6	kinetics	O
7	of	O
8	HIV	O
9	replication	O
10	when	O
11	present	O
12	in	O
13	the	O
14	context	O
15	of	O
16	an	O
17	LTR	O
18	containing	O
19	a	O
20	Sp1	B
21	mutation	I
22	(	O
23	deletion	O
24	or	O
25	site	O
26	specific	O
27	);	O
28	no	O
29	effect	O
30	was	O
31	observed	O
32	on	O
33	the	O
34	infectivity	O
35	of	O
36	wild	O
37	-	O
38	type	O
39	HIV	O
40	.	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	the	O
5	levels	O
6	of	O
7	oxygen	O
8	free	O
9	radicals	O
10	were	O
11	increased	O
12	in	O
13	hepatocytes	O
14	and	O
15	mitochondria	O
16	.	O

0	The	O
1	end	O
2	-	O
3	stage	O
4	or	O
5	involutional	O
6	phase	O
7	of	O
8	proliferative	O
9	diabetic	O
10	retinopathy	O
11	may	O
12	result	O
13	in	O
14	stabilization	O
15	of	O
16	vision	O
17	for	O
18	long	O
19	periods	O
20	of	O
21	time	O
22	.	O

0	BACKGROUND	O
1	:	O
2	Fluoroquinolones	O
3	(	O
4	FQ	O
5	)	O
6	are	O
7	contraindicated	O
8	in	O
9	children	O
10	because	O
11	of	O
12	the	O
13	risk	O
14	of	O
15	cartilage	O
16	damage	O
17	.	O

0	Nephrectomy	O
1	applied	O
2	to	O
3	cattle	O

0	In	O
1	about	O
2	770	O
3	bp	O
4	upstream	O
5	region	O
6	of	O
7	Spam1	B
8	that	O
9	has	O
10	been	O
11	cloned	O
12	and	O
13	sequenced	O
14	,	O
15	multiple	O
16	transcription	O
17	factor	O
18	binding	O
19	sites	O
20	including	O
21	a	O
22	CRE	O
23	(	O
24	cAMP	O
25	-	O
26	responsive	O
27	element	O
28	)	O
29	were	O
30	found	O
31	.	O

0	Furthermore	O
1	,	O
2	the	O
3	initial	O
4	plasma	O
5	retinol	O
6	level	O
7	in	O
8	conjunction	O
9	with	O
10	RBP	B
11	was	O
12	found	O
13	to	O
14	be	O
15	even	O
16	lower	O
17	in	O
18	12	O
19	patients	O
20	(	O
21	35	O
22	.	O
23	1	O
24	micrograms	O
25	dl	O
26	-	O
27	1	O
28	,	O
29	3	O
30	.	O
31	7	O
32	mg	O
33	dl	O
34	-	O
35	1	O
36	)	O
37	who	O
38	subsequently	O
39	had	O
40	cancer	O
41	recurrence	O
42	than	O
43	in	O
44	those	O
45	who	O
46	remained	O
47	free	O
48	of	O
49	apparent	O
50	cancer	O
51	(	O
52	44	O
53	.	O
54	5	O
55	micrograms	O
56	dl	O
57	-	O
58	1	O
59	,	O
60	4	O
61	.	O
62	6	O
63	mg	O
64	dl	O
65	-	O
66	1	O
67	).	O

0	Hair	O
1	and	O
2	blood	O
3	samples	O
4	were	O
5	taken	O
6	before	O
7	vitamin	O
8	C	O
9	or	O
10	placebo	O
11	supplementation	O
12	was	O
13	started	O
14	and	O
15	at	O
16	monthly	O
17	intervals	O
18	thereafter	O
19	for	O
20	three	O
21	months	O
22	.	O

0	After	O
1	tilting	O
2	,	O
3	systolic	O
4	blood	O
5	pressure	O
6	fell	O
7	an	O
8	average	O
9	of	O
10	17	O
11	%	O
12	in	O
13	patients	O
14	who	O
15	cramped	O
16	infrequently	O
17	(	O
18	p	O
19	=	O
20	0	O
21	.	O
22	0031	O
23	)	O
24	but	O
25	only	O
26	10	O
27	%	O
28	in	O
29	frequently	O
30	cramping	O
31	patients	O
32	.	O

0	Two	O
1	major	O
2	and	O
3	one	O
4	minor	O
5	transcription	O
6	initiation	O
7	sites	O
8	were	O
9	assigned	O
10	to	O
11	positions	O
12	+	O
13	1	O
14	and	O
15	+	O
16	24	O
17	and	O
18	position	O
19	+	O
20	14	O
21	,	O
22	respectively	O
23	,	O
24	by	O
25	a	O
26	combination	O
27	of	O
28	ribonuclease	O
29	protection	O
30	,	O
31	primer	O
32	extension	O
33	,	O
34	and	O
35	5	O
36	'	O
37	RACE	O
38	analyses	O
39	.	O

0	This	O
1	is	O
2	predicted	O
3	to	O
4	encode	O
5	a	O
6	315	O
7	-	O
8	residue	O
9	protein	O
10	containing	O
11	seven	O
12	hydrophobic	O
13	helical	O
14	regions	O
15	and	O
16	a	O
17	17	O
18	amino	O
19	acid	O
20	motif	O
21	characteristic	O
22	of	O
23	the	O
24	R7G	B
25	family	I
26	of	O
27	G	B
28	-	I
29	protein	I
30	coupled	I
31	membrane	I
32	-	I
33	bound	I
34	receptors	I
35	.	O

0	We	O
1	have	O
2	been	O
3	able	O
4	to	O
5	map	O
6	specific	O
7	DNA	O
8	fragments	O
9	at	O
10	the	O
11	bases	O
12	of	O
13	chromatin	O
14	loops	O
15	with	O
16	the	O
17	help	O
18	of	O
19	a	O
20	novel	O
21	extraction	O
22	procedure	O
23	by	O
24	using	O
25	lithium	O
26	-	O
27	3	O
28	',	O
29	5	O
30	'-	O
31	diiodosalicylate	O
32	.	O

0	Examination	O
1	of	O
2	nuclear	O
3	magnetic	O
4	resonance	O
5	(	O
6	NMR	O
7	)	O
8	spectra	O
9	of	O
10	a	O
11	series	O
12	of	O
13	N	O
14	-	O
15	terminally	O
16	truncated	O
17	MIP	B
18	-	I
19	1	I
20	beta	I
21	variants	I
22	reveals	O
23	that	O
24	these	O
25	proteins	O
26	possess	O
27	a	O
28	range	O
29	of	O
30	ability	O
31	to	O
32	dimerize	O
33	.	O

0	Another	O
1	stem	O
2	-	O
3	loop	O
4	called	O
5	structure	O
6	III	O
7	near	O
8	the	O
9	3	O
10	'-	O
11	end	O
12	of	O
13	repY	B
14	sequesters	O
15	both	O
16	the	O
17	5	O
18	'-	O
19	rCGCC	O
20	-	O
21	3	O
22	'	O
23	sequence	O
24	and	O
25	the	O
26	repZ	B
27	ribosome	I
28	-	I
29	binding	I
30	site	I
31	.	O

0	The	O
1	uteroglobin	B
2	promoter	I
3	contains	O
4	a	O
5	noncanonical	O
6	estrogen	O
7	responsive	O
8	element	O
9	.	O

0	In	O
1	summary	O
2	,	O
3	Ca	O
4	(	O
5	2	O
6	+)-	O
7	dependent	O
8	activation	O
9	of	O
10	NO	O
11	production	O
12	mediates	O
13	apoptosis	O
14	after	O
15	TG	O
16	exposure	O
17	in	O
18	JT	O
19	/	O
20	Neo	O
21	cells	O
22	.	O

0	At	O
1	least	O
2	some	O
3	of	O
4	the	O
5	difference	O
6	in	O
7	stability	O
8	of	O
9	the	O
10	two	O
11	kinds	O
12	of	O
13	complexes	O
14	was	O
15	due	O
16	to	O
17	the	O
18	fact	O
19	that	O
20	the	O
21	dissociation	O
22	rate	O
23	of	O
24	the	O
25	A	O
26	stem	O
27	substrate	O
28	from	O
29	the	O
30	protein	O
31	-	O
32	DNA	O
33	complexes	O
34	was	O
35	approximately	O
36	fourfold	O
37	faster	O
38	than	O
39	that	O
40	of	O
41	the	O
42	complete	O
43	TR	O
44	.	O

0	Mutations	O
1	in	O
2	three	O
3	loci	O
4	(	O
5	SIC1	B
6	,	O
7	SWI5	B
8	,	O
9	and	O
10	RIC3	B
11	)	O
12	were	O
13	identified	O
14	.	O

0	In	O
1	contrast	O
2	,	O
3	receptor	O
4	/	O
5	G	O
6	protein	O
7	coupling	O
8	appeared	O
9	unaffected	O
10	by	O
11	expression	O
12	of	O
13	loop	O
14	3i	O
15	domains	O
16	derived	O
17	from	O
18	two	O
19	receptors	O
20	coupled	O
21	to	O
22	G	B
23	(	I
24	i	I
25	/	I
26	o	I
27	)	I
28	proteins	I
29	(	O
30	M2Ach	B
31	-	O
32	muscarinic	B
33	and	O
34	alpha2A	B
35	-	I
36	adrenergic	I
37	receptors	I
38	).	O

0	The	O
1	plasmid	O
2	shuffle	O
3	technique	O
4	was	O
5	used	O
6	to	O
7	replace	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	gene	O
13	with	O
14	the	O
15	mutant	O
16	form	O
17	,	O
18	resulting	O
19	in	O
20	failure	O
21	of	O
22	the	O
23	yeast	O
24	cells	O
25	to	O
26	grow	O
27	.	O

0	The	O
1	various	O
2	muscles	O
3	of	O
4	the	O
5	pelvic	O
6	floor	O
7	region	O
8	could	O
9	be	O
10	reflexly	O
11	activated	O
12	either	O
13	individually	O
14	or	O
15	as	O
16	a	O
17	mass	O
18	unit	O
19	depending	O
20	on	O
21	the	O
22	intensity	O
23	of	O
24	stimulation	O
25	.	O

0	Negatively	O
1	supercoiled	O
2	plasmid	O
3	pUC19	O
4	did	O
5	not	O
6	compete	O
7	,	O
8	whereas	O
9	an	O
10	otherwise	O
11	identical	O
12	plasmid	O
13	pUC19	O
14	(	O
15	CG	O
16	),	O
17	which	O
18	contained	O
19	a	O
20	(	O
21	dG	O
22	-	O
23	dC	O
24	)	O
25	7	O
26	segment	O
27	in	O
28	the	O
29	Z	O
30	-	O
31	form	O
32	was	O
33	an	O
34	excellent	O
35	competitor	O
36	.	O

0	Control	O
1	of	O
2	fatty	O
3	liver	O
4	syndrome	O
5	in	O
6	a	O
7	Jersey	O
8	herd	O
9	by	O
10	a	O
11	change	O
12	of	O
13	diet	O
14	and	O
15	the	O
16	use	O
17	of	O
18	recombinant	B
19	bovine	I
20	somatotrophin	I
21	.	O

0	Mutational	O
1	analysis	O
2	shows	O
3	that	O
4	both	O
5	an	O
6	AP	B
7	-	I
8	1	I
9	like	I
10	sequence	I
11	(-	O
12	294	O
13	/-	O
14	285	O
15	,	O
16	TGAATCATCA	O
17	)	O
18	and	O
19	an	O
20	A	B
21	/	I
22	T	I
23	-	O
24	rich	O
25	myocyte	B
26	enhancer	I
27	factor	I
28	(	O
29	MEF	B
30	)-	I
31	2	I
32	like	O
33	sequence	O
34	(-	O
35	310	O
36	/-	O
37	298	O
38	,	O
39	TTAAAAATAAAAA	O
40	)	O
41	in	O
42	the	O
43	33	O
44	-	O
45	bp	O
46	region	O
47	are	O
48	necessary	O
49	for	O
50	the	O
51	OP	B
52	-	I
53	1	I
54	effect	O
55	.	O

0	To	O
1	analyze	O
2	the	O
3	VH	B
4	regions	I
5	of	O
6	polyreactive	O
7	antibodies	O
8	,	O
9	with	O
10	particular	O
11	attention	O
12	at	O
13	their	O
14	somatically	O
15	mutated	O
16	status	O
17	,	O
18	we	O
19	generated	O
20	five	O
21	IgG	B
22	(	O
23	three	O
24	IgG1	B
25	and	O
26	two	O
27	IgG3	B
28	)	O
29	mAb	O
30	(	O
31	using	O
32	B	O
33	cells	O
34	from	O
35	a	O
36	healthy	O
37	subject	O
38	,	O
39	a	O
40	patient	O
41	with	O
42	insulin	B
43	-	O
44	dependent	O
45	diabetes	O
46	mellitus	O
47	and	O
48	a	O
49	patient	O
50	with	O
51	SLE	B
52	),	O
53	which	O
54	bound	O
55	with	O
56	various	O
57	efficiencies	O
58	a	O
59	number	O
60	of	O
61	different	O
62	self	O
63	and	O
64	foreign	O
65	Ag	O
66	.	O

0	The	O
1	E1	B
2	nuclear	I
3	transport	I
4	motif	I
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	the	O
10	animal	O
11	and	O
12	human	O
13	papillomaviruses	O
14	and	O
15	is	O
16	encoded	O
17	in	O
18	a	O
19	similar	O
20	region	O
21	in	O
22	the	O
23	related	O
24	E1	B
25	genes	I
26	.	O

0	Purified	O
1	Hsk1	B
2	phosphorylates	O
3	the	O
4	Cdc19	B
5	(	O
6	Mcm2	B
7	)	O
8	subunit	O
9	of	O
10	the	O
11	six	B
12	-	I
13	member	I
14	minichromosome	I
15	maintenance	I
16	protein	I
17	complex	I
18	purified	O
19	from	O
20	fission	O
21	yeast	O
22	.	O

0	Vertebrate	B
1	synapsins	I
2	constitute	O
3	a	O
4	family	O
5	of	O
6	synaptic	O
7	proteins	O
8	that	O
9	participate	O
10	in	O
11	the	O
12	regulation	O
13	of	O
14	neurotransmitter	O
15	release	O
16	.	O

0	This	O
1	points	O
2	to	O
3	a	O
4	specific	O
5	interference	O
6	with	O
7	HSV	O
8	-	O
9	induced	O
10	DNA	O
11	amplification	O
12	.	O

0	DNA	B
1	polymerase	I
2	E	I
3	,	O
4	DNA	B
5	ligase	I
6	III	I
7	and	O
8	a	O
9	DNA	O
10	structure	O
11	-	O
12	specific	O
13	endonuclease	O
14	co	O
15	-	O
16	purify	O
17	with	O
18	the	O
19	five	O
20	polypeptide	O
21	complex	O
22	.	O

0	We	O
1	previously	O
2	described	O
3	the	O
4	purification	O
5	of	O
6	an	O
7	83	B
8	-	I
9	kDa	I
10	phosphatidic	I
11	acid	I
12	phosphatase	I
13	(	O
14	PAP	B
15	)	O
16	from	O
17	the	O
18	porcine	O
19	thymus	O
20	membranes	O
21	(	O
22	Kanoh	O
23	,	O
24	H	O
25	.,	O
26	Imai	O
27	,	O
28	S	O
29	.-	O
30	i	O
31	.,	O
32	Yamada	O
33	,	O
34	K	O
35	.	O
36	and	O
37	Sakane	O
38	,	O
39	F	O
40	.(	O
41	1992	O
42	)	O
43	J	O
44	.	O

0	Although	O
1	isl	B
2	-	I
3	1	I
4	binds	O
5	to	O
6	both	O
7	the	O
8	insulin	B
9	and	O
10	amylin	B
11	gene	I
12	promoter	I
13	elements	I
14	in	O
15	vitro	O
16	,	O
17	these	O
18	sequences	O
19	display	O
20	marked	O
21	differences	O
22	in	O
23	their	O
24	relative	O
25	transcriptional	O
26	properties	O
27	when	O
28	ligated	O
29	adjacent	O
30	to	O
31	a	O
32	heterologous	O
33	promoter	O
34	and	O
35	transfected	O
36	into	O
37	InR1	O
38	-	O
39	G9	O
40	islet	O
41	cells	O
42	.	O

0	Circulating	O
1	oxytocin	B
2	in	O
3	male	O
4	guinea	O
5	pigs	O
6	affected	O
7	by	O
8	the	O
9	female	O
10	cohabitation	O
11	and	O
12	reproductive	O
13	condition	O
14	.	O

0	Conditions	O
1	influencing	O
2	inhibitors	O
3	of	O
4	the	O
5	colony	B
6	-	I
7	stimulating	I
8	factor	I
9	(	O
10	CSF	B
11	).	O

0	Large	O
1	strain	O
2	differences	O
3	were	O
4	found	O
5	for	O
6	all	O
7	variables	O
8	recorded	O
9	,	O
10	i	O
11	.	O
12	e	O
13	.,	O
14	the	O
15	proportion	O
16	of	O
17	attacking	O
18	males	O
19	,	O
20	the	O
21	time	O
22	spent	O
23	in	O
24	the	O
25	brightly	O
26	lit	O
27	box	O
28	,	O
29	and	O
30	the	O
31	number	O
32	of	O
33	transitions	O
34	between	O
35	the	O
36	lit	O
37	and	O
38	the	O
39	dark	O
40	boxes	O
41	.	O

0	Chronic	O
1	thyroiditis	O
2	as	O
3	a	O
4	risk	O
5	factor	O
6	of	O
7	B	O
8	-	O
9	cell	O
10	lymphoma	O
11	in	O
12	the	O
13	thyroid	O
14	gland	O
15	.	O

0	This	O
1	experiment	O
2	was	O
3	conducted	O
4	to	O
5	determine	O
6	if	O
7	the	O
8	sex	O
9	or	O
10	actual	O
11	egg	O
12	production	O
13	was	O
14	the	O
15	important	O
16	factor	O
17	.(	O
18	ABSTRACT	O
19	TRUNCATED	O
20	AT	O
21	250	O
22	WORDS	O
23	)	O

0	12	O
1	:	O
2	2684	O
3	-	O
4	2697	O
5	,	O
6	1998	O
7	):	O
8	a	O
9	key	O
10	step	O
11	of	O
12	this	O
13	model	O
14	is	O
15	the	O
16	activation	O
17	of	O
18	the	O
19	MAPK	B
20	Fus3p	I
21	through	O
22	the	O
23	G	O
24	(	O
25	betagamma	O
26	)-	O
27	dependent	O
28	relocalization	O
29	of	O
30	the	O
31	Ste5p	B
32	-	O
33	MAPK	B
34	cascade	O
35	to	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O

0	The	O
1	ORF	B
2	4	I
3	gene	I
4	was	O
5	minimally	O
6	active	O
7	,	O
8	whereas	O
9	the	O
10	ORF	B
11	62	I
12	gene	I
13	gave	O
14	twofold	O
15	induction	O
16	;	O
17	both	O
18	genes	O
19	,	O
20	acting	O
21	together	O
22	,	O
23	gave	O
24	fivefold	O
25	induction	O
26	.	O

0	The	O
1	duration	O
2	of	O
3	diabetes	O
4	mellitus	O
5	in	O
6	these	O
7	patients	O
8	was	O
9	from	O
10	5	O
11	months	O
12	to	O
13	6	O
14	years	O
15	,	O
16	and	O
17	in	O
18	all	O
19	patients	O
20	this	O
21	was	O
22	the	O
23	first	O
24	myocardial	O
25	infarction	O
26	.	O

0	We	O
1	evaluated	O
2	regional	O
3	right	O
4	ventricular	O
5	wall	O
6	motion	O
7	during	O
8	systole	O
9	in	O
10	patients	O
11	with	O
12	surgically	O
13	repaired	O
14	tetralogy	O
15	of	O
16	Fallot	O
17	(	O
18	TOF	O
19	)	O
20	using	O
21	color	O
22	kinesis	O
23	imaging	O
24	.	O

0	The	O
1	scr	B
2	regulon	I
3	of	I
4	pUR400	I
5	and	O
6	the	O
7	chromosomally	O
8	encoded	O
9	scr	B
10	regulon	I
11	of	I
12	Klebsiella	I
13	pneumoniae	I
14	KAY2026	I
15	are	O
16	both	O
17	negatively	O
18	controlled	O
19	by	O
20	a	O
21	specific	O
22	repressor	O
23	(	O
24	ScrR	B
25	).	O

0	Members	O
1	of	O
2	SVA	B
3	are	O
4	also	O
5	present	O
6	in	O
7	the	O
8	complement	B
9	C2	I
10	gene	I
11	located	O
12	about	O
13	20	O
14	kilobases	O
15	upstream	O
16	of	O
17	RP1	B
18	in	O
19	the	O
20	HLA	O
21	and	O
22	in	O
23	the	O
24	cytochrome	B
25	CYP1A1	I
26	gene	I
27	.	O

0	Quantitative	O
1	analysis	O
2	of	O
3	DNA	O
4	using	O
5	flow	O
6	cytometry	O
7	and	O
8	immunocytochemical	O
9	findings	O
10	in	O
11	16	O
12	cases	O
13	of	O
14	cardiac	O
15	myxomas	O

0	Parodoxical	O
1	rise	O
2	in	O
3	urinary	B
4	albumin	B
5	levels	O
6	after	O
7	treatment	O
8	of	O
9	essential	O
10	hypertension	O
11	.	O

0	The	O
1	human	B
2	eps15	I
3	gene	I
4	,	O
5	encoding	O
6	a	O
7	tyrosine	B
8	kinase	I
9	substrate	O
10	,	O
11	is	O
12	conserved	O
13	in	O
14	evolution	O
15	and	O
16	maps	O
17	to	O
18	1p31	O
19	-	O
20	p32	O
21	.	O

0	We	O
1	then	O
2	demonstrated	O
3	that	O
4	1	O
5	)	O
6	GAL4	B
7	-	O
8	REV	B
9	-	O
10	erbA	B
11	alpha	O
12	chimeras	O
13	that	O
14	contain	O
15	the	O
16	'	O
17	AB	O
18	'	O
19	region	O
20	and	O
21	lack	O
22	the	O
23	'	O
24	E	O
25	'	O
26	region	O
27	activated	O
28	transcription	O
29	of	O
30	GAL4	B
31	response	O
32	elements	O
33	in	O
34	the	O
35	presence	O
36	of	O
37	8	O
38	-	O
39	Br	O
40	-	O
41	cAMP	O
42	and	O
43	2	O
44	)	O
45	the	O
46	ligand	O
47	-	O
48	binding	O
49	domain	O
50	(	O
51	LBD	O
52	)	O
53	contains	O
54	an	O
55	active	O
56	transcriptional	O
57	silencer	O
58	.	O

0	A	O
1	single	O
2	case	O
3	of	O
4	an	O
5	adenocarcinoma	O
6	,	O
7	arising	O
8	in	O
9	a	O
10	retroperitoneal	O
11	enterogenous	O
12	cyst	O
13	and	O
14	which	O
15	presented	O
16	as	O
17	a	O
18	left	O
19	renal	O
20	cyst	O
21	,	O
22	is	O
23	reported	O
24	.	O

0	Among	O
1	non	O
2	-	O
3	cirrhotics	O
4	,	O
5	lack	O
6	of	O
7	portal	O
8	vein	O
9	visualisation	O
10	had	O
11	a	O
12	90	O
13	%	O
14	sensitivity	O
15	,	O
16	88	O
17	%	O
18	specificity	O
19	,	O
20	94	O
21	%	O
22	negative	O
23	predictive	O
24	value	O
25	,	O
26	and	O
27	83	O
28	%	O
29	positive	O
30	predictive	O
31	value	O
32	in	O
33	the	O
34	diagnosis	O
35	of	O
36	pre	O
37	-	O
38	sinusoidal	O
39	portal	O
40	hypertension	O
41	.	O

0	The	O
1	5	O
2	'	O
3	end	O
4	of	O
5	the	O
6	genomic	O
7	RNA	O
8	of	O
9	rubella	O
10	virus	O
11	(	O
12	RUB	O
13	)	O
14	contains	O
15	a	O
16	14	O
17	-	O
18	nucleotide	O
19	(	O
20	nt	O
21	)	O
22	single	O
23	-	O
24	stranded	O
25	leader	O
26	(	O
27	ss	O
28	-	O
29	leader	O
30	)	O
31	followed	O
32	by	O
33	a	O
34	stem	O
35	-	O
36	and	O
37	-	O
38	loop	O
39	structure	O
40	[	O
41	5	O
42	'(+)	O
43	SL	O
44	]	O
45	(	O
46	nt	O
47	15	O
48	to	O
49	65	O
50	),	O
51	the	O
52	complement	O
53	of	O
54	which	O
55	at	O
56	the	O
57	3	O
58	'	O
59	end	O
60	of	O
61	the	O
62	minus	O
63	-	O
64	strand	O
65	RNA	O
66	[	O
67	3	O
68	'(-)	O
69	SL	O
70	]	O
71	has	O
72	been	O
73	proposed	O
74	to	O
75	function	O
76	as	O
77	a	O
78	promoter	O
79	for	O
80	synthesis	O
81	of	O
82	genomic	O
83	plus	O
84	strands	O
85	.	O

0	The	O
1	exon	O
2	-	O
3	intron	O
4	distribution	O
5	of	O
6	Cdebp	B
7	appears	O
8	strikingly	O
9	similar	O
10	to	O
11	that	O
12	of	O
13	the	O
14	App	B
15	gene	I
16	in	O
17	the	O
18	regions	O
19	encoding	O
20	the	O
21	conserved	O
22	domains	O
23	,	O
24	with	O
25	a	O
26	divergent	O
27	structure	O
28	in	O
29	the	O
30	other	O
31	parts	O
32	.	O

0	Glucose	O
1	disappearance	O
2	rate	O
3	and	O
4	changes	O
5	in	O
6	plasma	O
7	nutrients	O
8	after	O
9	intravenouly	O
10	injected	O
11	glucose	O
12	in	O
13	normoglycaemic	O
14	and	O
15	hypoglycaemic	O
16	underweight	O
17	newborns	O
18	.	O

0	Although	O
1	RAD17	B
2	,	O
3	RAD24	B
4	and	O
5	MEC3	B
6	are	O
7	not	O
8	required	O
9	for	O
10	cell	O
11	cycle	O
12	arrest	O
13	when	O
14	S	O
15	phase	O
16	is	O
17	inhibited	O
18	by	O
19	hydroxyurea	O
20	(	O
21	HU	O
22	),	O
23	they	O
24	do	O
25	contribute	O
26	to	O
27	the	O
28	viability	O
29	of	O
30	yeast	O
31	cells	O
32	grown	O
33	in	O
34	the	O
35	presence	O
36	of	O
37	HU	O
38	,	O
39	possibly	O
40	because	O
41	they	O
42	are	O
43	required	O
44	for	O
45	the	O
46	repair	O
47	of	O
48	HU	O
49	-	O
50	induced	O
51	DNA	O
52	damage	O
53	.	O

0	We	O
1	report	O
2	here	O
3	the	O
4	discovery	O
5	of	O
6	a	O
7	new	O
8	actin	B
9	-	I
10	related	I
11	gene	I
12	in	O
13	this	O
14	organism	O
15	,	O
16	which	O
17	we	O
18	have	O
19	named	O
20	ACT4	B
21	.	O

0	R	O
1	-	O
2	wave	O
3	voltage	O
4	in	O
5	the	O
6	right	O
7	precordial	O
8	leads	O
9	in	O
10	anthracycline	O
11	cardiomyopathy	O
12	:	O
13	a	O
14	clinical	O
15	study	O
16	.	O

0	To	O
1	investigate	O
2	the	O
3	mechanisms	O
4	involved	O
5	in	O
6	the	O
7	transcriptional	O
8	control	O
9	of	O
10	retinoid	B
11	X	I
12	receptor	I
13	(	O
14	RXR	B
15	)	O
16	gene	O
17	expression	O
18	,	O
19	the	O
20	5	O
21	'-	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	B
27	RXRgamma2	I
28	isoform	I
29	was	O
30	characterized	O
31	.	O

0	The	O
1	concentration	O
2	of	O
3	PGI2	O
4	on	O
5	the	O
6	newly	O
7	-	O
8	formed	O
9	luminal	O
10	surface	O
11	remained	O
12	low	O
13	.	O

0	Analysis	O
1	of	O
2	homologous	O
3	DNA	O
4	sequences	O
5	within	O
6	the	O
7	first	O
8	intron	O
9	of	O
10	the	O
11	mouse	B
12	and	I
13	human	I
14	mts1	I
15	genes	I
16	:	O
17	kB	O
18	-	O
19	like	O
20	site	O
21	and	O
22	microsatellite	O
23	DNA	O

0	In	O
1	the	O
2	chicken	O
3	liver	O
4	,	O
5	levels	O
6	of	O
7	chicken	B
8	MT	I
9	mRNA	I
10	were	O
11	rapidly	O
12	induced	O
13	by	O
14	metals	O
15	(	O
16	Cd2	O
17	+,	O
18	Zn2	O
19	+,	O
20	Cu2	O
21	+),	O
22	glucocorticoids	O
23	and	O
24	lipopolysaccharide	O
25	.	O

0	These	O
1	results	O
2	suggested	O
3	that	O
4	the	O
5	GG	O
6	motifs	O
7	contributed	O
8	to	O
9	the	O
10	cell	O
11	-	O
12	specific	O
13	transcription	O
14	of	O
15	the	O
16	human	B
17	insulin	I
18	gene	I
19	in	O
20	association	O
21	with	O
22	the	O
23	binding	O
24	of	O
25	the	O
26	sequence	O
27	-	O
28	specific	O
29	nuclear	O
30	factor	O
31	.	O

0	The	O
1	unphosphorylated	O
2	form	O
3	of	O
4	RNA	B
5	polymerase	I
6	II	I
7	is	O
8	designated	O
9	IIA	B
10	,	O
11	whereas	O
12	the	O
13	phosphorylated	O
14	form	O
15	is	O
16	designated	O
17	IIO	B
18	.	O

0	Within	O
1	this	O
2	sequence	O
3	the	O
4	MSAS	B
5	gene	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	5322	O
11	-	O
12	bp	O
13	-	O
14	long	O
15	open	O
16	reading	O
17	frame	O
18	coding	O
19	for	O
20	a	O
21	protein	O
22	of	O
23	1774	O
24	amino	O
25	acids	O
26	and	O
27	190	O
28	,	O
29	731	O
30	Da	O
31	molecular	O
32	mass	O
33	.	O

0	Identification	O
1	,	O
2	purification	O
3	,	O
4	and	O
5	molecular	O
6	cloning	O
7	of	O
8	autonomously	O
9	replicating	O
10	sequence	B
11	-	I
12	binding	I
13	protein	I
14	1	I
15	from	O
16	fission	O
17	yeast	O
18	Schizosaccharomyces	O
19	pombe	O
20	.	O

0	Common	O
1	history	O
2	and	O
3	prospects	O
4	in	O
5	surgical	O
6	gynecology	O
7	of	O
8	the	O
9	Charite	O
10	and	O
11	the	O
12	Vienna	O
13	University	O
14	Clinic	O

0	A	O
1	neuropsychological	O
2	test	O
3	battery	O
4	was	O
5	used	O
6	that	O
7	contained	O
8	the	O
9	Wisconsin	O
10	card	O
11	sorting	O
12	test	O
13	,	O
14	Street	O
15	completion	O
16	test	O
17	,	O
18	Stroop	O
19	test	O
20	,	O
21	a	O
22	dichotic	O
23	memory	O
24	listening	O
25	test	O
26	,	O
27	and	O
28	a	O
29	facial	O
30	recognition	O
31	test	O
32	.	O

0	A	O
1	total	O
2	of	O
3	1459	O
4	men	O
5	aged	O
6	48	O
7	to	O
8	84	O
9	years	O
10	,	O
11	who	O
12	were	O
13	diagnosed	O
14	for	O
15	the	O
16	first	O
17	time	O
18	by	O
19	physicians	O
20	as	O
21	having	O
22	BPH	O
23	in	O
24	1994	O
25	and	O
26	who	O
27	had	O
28	not	O
29	received	O
30	treatment	O
31	,	O
32	participated	O
33	in	O
34	the	O
35	study	O
36	.	O

0	GTRE	O
1	,	O
2	TRE	O
3	,	O
4	and	O
5	CRE	O
6	oligonucleotides	O
7	all	O
8	compete	O
9	more	O
10	efficiently	O
11	for	O
12	protein	O
13	binding	O
14	to	O
15	their	O
16	labeled	O
17	congeners	O
18	than	O
19	for	O
20	protein	O
21	binding	O
22	to	O
23	either	O
24	of	O
25	the	O
26	other	O
27	labeled	O
28	oligonucleotides	O
29	,	O
30	suggesting	O
31	that	O
32	the	O
33	GTRE	O
34	,	O
35	TRE	O
36	,	O
37	and	O
38	CRE	O
39	oligonucleotides	O
40	,	O
41	suggesting	O
42	that	O
43	the	O
44	GTRE	O
45	,	O
46	TRE	O
47	,	O
48	and	O
49	CRE	O
50	oligonucleotides	O
51	each	O
52	bind	O
53	unique	O
54	as	O
55	well	O
56	as	O
57	common	O
58	proteins	O
59	,	O
60	likely	O
61	to	O
62	be	O
63	members	O
64	of	O
65	the	O
66	Jun	B
67	/	O
68	Fos	B
69	and	O
70	cAMP	B
71	-	I
72	responsive	I
73	element	I
74	-	I
75	binding	I
76	protein	I
77	/	I
78	activating	I
79	transcription	I
80	factors	I
81	(	O
82	CREB	B
83	/	O
84	ATF	B
85	)	O
86	families	O
87	of	O
88	transcription	O
89	factors	O
90	,	O
91	in	O
92	chromaffin	O
93	cells	O
94	.	O

0	This	O
1	suggests	O
2	that	O
3	while	O
4	underpredictions	O
5	of	O
6	pain	O
7	do	O
8	not	O
9	hurt	O
10	more	O
11	,	O
12	disruption	O
13	on	O
14	primary	O
15	tasks	O
16	and	O
17	physiological	O
18	impact	O
19	are	O
20	higher	O
21	.	O

0	Serodiagnosis	O
1	of	O
2	trypanosomiasis	O
3	in	O
4	dromedary	O
5	camels	O
6	using	O
7	a	O
8	card	O
9	agglutination	O
10	test	O
11	set	O
12	(	O
13	Testryp	O
14	CATT	O
15	).	O

0	Finally	O
1	,	O
2	we	O
3	determined	O
4	that	O
5	the	O
6	P68	O
7	amino	O
8	terminus	O
9	was	O
10	both	O
11	necessary	O
12	and	O
13	sufficient	O
14	for	O
15	binding	O
16	dsRNA	O
17	as	O
18	we	O
19	were	O
20	able	O
21	to	O
22	transfer	O
23	dsRNA	O
24	-	O
25	binding	O
26	properties	O
27	to	O
28	a	O
29	reporter	O
30	gene	O
31	product	O
32	previously	O
33	unable	O
34	to	O
35	bind	O
36	RNA	O
37	.	O

0	For	O
1	sputum	B
2	interleukin	I
3	-	I
4	8	I
5	there	O
6	was	O
7	an	O
8	estimated	O
9	true	O
10	treatment	O
11	median	O
12	difference	O
13	of	O
14	142	O
15	pg	O
16	/	O
17	ml	O
18	(	O
19	95	O
20	%	O
21	confidence	O
22	interval	O
23	(	O
24	CI	O
25	)	O
26	8	O
27	to	O
28	2866	O
29	pg	O
30	/	O
31	ml	O
32	)	O
33	in	O
34	favour	O
35	of	O
36	placebo	O
37	;	O
38	while	O
39	for	O
40	maximal	O
41	expiratory	O
42	flow	O
43	at	O
44	25	O
45	%	O
46	(	O
47	MEF25	O
48	%)	O
49	remaining	O
50	forced	O
51	vital	O
52	capacity	O
53	predicted	O
54	for	O
55	sex	O
56	and	O
57	height	O
58	there	O
59	was	O
60	a	O
61	15	O
62	percentage	O
63	points	O
64	(	O
65	pp	O
66	)	O
67	(	O
68	95	O
69	%	O
70	CI	O
71	4	O
72	to	O
73	26	O
74	pp	O
75	)	O
76	mean	O
77	treatment	O
78	difference	O
79	in	O
80	favour	O
81	of	O
82	placebo	O
83	.	O

0	The	O
1	results	O
2	of	O
3	induced	O
4	coexpression	O
5	were	O
6	also	O
7	supported	O
8	by	O
9	rapid	O
10	generation	O
11	of	O
12	FeLV	O
13	recombinants	O
14	when	O
15	FeLV	O
16	-	O
17	C	O
18	was	O
19	used	O
20	to	O
21	infect	O
22	the	O
23	feline	O
24	3201B	O
25	cell	O
26	line	O
27	that	O
28	constitutively	O
29	expresses	O
30	high	O
31	levels	O
32	of	O
33	endogenous	O
34	FeLV	O
35	-	O
36	specific	O
37	mRNAs	O
38	.	O

0	The	O
1	sequenced	O
2	genomic	O
3	region	O
4	thus	O
5	accounts	O
6	for	O
7	essentially	O
8	all	O
9	of	O
10	the	O
11	longest	O
12	known	O
13	transcript	O
14	(	O
15	4	O
16	.	O
17	5	O
18	kb	O
19	),	O
20	although	O
21	the	O
22	precise	O
23	ends	O
24	of	O
25	this	O
26	transcript	O
27	have	O
28	not	O
29	been	O
30	defined	O
31	.	O

0	The	O
1	mutant	O
2	allele	O
3	of	O
4	the	O
5	alpha	B
6	1	I
7	-	I
8	tubulin	I
9	gene	I
10	was	O
11	designated	O
12	tua1	B
13	-	I
14	1	I
15	.	O

0	Plasmid	O
1	pAL618	O
2	contains	O
3	the	O
4	genetic	O
5	determinants	O
6	for	O
7	H2	O
8	uptake	O
9	(	O
10	hup	O
11	)	O
12	from	O
13	Rhizobium	O
14	leguminosarum	O
15	bv	O
16	.	O
17	viciae	O
18	,	O
19	including	O
20	a	O
21	cluster	O
22	of	O
23	17	O
24	genes	O
25	named	O
26	hupSLCDEFGHIJK	B
27	-	O
28	hypABFCDE	B
29	.	O

0	We	O
1	suggest	O
2	that	O
3	CT	O
4	scan	O
5	be	O
6	preferable	O
7	in	O
8	diagnosis	O
9	of	O
10	tumors	O
11	in	O
12	that	O
13	area	O
14	.	O

0	The	O
1	transposon	O
2	-	O
3	inactivated	O
4	gene	O
5	,	O
6	designated	O
7	pilP	B
8	,	O
9	is	O
10	525	O
11	bp	O
12	long	O
13	,	O
14	potentially	O
15	encoding	O
16	a	O
17	19	O
18	.	O
19	1	O
20	-	O
21	kDa	O
22	protein	O
23	precursor	O
24	that	O
25	contains	O
26	a	O
27	typical	O
28	membrane	O
29	lipoprotein	O
30	leader	O
31	sequence	O
32	.	O

0	A	O
1	technique	O
2	for	O
3	thermal	O
4	imaging	O
5	of	O
6	the	O
7	animal	O
8	and	O
9	human	O
10	brain	O
11	cortex	O
12	using	O
13	an	O
14	infrared	O
15	optical	O
16	system	O
17	is	O
18	described	O
19	.	O

0	The	O
1	CRE	O
2	,	O
3	5	O
4	'-	O
5	TGACGTCA	O
6	-	O
7	3	O
8	',	O
9	has	O
10	been	O
11	described	O
12	as	O
13	the	O
14	consensus	O
15	sequence	O
16	for	O
17	the	O
18	cis	O
19	-	O
20	element	O
21	that	O
22	directs	O
23	cAMP	O
24	-	O
25	regulated	O
26	gene	O
27	expression	O
28	.	O

0	Transcription	O
1	factors	O
2	of	O
3	the	O
4	Stat	B
5	family	I
6	are	O
7	controlled	O
8	by	O
9	protein	O
10	kinases	O
11	.	O

0	The	O
1	first	O
2	group	O
3	of	O
4	sequential	O
5	BMB	O
6	showed	O
7	a	O
8	significant	O
9	progress	O
10	to	O
11	myelofibrosis	O
12	in	O
13	so	O
14	-	O
15	called	O
16	"	O
17	Chronic	O
18	Megakaryocytic	O
19	-	O
20	Granulocytic	O
21	Myelosis	O
22	"--	O
23	CMGM	O
24	-,	O
25	which	O
26	corresponds	O
27	to	O
28	Agnogenic	O
29	Myeloid	O
30	Metaplasia	O
31	-	O
32	AMM	O
33	-	O
34	in	O
35	72	O
36	.	O
37	4	O
38	%	O
39	(	O
40	21	O
41	/	O
42	29	O
43	patients	O
44	),	O
45	as	O
46	well	O
47	as	O
48	in	O
49	CML	O
50	with	O
51	megakaryocytic	O
52	increase	O
53	-	O
54	CML	O
55	.	O
56	MI	O
57	-	O
58	in	O
59	39	O
60	.	O
61	2	O
62	%	O
63	(	O
64	20	O
65	/	O
66	51	O
67	).	O

0	Confirmatory	O
1	statistics	O
2	included	O
3	item	O
4	2	O
5	of	O
6	the	O
7	Clinical	O
8	Global	O
9	Impression	O
10	(	O
11	CGI	O
12	),	O
13	the	O
14	total	O
15	score	O
16	of	O
17	the	O
18	Sandoz	O
19	Clinical	O
20	Assessment	O
21	Geriatric	O
22	(	O
23	SCAG	O
24	)	O
25	scale	O
26	,	O
27	the	O
28	subscale	O
29	'	O
30	need	O
31	for	O
32	help	O
33	'	O
34	of	O
35	the	O
36	nurse	O
37	'	O
38	s	O
39	rating	O
40	of	O
41	geriatric	O
42	patients	O
43	(	O
44	Beurteilungsskala	O
45	fur	O
46	geriatrische	O
47	Patienten	O
48	;	O
49	BGP	O
50	)	O
51	and	O
52	the	O
53	total	O
54	score	O
55	of	O
56	the	O
57	Short	O
58	Cognitive	O
59	Performance	O
60	Test	O
61	(	O
62	Syndrom	O
63	-	O
64	Kurztest	O
65	;	O
66	SKT	O
67	).	O

0	Recipients	O
1	with	O
2	acute	O
3	leukaemia	O
4	in	O
5	first	O
6	remission	O
7	or	O
8	chronic	O
9	myeloid	O
10	leukaemia	O
11	in	O
12	first	O
13	chronic	O
14	phase	O
15	were	O
16	analysed	O
17	as	O
18	good	O
19	risk	O
20	,	O
21	and	O
22	those	O
23	beyond	O
24	these	O
25	stages	O
26	,	O
27	as	O
28	poor	O
29	risk	O
30	patients	O
31	.	O

0	Analysis	O
1	of	O
2	RAR	B
3	alpha	I
4	mutants	I
5	in	O
6	transfection	O
7	studies	O
8	reveals	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	is	O
15	sufficient	O
16	for	O
17	inhibition	O
18	of	O
19	BZLF1	B
20	activity	O
21	.	O

0	A	O
1	coiled	O
2	-	O
3	coil	O
4	domain	O
5	,	O
6	conserved	O
7	within	O
8	each	O
9	encoded	O
10	protein	O
11	,	O
12	serves	O
13	as	O
14	a	O
15	potential	O
16	interaction	O
17	motif	O
18	for	O
19	FLI	B
20	LRR	I
21	.	O

0	The	O
1	N1	O
2	and	O
3	P2	O
4	were	O
5	comparable	O
6	in	O
7	amplitude	O
8	and	O
9	both	O
10	had	O
11	prolonged	O
12	refractory	O
13	periods	O
14	.	O

0	Because	O
1	of	O
2	the	O
3	small	O
4	number	O
5	of	O
6	visceral	O
7	angiography	O
8	procedures	O
9	performed	O
10	(	O
11	38	O
12	),	O
13	no	O
14	definitive	O
15	conclusions	O
16	could	O
17	be	O
18	drawn	O
19	as	O
20	to	O
21	the	O
22	differences	O
23	between	O
24	ionic	O
25	and	O
26	nonionic	O
27	agents	O
28	regarding	O
29	grade	O
30	-	O
31	2	O
32	and	O
33	grade	O
34	-	O
35	3	O
36	adverse	O
37	events	O
38	.	O

0	Organization	O
1	of	O
2	the	O
3	human	B
4	LU	I
5	gene	I
6	and	O
7	molecular	O
8	basis	O
9	of	O
10	the	O
11	Lu	B
12	(	I
13	a	I
14	)/	O
15	Lu	B
16	(	I
17	b	I
18	)	O
19	blood	O
20	group	O
21	polymorphism	O
22	.	O

0	After	O
1	28	O
2	days	O
3	of	O
4	haloperidol	O
5	treatment	O
6	,	O
7	similar	O
8	changes	O
9	were	O
10	observed	O
11	for	O
12	delta	O
13	,	O
14	together	O
15	with	O
16	an	O
17	increase	O
18	of	O
19	alpha	B
20	1	I
21	,	O
22	and	O
23	a	O
24	decrease	O
25	of	O
26	fast	B
27	beta	I
28	.	O

0	All	O
1	six	O
2	ARF	B
3	cDNAs	I
4	are	O
5	more	O
6	similar	O
7	to	O
8	each	O
9	other	O
10	than	O
11	to	O
12	other	O
13	approximately	B
14	20	I
15	-	I
16	kDa	I
17	guanine	I
18	nucleotide	I
19	-	I
20	binding	I
21	proteins	I
22	.	O

0	Monitoring	O
1	patients	O
2	with	O
3	acute	O
4	leukemia	O
5	for	O
6	IL	B
7	-	I
8	1	I
9	and	O
10	TNF	B
11	levels	O
12	throughout	O
13	the	O
14	clinical	O
15	course	O
16	of	O
17	disease	O
18	may	O
19	help	O
20	clarify	O
21	the	O
22	causes	O
23	of	O
24	febrile	O
25	episodes	O
26	.	O

0	METHODS	O
1	:	O
2	Forty	O
3	-	O
4	nine	O
5	cases	O
6	with	O
7	intrahepatic	O
8	multiple	O
9	nodules	O
10	of	O
11	HCC	O
12	,	O
13	by	O
14	gross	O
15	examination	O
16	,	O
17	among	O
18	184	O
19	consecutive	O
20	resected	O
21	HCCs	O
22	were	O
23	examined	O
24	clinicopathologically	O
25	.	O

0	This	O
1	reveals	O
2	a	O
3	new	O
4	test	O
5	for	O
6	short	O
7	saphenous	O
8	incompetence	O
9	and	O
10	shows	O
11	that	O
12	14	O
13	per	O
14	cent	O
15	of	O
16	varices	O
17	stem	O
18	from	O
19	a	O
20	saphenopopliteal	O
21	reflux	O
22	.	O

0	In	O
1	26	O
2	patients	O
3	with	O
4	angina	O
5	pectoris	O
6	,	O
7	the	O
8	changes	O
9	of	O
10	LVEF	O
11	,	O
12	LVESV	O
13	and	O
14	PSP	O
15	/	O
16	LVESV	O
17	were	O
18	more	O
19	sensitive	O
20	for	O
21	the	O
22	detection	O
23	of	O
24	exercise	O
25	-	O
26	induced	O
27	ischemia	O
28	than	O
29	the	O
30	appearance	O
31	of	O
32	chest	O
33	pain	O
34	and	O
35	the	O
36	changes	O
37	of	O
38	ECG	O
39	.	O

0	I	O
1	.	O

0	Purification	O
1	and	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	serine	B
7	protease	I
8	,	O
9	RNK	B
10	-	I
11	Met	I
12	-	I
13	1	I
14	,	O
15	from	O
16	the	O
17	granules	O
18	of	O
19	a	O
20	rat	O
21	natural	O
22	killer	O
23	cell	O
24	leukemia	O
25	.	O

0	At	O
1	some	O
2	sites	O
3	,	O
4	%	O
5	T	O
6	is	O
7	greatly	O
8	increased	O
9	by	O
10	Cl	O
11	-	O
12	concentrations	O
13	up	O
14	to	O
15	1	O
16	M	O
17	,	O
18	while	O
19	at	O
20	other	O
21	sites	O
22	%	O
23	T	O
24	is	O
25	reduced	O
26	or	O
27	unaffected	O
28	by	O
29	these	O
30	conditions	O
31	.	O

0	The	O
1	MVV	O
2	-	O
3	value	O
4	is	O
5	under	O
6	the	O
7	predicted	O
8	level	O
9	in	O
10	the	O
11	case	O
12	of	O
13	67	O
14	-	O
15	76	O
16	percent	O
17	.	O

0	We	O
1	have	O
2	utilized	O
3	the	O
4	human	B
5	4F2	I
6	heavy	I
7	chain	I
8	(	O
9	4F2HC	B
10	)	O
11	gene	O
12	as	O
13	a	O
14	model	O
15	system	O
16	in	O
17	studies	O
18	designed	O
19	to	O
20	elucidate	O
21	the	O
22	molecular	O
23	events	O
24	involved	O
25	in	O
26	regulating	O
27	inducible	O
28	gene	O
29	expression	O
30	during	O
31	normal	O
32	human	O
33	T	O
34	-	O
35	cell	O
36	activation	O
37	.	O

0	Detailed	O
1	molecular	O
2	organization	O
3	of	O
4	the	O
5	coding	O
6	and	O
7	upstream	O
8	regulatory	O
9	regions	O
10	of	O
11	the	O
12	murine	B
13	homeodomain	I
14	-	I
15	containing	I
16	gene	I
17	,	O
18	Msx	B
19	-	I
20	1	I
21	,	O
22	is	O
23	reported	O
24	.	O

0	A	O
1	total	O
2	of	O
3	174	O
4	primer	O
5	pairs	O
6	gave	O
7	interpretable	O
8	banding	O
9	patterns	O
10	,	O
11	137	O
12	(	O
13	79	O
14	%)	O
15	of	O
16	which	O
17	revealed	O
18	at	O
19	least	O
20	two	O
21	alleles	O
22	on	O
23	native	O
24	polyacrylamide	O
25	gels	O
26	.	O

0	STP1	B
1	is	O
2	an	O
3	unessential	O
4	yeast	O
5	gene	O
6	involved	O
7	in	O
8	the	O
9	removal	O
10	of	O
11	intervening	O
12	sequences	O
13	from	O
14	some	O
15	,	O
16	but	O
17	not	O
18	all	O
19	,	O
20	families	O
21	of	O
22	intervening	O
23	sequence	O
24	-	O
25	containing	O
26	pre	O
27	-	O
28	tRNAs	O
29	.	O

0	Enoxacin	O
1	appears	O
2	to	O
3	be	O
4	well	O
5	suited	O
6	for	O
7	the	O
8	treatment	O
9	of	O
10	complicated	O
11	UTI	O
12	.	O

0	The	O
1	effect	O
2	of	O
3	low	O
4	dosage	O
5	radiation	O
6	on	O
7	metabolism	O
8	and	O
9	function	O
10	of	O
11	the	O
12	rat	O
13	kidney	O
14	damaged	O
15	by	O
16	ischemia	O

0	The	O
1	critical	O
2	mutations	O
3	were	O
4	likely	O
5	to	O
6	have	O
7	been	O
8	multiple	O
9	and	O
10	dispersed	O
11	,	O
12	including	O
13	elongation	O
14	of	O
15	the	O
16	TM	B
17	and	O
18	Nef	B
19	coding	O
20	sequences	O
21	;	O
22	changes	O
23	in	O
24	RNA	O
25	splice	O
26	donor	O
27	and	O
28	acceptor	O
29	sites	O
30	,	O
31	TATA	O
32	box	O
33	sites	O
34	,	O
35	and	O
36	Sp1	B
37	sites	I
38	;	O
39	multiple	O
40	changes	O
41	in	O
42	the	O
43	V2	O
44	region	O
45	of	O
46	SU	B
47	,	O
48	including	O
49	a	O
50	consensus	O
51	neutralization	O
52	epitope	O
53	;	O
54	and	O
55	five	O
56	new	O
57	N	O
58	-	O
59	linked	O
60	glycosylation	O
61	sites	O
62	in	O
63	SU	B
64	.	O

0	In	O
1	the	O
2	premating	O
3	period	O
4	male	O
5	rate	O
6	of	O
7	aggression	O
8	was	O
9	not	O
10	significantly	O
11	correlated	O
12	with	O
13	testosterone	O
14	level	O
15	.	O

0	To	O
1	test	O
2	the	O
3	feasibility	O
4	of	O
5	using	O
6	liposomes	O
7	to	O
8	deliver	O
9	therapeutic	O
10	agents	O
11	to	O
12	the	O
13	lungs	O
14	,	O
15	the	O
16	effect	O
17	of	O
18	liposome	B
19	-	I
20	encapsulated	I
21	superoxide	I
22	dismutase	I
23	(	O
24	SOD	B
25	)	O
26	or	O
27	catalase	B
28	on	O
29	pulmonary	O
30	oxygen	O
31	toxicity	O
32	was	O
33	studied	O
34	in	O
35	rats	O
36	.	O

0	Importantly	O
1	,	O
2	in	O
3	HeLa	O
4	and	O
5	293	O
6	cells	O
7	,	O
8	endogenous	O
9	and	O
10	transfected	O
11	I	B
12	kappaB	I
13	alpha	I
14	coimmunoprecipitated	O
15	with	O
16	Myc	B
17	-	O
18	tagged	O
19	or	O
20	endogenous	B
21	Dlc	B
22	-	I
23	1	I
24	.	O

0	The	O
1	coexpression	O
2	of	O
3	full	O
4	-	O
5	length	O
6	expression	O
7	constructs	O
8	for	O
9	both	O
10	DBP	B
11	and	O
12	hepatic	B
13	leukemia	I
14	factor	I
15	resulted	O
16	in	O
17	a	O
18	dramatic	O
19	increase	O
20	in	O
21	activation	O
22	mediated	O
23	by	O
24	the	O
25	GAL4	B
26	-	O
27	DBP	B
28	fusion	O
29	proteins	O
30	,	O
31	suggesting	O
32	the	O
33	involvement	O
34	of	O
35	a	O
36	regulated	O
37	coactivator	O
38	in	O
39	this	O
40	process	O
41	.	O

0	MEK	B
1	itself	O
2	is	O
3	activated	O
4	via	O
5	serine	O
6	phosphorylation	O
7	by	O
8	upstream	B
9	activator	I
10	kinases	I
11	,	O
12	including	O
13	c	B
14	-	I
15	raf	I
16	,	O
17	mos	B
18	and	O
19	MEK	B
20	kinase	I
21	.	O

0	A	O
1	multi	O
2	-	O
3	centre	O
4	evaluation	O
5	of	O
6	the	O
7	card	O
8	indirect	O
9	agglutination	O
10	test	O
11	for	O
12	trypanosomiasis	O
13	(	O
14	TrypTect	O
15	CIATT	O
16	).	O

0	The	O
1	7	O
2	-	O
3	day	O
4	treatment	O
5	resulted	O
6	in	O
7	a	O
8	decrease	O
9	in	O
10	mitochondrial	O
11	uptake	O
12	of	O
13	Rh123	B
14	and	O
15	an	O
16	increase	O
17	in	O
18	NAO	O
19	uptake	O
20	.	O

0	Oxidative	O
1	degradation	O
2	of	O
3	adrenaline	O
4	solutions	O
5	:	O
6	study	O
7	of	O
8	the	O
9	intermediate	O
10	stages	O
11	and	O
12	their	O
13	analytic	O
14	value	O
15	for	O
16	the	O
17	control	O
18	of	O
19	this	O
20	solute	O

0	The	O
1	P165	O
2	component	O
3	,	O
4	however	O
5	,	O
6	could	O
7	be	O
8	differentiated	O
9	from	O
10	the	O
11	two	O
12	later	O
13	components	O
14	since	O
15	it	O
16	increased	O
17	in	O
18	amplitude	O
19	with	O
20	increased	O
21	task	O
22	demands	O
23	while	O
24	the	O
25	N2	O
26	and	O
27	P3	O
28	amplitudes	O
29	remained	O
30	constant	O
31	.	O

0	During	O
1	the	O
2	conditioning	O
3	procedure	O
4	,	O
5	the	O
6	C	O
7	-	O
8	fiber	O
9	reflex	O
10	was	O
11	facilitated	O
12	(	O
13	wind	O
14	-	O
15	up	O
16	)	O
17	in	O
18	a	O
19	stimulus	O
20	-	O
21	dependent	O
22	fashion	O
23	in	O
24	intact	O
25	,	O
26	anesthetized	O
27	animals	O
28	during	O
29	the	O
30	application	O
31	of	O
32	the	O
33	first	O
34	seven	O
35	conditioning	O
36	stimuli	O
37	;	O
38	thereafter	O
39	,	O
40	the	O
41	magnitude	O
42	of	O
43	the	O
44	responses	O
45	reached	O
46	a	O
47	plateau	O
48	and	O
49	then	O
50	decreased	O
51	.	O

0	Of	O
1	the	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	transformants	O
7	,	O
8	65	O
9	%	O
10	resulted	O
11	from	O
12	replacement	O
13	of	O
14	the	O
15	resident	O
16	met2	I
17	mutation	I
18	by	O
19	the	O
20	exogenous	O
21	wild	O
22	-	O
23	type	O
24	allele	O
25	.	O

0	Their	O
1	use	O
2	resulted	O
3	in	O
4	a	O
5	sensitivity	O
6	of	O
7	73	O
8	%	O
9	and	O
10	a	O
11	specificity	O
12	of	O
13	74	O
14	%	O
15	with	O
16	regard	O
17	to	O
18	predictability	O
19	of	O
20	ALT	B
21	levels	O
22	increasing	O
23	during	O
24	the	O
25	trial	O
26	.	O

0	Fourteen	O
1	patients	O
2	were	O
3	in	O
4	the	O
5	multifocal	O
6	disease	O
7	group	O
8	;	O
9	13	O
10	were	O
11	detected	O
12	by	O
13	SPECT	O
14	and	O
15	10	O
16	by	O
17	TCT	O
18	.	O

0	The	O
1	application	O
2	of	O
3	ISH	O
4	and	O
5	IHC	O
6	did	O
7	not	O
8	change	O
9	significantly	O
10	the	O
11	routine	O
12	histologic	O
13	classification	O
14	of	O
15	pneumonias	O
16	into	O
17	CMV	O
18	-	O
19	IP	O
20	and	O
21	IIP	O
22	.	O

0	The	O
1	ultrastructure	O
2	of	O
3	retinal	O
4	vessels	O
5	was	O
6	examined	O
7	in	O
8	three	O
9	eyes	O
10	from	O
11	diabetic	O
12	patients	O
13	and	O
14	two	O
15	eyes	O
16	from	O
17	control	O
18	subjects	O
19	.	O

0	A	O
1	study	O
2	in	O
3	vivo	O
4	of	O
5	adrenergic	B
6	receptors	I
7	in	O
8	the	O
9	rectum	O
10	and	O
11	in	O
12	the	O
13	internal	O
14	and	O
15	sphincter	O
16	of	O
17	the	O
18	cat	O
19	.	O

0	Among	O
1	953	O
2	infants	O
3	in	O
4	22	O
5	neonatal	O
6	care	O
7	units	O
8	studied	O
9	,	O
10	23	O
11	%	O
12	(	O
13	median	O
14	value	O
15	,	O
16	range	O
17	0	O
18	-	O
19	78	O
20	)	O
21	were	O
22	found	O
23	to	O
24	be	O
25	faecally	O
26	colonized	O
27	with	O
28	one	O
29	of	O
30	21	O
31	distinct	O
32	nosocomial	O
33	strains	O
34	of	O
35	Escherichia	O
36	coli	O
37	,	O
38	Klebsiella	O
39	or	O
40	Enterobacter	O
41	spp	O
42	.	O

0	Surgical	O
1	treatment	O
2	of	O
3	pulmonary	O
4	metastases	O
5	.	O

0	Negative	O
1	-	O
2	staining	O
3	,	O
4	refractile	O
5	mycobacteria	O
6	in	O
7	Romanowsky	O
8	-	O
9	stained	O
10	smears	O
11	.	O

0	We	O
1	also	O
2	localized	O
3	the	O
4	Fra	B
5	-	I
6	2	I
7	phosphorylation	O
8	sites	O
9	by	O
10	MAPK	B
11	to	O
12	three	O
13	threonine	O
14	and	O
15	three	O
16	serine	O
17	residues	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	region	O
24	by	O
25	means	O
26	of	O
27	site	O
28	-	O
29	directed	O
30	mutagenesis	O
31	and	O
32	showed	O
33	that	O
34	the	O
35	threonine	O
36	residues	O
37	were	O
38	more	O
39	susceptible	O
40	to	O
41	MAPK	B
42	.	O

0	Six	O
1	tandem	O
2	repeats	O
3	of	O
4	the	O
5	P	O
6	element	O
7	linked	O
8	to	O
9	the	O
10	SV40	B
11	promoter	I
12	responded	O
13	to	O
14	phorbol	O
15	12	O
16	-	O
17	myristate	O
18	13	O
19	-	O
20	acetate	O
21	,	O
22	while	O
23	that	O
24	of	O
25	other	O
26	elements	O
27	did	O
28	not	O
29	.	O

0	Soluble	O
1	FasR	I
2	ligand	I
3	-	I
4	binding	I
5	domain	I
6	:	O
7	high	O
8	-	O
9	yield	O
10	production	O
11	of	O
12	active	O
13	fusion	O
14	and	O
15	non	O
16	-	O
17	fusion	O
18	recombinant	O
19	proteins	O
20	using	O
21	the	O
22	baculovirus	O
23	/	O
24	insect	O
25	cell	O
26	system	O
27	.	O

0	Upon	O
1	induction	O
2	of	O
3	SOS	O
4	,	O
5	viability	O
6	increased	O
7	2	O
8	-	O
9	6	O
10	-	O
11	fold	O
12	.	O

0	Radioligand	O
1	binding	O
2	was	O
3	indistinguishable	O
4	for	O
5	both	O
6	transiently	O
7	expressed	O
8	constructs	O
9	.	O

0	The	O
1	mean	O
2	serum	O
3	creatinine	O
4	levels	O
5	were	O
6	similar	O
7	at	O
8	one	O
9	year	O
10	(	O
11	SPK	O
12	1	O
13	.	O
14	8	O
15	,	O
16	KTA	O
17	1	O
18	.	O
19	9	O
20	mg	O
21	/	O
22	d	O
23	).(	O
24	ABSTRACT	O
25	TRUNCATED	O
26	AT	O
27	250	O
28	WORDS	O
29	)	O

0	The	O
1	test	O
2	was	O
3	not	O
4	performed	O
5	in	O
6	3923	O
7	patients	O
8	because	O
9	of	O
10	contraindications	O
11	.	O

0	These	O
1	results	O
2	suggest	O
3	that	O
4	less	O
5	antidopaminergic	O
6	activity	O
7	of	O
8	RHAL	B
9	in	O
10	this	O
11	neuroleptic	O
12	test	O
13	might	O
14	be	O
15	explained	O
16	by	O
17	the	O
18	lesser	O
19	conversion	O
20	of	O
21	RHAL	O
22	to	O
23	HAL	O
24	.	O

0	Although	O
1	the	O
2	fertility	O
3	decline	O
4	in	O
5	the	O
6	black	O
7	population	O
8	in	O
9	the	O
10	Mississippi	O
11	Delta	O
12	between	O
13	the	O
14	late	O
15	1870	O
16	'	O
17	s	O
18	and	O
19	early	O
20	1930	O
21	'	O
22	s	O
23	closely	O
24	paralleled	O
25	that	O
26	of	O
27	the	O
28	national	O
29	black	O
30	population	O
31	,	O
32	it	O
33	rose	O
34	much	O
35	more	O
36	dramatically	O
37	in	O
38	the	O
39	1940	O
40	'	O
41	s	O
42	and	O
43	1950	O
44	'	O
45	s	O
46	to	O
47	almost	O
48	1880	O
49	levels	O
50	.	O

0	In	O
1	contrast	O
2	,	O
3	the	O
4	differentiation	O
5	of	O
6	neoplastically	O
7	transformed	O
8	cells	O
9	does	O
10	not	O
11	repress	O
12	mitogenic	O
13	responsiveness	O
14	or	O
15	junB	B
16	or	O
17	c	B
18	-	I
19	fos	I
20	inducibility	O
21	.	O

0	Neither	O
1	Ha	B
2	-	I
3	Ras	I
4	(	O
5	G12V	B
6	,	O
7	T35S	B
8	)	O
9	(	O
10	Ha	B
11	-	I
12	RasV12S35	I
13	),	O
14	which	O
15	activates	O
16	the	O
17	Rafl	B
18	signaling	O
19	pathway	O
20	,	O
21	nor	O
22	Ha	B
23	-	I
24	Ras	I
25	(	O
26	G12V	B
27	,	O
28	E37G	B
29	)	O
30	(	O
31	Ha	B
32	-	I
33	RasV12G37	I
34	),	O
35	which	O
36	stimulates	O
37	the	O
38	RalGDS	B
39	pathway	O
40	,	O
41	did	O
42	not	O
43	have	O
44	significant	O
45	effects	O
46	on	O
47	factor	O
48	-	O
49	withdrawal	O
50	apoptosis	O
51	of	O
52	myeloid	O
53	cells	O
54	.	O

0	Redistribution	O
1	of	O
2	mannosidase	B
3	I	I
4	was	O
5	also	O
6	observed	O
7	in	O
8	cells	O
9	incubated	O
10	at	O
11	15	O
12	degrees	O
13	C	O
14	.	O

0	Copyright	O
1	2000	O
2	The	O
3	Royal	O
4	College	O
5	of	O
6	Radiologists	O
7	.	O

0	Under	O
1	resting	O
2	conditions	O
3	,	O
4	activity	O
5	levels	O
6	of	O
7	cardiac	O
8	vagal	O
9	and	O
10	sympathetic	O
11	outflows	O
12	are	O
13	not	O
14	related	O
15	across	O
16	young	O
17	,	O
18	healthy	O
19	human	O
20	subjects	O
21	and	O
22	peripheral	O
23	interaction	O
24	is	O
25	not	O
26	manifest	O
27	between	O
28	the	O
29	autonomic	O
30	divisions	O
31	.	O

0	Using	O
1	16	O
2	strains	O
3	of	O
4	C	O
5	.	O
6	trachomatis	O
7	in	O
8	triplicate	O
9	assays	O
10	,	O
11	we	O
12	found	O
13	the	O
14	RT	O
15	-	O
16	PCR	O
17	method	O
18	consistently	O
19	more	O
20	sensitive	O
21	than	O
22	the	O
23	conventional	O
24	technique	O
25	for	O
26	all	O
27	eight	O
28	antimicrobials	O
29	tested	O
30	,	O
31	with	O
32	resultant	O
33	MICs	O
34	determined	O
35	by	O
36	RT	O
37	-	O
38	PCR	O
39	ranging	O
40	from	O
41	1	O
42	.	O
43	6	O
44	-	O
45	fold	O
46	higher	O
47	(	O
48	erythromycin	O
49	)	O
50	to	O
51	>/=	O
52	195	O
53	-	O
54	fold	O
55	higher	O
56	(	O
57	amoxicillin	O
58	).	O

0	Autotransfusion	O
1	was	O
2	performed	O
3	as	O
4	follows	O
5	:	O
6	Heparin	O
7	-	O
8	ACD	O
9	-	O
10	B	O
11	-	O
12	Heparin	O
13	-	O
14	DPD	O
15	-	O
16	Heparin	O
17	-	O
18	ACD	O
19	-	O
20	B	O
21	etc	O
22	.	O

0	Infection	O
1	with	O
2	Neisseria	O
3	meningitidis	O
4	group	O
5	B	O
6	has	O
7	been	O
8	difficult	O
9	to	O
10	detect	O
11	,	O
12	partly	O
13	because	O
14	this	O
15	bacterial	O
16	group	O
17	'	O
18	s	O
19	polysaccharide	O
20	is	O
21	a	O
22	weak	O
23	immunogen	O
24	.	O

0	These	O
1	mutants	O
2	were	O
3	tested	O
4	for	O
5	ability	O
6	to	O
7	bind	O
8	each	O
9	of	O
10	the	O
11	Site	B
12	II	I
13	cognate	I
14	proteins	I
15	,	O
16	and	O
17	subsequently	O
18	evaluated	O
19	for	O
20	ability	O
21	to	O
22	confer	O
23	H4	B
24	transcriptional	O
25	activity	O
26	using	O
27	chimeric	O
28	H4	B
29	promoter	I
30	/	O
31	CAT	B
32	fusion	O
33	constructs	O
34	in	O
35	different	O
36	cell	O
37	types	O
38	.	O

0	However	O
1	,	O
2	essential	O
3	contrast	O
4	differences	O
5	existing	O
6	between	O
7	the	O
8	FSE	B
9	sequences	I
10	and	O
11	their	O
12	routine	O
13	asymmetric	O
14	dual	O
15	SE	O
16	counterpart	O
17	can	O
18	be	O
19	identified	O
20	.	O

0	For	O
1	replication	O
2	reporter	O
3	constructs	O
4	where	O
5	E1	O
6	and	O
7	E2	O
8	are	O
9	supplied	O
10	in	O
11	trans	O
12	by	O
13	the	O
14	respective	O
15	expression	O
16	vectors	O
17	,	O
18	distance	O
19	between	O
20	the	O
21	half	O
22	sites	O
23	seems	O
24	to	O
25	play	O
26	a	O
27	major	O
28	role	O
29	,	O
30	yet	O
31	the	O
32	phasing	O
33	relationships	O
34	are	O
35	measurable	O
36	.	O

0	Regulation	O
1	of	O
2	myosin	B
3	phosphatase	I
4	activity	O
5	involves	O
6	changes	O
7	in	O
8	subunit	O
9	interactions	O
10	,	O
11	although	O
12	molecular	O
13	mechanisms	O
14	are	O
15	not	O
16	defined	O
17	.	O

0	Significance	O
1	of	O
2	the	O
3	pulmonary	O
4	gas	O
5	exchange	O
6	reaction	O
7	to	O
8	physical	O
9	loading	O
10	in	O
11	evaluating	O
12	the	O
13	effectiveness	O
14	of	O
15	mitral	O
16	commissurotomy	O

0	The	O
1	227	O
2	-	O
3	to	O
4	-	O
5	239	O
6	region	O
7	blocked	O
8	ADR1	B
9	activity	O
10	independently	O
11	of	O
12	the	O
13	TAD	O
14	present	O
15	on	O
16	ADR1	B
17	,	O
18	ADR1	B
19	DNA	O
20	binding	O
21	,	O
22	and	O
23	specific	O
24	ADH2	B
25	promoter	I
26	sequences	I
27	.	O

0	Dissociation	O
1	and	O
2	complexation	O
3	of	O
4	the	O
5	fluoroquinolone	O
6	antimicrobials	O
7	--	O
8	an	O
9	update	O
10	.	O

0	The	O
1	hIGF	B
2	-	I
3	I	I
4	gene	I
5	has	O
6	two	O
7	promoters	O
8	,	O
9	P1	O
10	and	O
11	P2	O
12	.	O

0	Mining	O
1	the	O
2	diagnostic	O
3	iron	O
4	ore	O
5	.	O

0	Arm	O
1	function	O
2	tests	O
3	.	O

0	Expression	O
1	of	O
2	the	O
3	human	B
4	papillomavirus	I
5	type	I
6	11	I
7	E5A	I
8	protein	I
9	from	O
10	the	O
11	E1E4	B
12	,	O
13	E5	B
14	transcript	I
15	.	O

0	Second	O
1	report	O
2	of	O
3	the	O
4	Norwegian	O
5	Cancer	O
6	Society	O
7	.	O

0	Endogenous	O
1	RMP	I
2	was	O
3	immunologically	O
4	detected	O
5	interacting	O
6	with	O
7	assembled	O
8	RPB5	B
9	in	O
10	RNA	B
11	polymerase	I
12	in	O
13	mammalian	O
14	cells	O
15	.	O

0	Endostatin	B
1	treatment	O
2	for	O
3	10	O
4	minutes	O
5	or	O
6	24	O
7	hours	O
8	induced	O
9	tyrosine	O
10	phosphorylation	O
11	of	O
12	Shb	B
13	and	O
14	formation	O
15	of	O
16	multiprotein	O
17	complexes	O
18	.	O

0	The	O
1	mean	O
2	power	O
3	(	O
4	in	O
5	mu	O
6	W	O
7	)	O
8	required	O
9	to	O
10	produce	O
11	the	O
12	observed	O
13	flow	O
14	rate	O
15	was	O
16	estimated	O
17	at	O
18	each	O
19	outflow	O
20	pressure	O
21	as	O
22	the	O
23	product	O
24	of	O
25	the	O
26	flow	O
27	rate	O
28	and	O
29	the	O
30	pressure	O
31	across	O
32	the	O
33	lymphatic	O
34	vessel	O
35	.	O

0	Surgical	O
1	treatment	O
2	of	O
3	pathologic	O
4	scars	O
5	of	O
6	myocardial	O
7	infarct	O

0	PURPOSE	O
1	:	O
2	To	O
3	evaluate	O
4	the	O
5	disease	O
6	-	O
7	free	O
8	survival	O
9	(	O
10	DFS	O
11	)	O
12	and	O
13	overall	O
14	survival	O
15	(	O
16	OS	O
17	),	O
18	prognostic	O
19	factors	O
20	,	O
21	and	O
22	treatment	O
23	-	O
24	related	O
25	mortality	O
26	of	O
27	women	O
28	with	O
29	stage	O
30	IIIB	O
31	inflammatory	O
32	breast	O
33	cancer	O
34	(	O
35	IBC	O
36	)	O
37	treated	O
38	with	O
39	combined	O
40	modality	O
41	therapy	O
42	(	O
43	CMT	O
44	)	O
45	and	O
46	high	O
47	-	O
48	dose	O
49	chemotherapy	O
50	(	O
51	HDCT	O
52	)	O
53	with	O
54	autologous	O
55	stem	O
56	-	O
57	cell	O
58	transplantation	O
59	.	O

0	Collaborative	O
1	study	O
2	of	O
3	Japanese	O
4	Pharmacopoeia	O
5	Heparin	O
6	Sodium	O
7	Reference	O
8	Standard	O

0	We	O
1	have	O
2	identified	O
3	and	O
4	characterized	O
5	the	O
6	structure	O
7	of	O
8	the	O
9	Spec1	B
10	gene	I
11	in	O
12	the	O
13	sea	O
14	urchin	O
15	Strongylocentrotus	O
16	purpuratus	O
17	.	O

0	Among	O
1	the	O
2	mixed	O
3	race	O
4	persons	O
5	one	O
6	Chukcha	O
7	-	O
8	Eskimo	O
9	had	O
10	AS	O
11	,	O
12	one	O
13	Eskimo	O
14	-	O
15	Russian	O
16	had	O
17	psoriatic	O
18	arthritis	O
19	(	O
20	PsA	O
21	).	O

0	Thromboxane	O
1	B2	O
2	increased	O
3	(	O
4	97	O
5	+/-	O
6	105	O
7	versus	O
8	40	O
9	+/-	O
10	26	O
11	pg	O
12	/	O
13	ml	O
14	)	O
15	and	O
16	was	O
17	significantly	O
18	higher	O
19	during	O
20	heparin	O
21	free	O
22	hemodialysis	O
23	than	O
24	during	O
25	hemodialysis	O
26	with	O
27	heparin	O
28	(	O
29	p	O
30	=	O
31	0	O
32	.	O
33	01	O
34	,	O
35	Wilcoxon	O
36	matched	O
37	pairs	O
38	signed	O
39	rank	O
40	test	O
41	).	O

0	BACKGROUND	O
1	:	O
2	Left	O
3	ventricular	O
4	hypertrophy	O
5	is	O
6	a	O
7	heterogeneous	O
8	disorder	O
9	with	O
10	distinct	O
11	morphologies	O
12	.	O

0	In	O
1	contrast	O
2	,	O
3	AP	B
4	-	I
5	2	I
6	binding	O
7	activity	O
8	was	O
9	significantly	O
10	greater	O
11	in	O
12	T47D	O
13	cells	O
14	,	O
15	and	O
16	Western	O
17	blots	O
18	confirmed	O
19	increased	O
20	AP	B
21	-	I
22	2	I
23	protein	I
24	levels	O
25	in	O
26	these	O
27	cells	O
28	.	O

0	It	O
1	has	O
2	been	O
3	proposed	O
4	that	O
5	the	O
6	parCBA	B
7	operon	I
8	encodes	O
9	a	O
10	plasmid	O
11	partitioning	O
12	system	O
13	(	O
14	M	O
15	.	O

0	The	O
1	encoded	O
2	sequence	O
3	revealed	O
4	a	O
5	typical	O
6	signal	O
7	peptide	O
8	,	O
9	a	O
10	predominantly	O
11	hydrophilic	O
12	707	O
13	amino	O
14	acid	O
15	residue	O
16	domain	O
17	with	O
18	8	O
19	N	O
20	-	O
21	glycosylation	O
22	sites	O
23	,	O
24	a	O
25	transmembrane	O
26	domain	O
27	,	O
28	and	O
29	a	O
30	C	O
31	-	O
32	terminal	O
33	domain	O
34	of	O
35	52	O
36	amino	O
37	acids	O
38	.	O

0	Both	O
1	genes	O
2	comprise	O
3	three	O
4	exons	O
5	,	O
6	two	O
7	introns	O
8	and	O
9	an	O
10	unusually	O
11	long	O
12	3	O
13	'-	O
14	untranslated	O
15	region	O
16	(	O
17	3	O
18	.	O
19	2	O
20	kilobase	O
21	pairs	O
22	),	O
23	specificying	O
24	a	O
25	mRNA	O
26	of	O
27	approximately	O
28	4	O
29	.	O
30	1	O
31	kilobases	O
32	.	O

0	Mycobacterium	O
1	avium	O
2	-	O
3	intracellulare	O
4	complex	O
5	infections	O
6	in	O
7	the	O
8	acquired	O
9	immunodeficiency	O
10	syndrome	O
11	.	O

0	LH	B
1	/	O
2	CG	B
3	receptor	I
4	activation	O
5	of	O
6	ARNO	B
7	is	O
8	not	O
9	mediated	O
10	by	O
11	activation	O
12	of	O
13	phosphatidylinositol	B
14	3	I
15	-	I
16	kinase	I
17	(	O
18	PI	B
19	3	I
20	-	I
21	kinase	I
22	)	O
23	or	O
24	by	O
25	G	B
26	protein	I
27	beta	I
28	gamma	I
29	subunits	I
30	.	O

0	Volume	O
1	of	O
2	distribution	O
3	of	O
4	total	O
5	DMDZ	O
6	(	O
7	range	O
8	,	O
9	1	O
10	.	O
11	33	O
12	to	O
13	6	O
14	.	O
15	30	O
16	l	O
17	/	O
18	kg	O
19	)	O
20	and	O
21	of	O
22	unbound	O
23	DMDZ	O
24	after	O
25	correction	O
26	for	O
27	protein	O
28	binding	O
29	(	O
30	range	O
31	,	O
32	43	O
33	to	O
34	243	O
35	l	O
36	/	O
37	kg	O
38	)	O
39	was	O
40	larger	O
41	in	O
42	women	O
43	than	O
44	in	O
45	men	O
46	of	O
47	all	O
48	ages	O
49	,	O
50	and	O
51	in	O
52	the	O
53	elderly	O
54	as	O
55	opposed	O
56	to	O
57	the	O
58	young	O
59	.	O

0	Brucellosis	O
1	--	O
2	1990	O

0	This	O
1	computerized	O
2	list	O
3	was	O
4	linked	O
5	to	O
6	the	O
7	central	O
8	files	O
9	of	O
10	the	O
11	Massachusetts	O
12	Cancer	O
13	Registry	O
14	and	O
15	cases	O
16	diagnosed	O
17	between	O
18	1982	O
19	and	O
20	1988	O
21	were	O
22	identified	O
23	.	O

0	Its	O
1	cognate	O
2	binding	O
3	protein	O
4	,	O
5	REST	B
6	/	O
7	NRSF	B
8	,	O
9	is	O
10	an	O
11	essential	O
12	transcription	O
13	factor	O
14	;	O
15	its	O
16	null	O
17	mutations	O
18	result	O
19	in	O
20	embryonic	O
21	lethality	O
22	,	O
23	and	O
24	its	O
25	dominant	O
26	negative	O
27	mutants	O
28	produce	O
29	aberrant	O
30	expression	O
31	of	O
32	neuron	O
33	-	O
34	specific	O
35	genes	O
36	.	O

0	Determination	O
1	of	O
2	potassium	O
3	iodide	O
4	in	O
5	Polish	O
6	edible	O
7	salt	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	the	O
5	sulfhydryl	O
6	group	O
7	of	O
8	certain	O
9	angiotensin	B
10	converting	I
11	enzyme	I
12	inhibitors	O
13	can	O
14	potentiate	O
15	their	O
16	effect	O
17	on	O
18	the	O
19	endogenous	O
20	nitrovasodilator	O
21	EDRF	O
22	.	O

0	Human	B
1	thymine	I
2	-	I
3	DNA	I
4	glycosylase	I
5	maps	O
6	at	O
7	chromosome	O
8	12q22	O
9	-	O
10	q24	O
11	.	O
12	1	O
13	:	O
14	a	O
15	region	O
16	of	O
17	high	O
18	loss	O
19	of	O
20	heterozygosity	O
21	in	O
22	gastric	O
23	cancer	O
24	.	O

0	Copyright	O
1	2000	O
2	Academic	O
3	Press	O
4	.	O

0	An	O
1	examination	O
2	was	O
3	performed	O
4	in	O
5	15	O
6	patients	O
7	who	O
8	had	O
9	developed	O
10	pronounced	O
11	osteomalacia	O
12	following	O
13	gastric	O
14	resection	O
15	.	O

0	Several	O
1	lines	O
2	of	O
3	evidence	O
4	demonstrate	O
5	that	O
6	this	O
7	growth	O
8	inhibition	O
9	requires	O
10	active	O
11	PKA	B
12	subunits	I
13	and	O
14	cAMP	O
15	:	O
16	(	O
17	i	O
18	)	O
19	this	O
20	phenotype	O
21	is	O
22	dependent	O
23	on	O
24	cAMP	O
25	since	O
26	it	O
27	is	O
28	not	O
29	seen	O
30	in	O
31	a	O
32	strain	O
33	lacking	O
34	adenylyl	B
35	cyclase	I
36	activity	O
37	,	O
38	but	O
39	the	O
40	growth	O
41	rate	O
42	of	O
43	these	O
44	transformants	O
45	is	O
46	slower	O
47	when	O
48	exogenous	O
49	cAMP	O
50	is	O
51	added	O
52	;	O
53	(	O
54	ii	O
55	)	O
56	normal	O
57	growth	O
58	occurs	O
59	when	O
60	wild	B
61	-	I
62	type	I
63	RI	I
64	cDNA	I
65	is	O
66	replaced	O
67	by	O
68	a	O
69	mutant	B
70	RI	I
71	cDNA	I
72	encoding	O
73	a	O
74	RI	B
75	protein	I
76	with	O
77	reduced	O
78	cAMP	O
79	binding	O
80	;	O
81	and	O
82	(	O
83	iii	O
84	)	O
85	the	O
86	growth	O
87	-	O
88	inhibited	O
89	phenotype	O
90	of	O
91	the	O
92	transformed	O
93	BL21	O
94	(	O
95	DE3	O
96	)	O
97	cells	O
98	requires	O
99	soluble	O
100	,	O
101	active	O
102	C	B
103	alpha	I
104	protein	I
105	.	O

0	The	O
1	models	O
2	accurately	O
3	localized	O
4	the	O
5	common	O
6	boundaries	O
7	between	O
8	the	O
9	PBB	O
10	and	O
11	CN	O
12	.	O

0	Prostaglandin	O
1	synthesis	O
2	inhibitors	O
3	have	O
4	been	O
5	shown	O
6	to	O
7	delay	O
8	healing	O
9	of	O
10	bone	O
11	and	O
12	this	O
13	has	O
14	led	O
15	to	O
16	limitations	O
17	on	O
18	their	O
19	use	O
20	clinically	O
21	in	O
22	some	O
23	situations	O
24	.	O

0	We	O
1	further	O
2	demonstrate	O
3	that	O
4	the	O
5	Stress	B
6	-	I
7	Activated	I
8	-	I
9	Protein	I
10	-	I
11	Kinase	I
12	(	O
13	SAPK	B
14	)	O
15	target	O
16	sites	O
17	of	O
18	ATF2	B
19	,	O
20	Thr69	O
21	and	O
22	Thr71	O
23	are	O
24	not	O
25	required	O
26	for	O
27	the	O
28	formation	O
29	of	O
30	the	O
31	p300	B
32	/	O
33	CBP	B
34	-	O
35	ATF2	B
36	multiprotein	O
37	complex	O
38	.	O

0	The	O
1	ATR	O
2	-	O
3	X	O
4	syndrome	O
5	results	O
6	from	O
7	mutations	O
8	of	O
9	the	O
10	XH2	B
11	gene	I
12	,	O
13	located	O
14	on	O
15	the	O
16	X	O
17	chromosome	O
18	(	O
19	Xq13	O
20	.	O
21	3	O
22	)	O
23	and	O
24	coding	O
25	for	O
26	a	O
27	transacting	O
28	factor	O
29	which	O
30	regulates	O
31	gene	O
32	expression	O
33	.	O

0	Transcription	O
1	start	O
2	site	O
3	mapping	O
4	identified	O
5	the	O
6	presence	O
7	of	O
8	an	O
9	aphidicolin	B
10	-	O
11	sensitive	O
12	late	O
13	transcript	O
14	arising	O
15	from	O
16	a	O
17	TAAG	O
18	motif	O
19	located	O
20	at	O
21	-	O
22	352	O
23	nucleotides	O
24	and	O
25	an	O
26	aphidicolin	B
27	-	O
28	insensitive	O
29	early	O
30	transcript	O
31	originating	O
32	from	O
33	a	O
34	TTGT	O
35	motif	O
36	located	O
37	35	O
38	nucleotides	O
39	downstream	O
40	to	O
41	a	O
42	TATA	O
43	box	O
44	at	O
45	-	O
46	312	O
47	nucleotides	O
48	,	O
49	with	O
50	respect	O
51	to	O
52	the	O
53	+	O
54	1	O
55	ATG	O
56	of	O
57	lef2	B
58	.	O

0	About	O
1	20	O
2	%	O
3	of	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	binding	O
9	was	O
10	observed	O
11	in	O
12	the	O
13	presence	O
14	of	O
15	MgdTDP	O
16	,	O
17	but	O
18	none	O
19	was	O
20	detectable	O
21	in	O
22	the	O
23	absence	O
24	of	O
25	nucleotides	O
26	.	O

0	Our	O
1	results	O
2	indicate	O
3	that	O
4	RA	O
5	-	O
6	mediated	O
7	repression	O
8	of	O
9	the	O
10	hMGP	B
11	gene	I
12	is	O
13	due	O
14	to	O
15	binding	O
16	of	O
17	liganded	O
18	RAR	B
19	/	O
20	RXR	B
21	to	O
22	a	O
23	novel	O
24	negative	O
25	RA	O
26	response	O
27	element	O
28	.	O

0	The	O
1	IE0	B
2	gene	I
3	product	I
4	also	O
5	transactivated	O
6	the	O
7	IE1	B
8	promoter	I
9	but	O
10	did	O
11	not	O
12	affect	O
13	expression	O
14	from	O
15	its	O
16	own	O
17	promoter	O
18	.	O

0	Recombinant	B
1	AROM	I
2	-	I
3	p64	I
4	displayed	O
5	high	O
6	binding	O
7	to	O
8	single	O
9	-	O
10	stranded	O
11	DNA	O
12	and	O
13	poly	O
14	(	O
15	A	O
16	)	O
17	homopolymers	O
18	suggesting	O
19	that	O
20	this	O
21	protein	O
22	could	O
23	play	O
24	a	O
25	role	O
26	in	O
27	mRNA	O
28	maturation	O
29	/	O
30	metabolism	O
31	.	O

0	Selection	O
1	of	O
2	the	O
3	22	O
4	items	O
5	of	O
6	the	O
7	Clinical	O
8	Institute	O
9	Withdrawal	O
10	Assessment	O
11	-	O
12	Benzodiazepines	O
13	(	O
14	CIWA	O
15	-	O
16	B	O
17	)	O
18	was	O
19	based	O
20	on	O
21	statistically	O
22	significant	O
23	differences	O
24	between	O
25	baseline	O
26	and	O
27	critical	O
28	withdrawal	O
29	periods	O
30	in	O
31	high	O
32	-	O
33	dose	O
34	subjects	O
35	and	O
36	between	O
37	symptoms	O
38	associated	O
39	with	O
40	placebo	O
41	and	O
42	diazepam	O
43	in	O
44	low	O
45	-	O
46	dose	O
47	subjects	O
48	,	O
49	using	O
50	contingency	O
51	tables	O
52	and	O
53	logistic	O
54	regression	O
55	analysis	O
56	.	O

0	In	O
1	electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	,	O
6	the	O
7	PERE	B
8	formed	O
9	three	O
10	major	O
11	complexes	O
12	(	O
13	P1	O
14	,	O
15	P2	O
16	and	O
17	P3	B
18	)	O
19	with	O
20	proteins	O
21	in	O
22	nuclear	O
23	extracts	O
24	from	O
25	HeLa	O
26	or	O
27	293	O
28	cells	O
29	.	O

0	The	O
1	unexpected	O
2	presence	O
3	of	O
4	the	O
5	tRNA	B
6	(	I
7	trp	I
8	)(	I
9	CCA	I
10	)-	I
11	gene	I
12	transcript	I
13	in	O
14	mitochondria	O
15	is	O
16	also	O
17	reported	O
18	.	O

0	The	O
1	R	B
2	.	I
3	meliloti	I
4	nifH	I
5	promoter	I
6	but	O
7	not	O
8	the	O
9	K	B
10	.	I
11	pneumoniae	I
12	nifH	I
13	promoter	I
14	showed	O
15	sigma	O
16	54	O
17	-	O
18	dependent	O
19	methylation	O
20	protection	O
21	of	O
22	guanine	O
23	residues	O
24	at	O
25	-	O
26	14	O
27	,	O
28	-	O
29	25	O
30	and	O
31	-	O
32	26	O
33	,	O
34	the	O
35	most	O
36	conserved	O
37	nucleotides	O
38	characteristic	O
39	of	O
40	sigma	B
41	54	I
42	-	I
43	dependent	I
44	promoters	I
45	.	O

0	The	O
1	protein	B
2	-	I
3	tyrosine	I
4	kinase	I
5	fer	I
6	associates	O
7	with	O
8	signaling	O
9	complexes	O
10	containing	O
11	insulin	B
12	receptor	I
13	substrate	I
14	-	I
15	1	I
16	and	O
17	phosphatidylinositol	B
18	3	I
19	-	I
20	kinase	I
21	.	O

0	Abnormal	O
1	characteristics	O
2	and	O
3	verticillation	O
4	in	O
5	Platynothrus	O
6	peltifer	O

0	In	O
1	throttling	O
2	valves	O
3	,	O
4	the	O
5	aim	O
6	is	O
7	to	O
8	correlate	O
9	the	O
10	effect	O
11	of	O
12	shear	O
13	to	O
14	a	O
15	parameter	O
16	related	O
17	to	O
18	the	O
19	inner	O
20	geometry	O
21	of	O
22	the	O
23	valve	O
24	and	O
25	to	O
26	operating	O
27	conditions	O
28	.	O

0	To	O
1	this	O
2	end	O
3	,	O
4	we	O
5	analyzed	O
6	the	O
7	phosphorylation	O
8	status	O
9	of	O
10	a	O
11	universal	O
12	tyrosine	B
13	kinase	I
14	substrate	O
15	,	O
16	the	O
17	transforming	B
18	Shc	I
19	adapter	I
20	protein	I
21	,	O
22	in	O
23	fibroblasts	O
24	expressing	O
25	the	O
26	viral	O
27	oncogene	O
28	.	O

0	In	O
1	endemic	O
2	BL	O
3	,	O
4	the	O
5	RB2	B
6	/	O
7	p130	B
8	gene	O
9	is	O
10	mutated	O
11	in	O
12	most	O
13	of	O
14	the	O
15	cases	O
16	,	O
17	and	O
18	the	O
19	protein	O
20	is	O
21	restricted	O
22	to	O
23	the	O
24	cytoplasm	O
25	.	O

0	This	O
1	study	O
2	tested	O
3	the	O
4	hypothesis	O
5	that	O
6	sodium	O
7	channel	O
8	blocking	O
9	drugs	O
10	selectively	O
11	prolong	O
12	the	O
13	late	O
14	potential	O
15	,	O
16	or	O
17	terminal	O
18	low	O
19	amplitude	O
20	signal	O
21	,	O
22	portion	O
23	of	O
24	the	O
25	signal	O
26	-	O
27	averaged	O
28	QRS	B
29	complex	O
30	and	O
31	that	O
32	prolongation	O
33	of	O
34	the	O
35	late	O
36	potential	O
37	would	O
38	correlate	O
39	with	O
40	slowing	O
41	of	O
42	ventricular	O
43	tachycardia	O
44	.	O

0	Cells	O
1	respond	O
2	to	O
3	the	O
4	accumulation	O
5	of	O
6	unfolded	O
7	proteins	O
8	in	O
9	the	O
10	endoplasmic	O
11	reticulum	O
12	(	O
13	ER	O
14	)	O
15	by	O
16	increasing	O
17	the	O
18	transcription	O
19	of	O
20	the	O
21	genes	O
22	encoding	O
23	ER	B
24	-	I
25	resident	I
26	chaperone	I
27	proteins	I
28	.	O

0	Co	O
1	-	O
2	administration	O
3	of	O
4	5FU	B
5	,	O
6	angiotensin	B
7	II	I
8	and	O
9	microspheres	O
10	via	O
11	the	O
12	hepatic	O
13	artery	O
14	may	O
15	reduce	O
16	drug	O
17	exposure	O
18	in	O
19	the	O
20	systemic	O
21	compartment	O
22	and	O
23	therefore	O
24	may	O
25	increase	O
26	the	O
27	therapeutic	O
28	ratio	O
29	of	O
30	5FU	B
31	administration	O
32	via	O
33	the	O
34	hepatic	O
35	artery	O
36	.	O

0	Together	O
1	,	O
2	our	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	TR2	B
8	orphan	I
9	receptor	I
10	may	O
11	be	O
12	a	O
13	master	O
14	regulator	O
15	in	O
16	modulating	O
17	the	O
18	activation	O
19	of	O
20	two	O
21	key	O
22	HREs	O
23	,	O
24	RARE	B
25	beta	I
26	and	O
27	CRBPIIp	B
28	,	O
29	involved	O
30	in	O
31	the	O
32	retinoic	O
33	acid	O
34	signal	O
35	transduction	O
36	pathway	O
37	.	O

0	The	O
1	transcription	B
2	factor	I
3	Sp1	I
4	bound	O
5	to	O
6	eight	O
7	sites	O
8	,	O
9	as	O
10	demonstrated	O
11	by	O
12	footprinting	O
13	assays	O
14	and	O
15	gel	O
16	shift	O
17	analysis	O
18	with	O
19	purified	O
20	Sp1	B
21	.	O

0	Both	O
1	parents	O
2	are	O
3	clinically	O
4	normal	O
5	and	O
6	unrelated	O
7	.	O

0	Identification	O
1	of	O
2	an	O
3	AfsA	B
4	homologue	I
5	(	O
6	BarX	B
7	)	O
8	from	O
9	Streptomyces	O
10	virginiae	O
11	as	O
12	a	O
13	pleiotropic	O
14	regulator	O
15	controlling	O
16	autoregulator	O
17	biosynthesis	O
18	,	O
19	virginiamycin	O
20	biosynthesis	O
21	and	O
22	virginiamycin	O
23	M1	O
24	resistance	O
25	.	O

0	As	O
1	control	O
2	,	O
3	the	O
4	cells	O
5	were	O
6	transfected	O
7	with	O
8	DNA	O
9	mixtures	O
10	containing	O
11	vector	O
12	mU6	B
13	-	O
14	C1	O
15	or	O
16	mU6	B
17	-	O
18	C2	O
19	.	O

0	The	O
1	ns2	B
2	gene	I
3	comprises	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	(	O
9	ORF	O
10	)	O
11	encoding	O
12	a	O
13	putative	O
14	nonstructural	O
15	(	O
16	ns	O
17	)	O
18	protein	O
19	of	O
20	279	O
21	amino	O
22	acids	O
23	with	O
24	a	O
25	predicted	O
26	molecular	O
27	mass	O
28	of	O
29	32	O
30	-	O
31	kDa	O
32	.	O

0	Taken	O
1	together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	Dbf8p	B
8	plays	O
9	an	O
10	essential	O
11	role	O
12	in	O
13	chromosome	O
14	segregation	O
15	.	O

0	We	O
1	have	O
2	identified	O
3	in	O
4	the	O
5	5	O
6	'	O
7	untranslated	O
8	region	O
9	of	O
10	the	O
11	Drosophila	B
12	copia	I
13	retrotransposon	I
14	,	O
15	3	O
16	'	O
17	to	O
18	the	O
19	left	O
20	LTR	O
21	,	O
22	a	O
23	sequence	O
24	for	O
25	transcriptional	O
26	regulation	O
27	by	O
28	homeoproteins	O
29	.	O

0	T	B
1	antigen	I
2	contains	O
3	four	O
4	H	B
5	-	I
6	2Db	I
7	-	O
8	restricted	O
9	cytotoxic	O
10	T	O
11	lymphocyte	O
12	(	O
13	CTL	O
14	)	O
15	recognition	O
16	epitopes	O
17	that	O
18	are	O
19	targets	O
20	for	O
21	CTL	B
22	clones	I
23	Y	I
24	-	I
25	1	I
26	,	O
27	Y	O
28	-	O
29	2	O
30	,	O
31	Y	O
32	-	O
33	3	O
34	,	O
35	and	O
36	Y	B
37	-	I
38	5	I
39	.	O

0	Identification	O
1	and	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	for	O
7	the	O
8	cytotactin	B
9	gene	I
10	.	O

0	The	O
1	COOH	O
2	-	O
3	terminal	O
4	region	O
5	of	O
6	the	O
7	transcripts	O
8	contained	O
9	fifteen	O
10	triplet	O
11	repeats	O
12	(	O
13	GCT	O
14	;	O
15	alanine	O
16	)	O
17	at	O
18	nucleotide	O
19	465	O
20	to	O
21	509	O
22	,	O
23	which	O
24	is	O
25	significantly	O
26	expanded	O
27	compared	O
28	to	O
29	the	O
30	rat	B
31	RL14	I
32	.	O

0	In	O
1	a	O
2	gntR	B
3	deletion	O
4	mutant	O
5	,	O
6	the	O
7	expression	O
8	of	O
9	a	O
10	chromosomal	B
11	gntT	I
12	::	O
13	lacZ	B
14	fusion	O
15	is	O
16	both	O
17	high	O
18	and	O
19	constitutive	O
20	,	O
21	confirming	O
22	that	O
23	GntR	B
24	is	O
25	the	O
26	negative	O
27	regulator	O
28	of	O
29	gntT	B
30	.	O

0	Mean	O
1	(+/-	O
2	SE	O
3	)	O
4	measurements	O
5	of	O
6	clearance	O
7	(	O
8	24	O
9	.	O
10	5	O
11	+/-	O
12	2	O
13	.	O
14	06	O
15	v	O
16	26	O
17	.	O
18	5	O
19	+/-	O
20	2	O
21	.	O
22	05	O
23	mL	O
24	/	O
25	min	O
26	/	O
27	m2	O
28	),	O
29	half	O
30	-	O
31	life	O
32	(	O
33	5	O
34	.	O
35	7	O
36	+/-	O
37	0	O
38	.	O
39	5	O
40	v	O
41	6	O
42	.	O
43	4	O
44	+/-	O
45	0	O
46	.	O
47	5	O
48	hours	O
49	),	O
50	and	O
51	volume	O
52	of	O
53	distribution	O
54	(	O
55	12	O
56	.	O
57	4	O
58	+/-	O
59	1	O
60	.	O
61	1	O
62	v	O
63	13	O
64	.	O
65	7	O
66	+/-	O
67	1	O
68	.	O
69	6	O
70	L	O
71	/	O
72	m2	O
73	)	O
74	were	O
75	not	O
76	significantly	O
77	different	O
78	in	O
79	patients	O
80	with	O
81	jaundice	O
82	when	O
83	compared	O
84	with	O
85	controls	O
86	.	O

0	Normocapnic	O
1	(	O
2	PACO2	O
3	=	O
4	40	O
5	mm	O
6	Hg	O
7	)	O
8	ventilatory	O
9	drive	O
10	increased	O
11	significantly	O
12	(	O
13	p	O
14	less	O
15	than	O
16	0	O
17	.	O
18	05	O
19	)	O
20	in	O
21	six	O
22	subjects	O
23	(	O
24	Type	O
25	1	O
26	response	O
27	)	O
28	and	O
29	decreased	O
30	substantially	O
31	in	O
32	the	O
33	others	O
34	(	O
35	Type	O
36	2	O
37	response	O
38	);	O
39	with	O
40	hypercapnia	O
41	,	O
42	the	O
43	changes	O
44	in	O
45	drive	O
46	were	O
47	attenuated	O
48	in	O
49	both	O
50	groups	O
51	.	O

0	Determination	O
1	of	O
2	transaminases	O
3	with	O
4	an	O
5	autoanalyzer	O

0	The	O
1	data	O
2	show	O
3	conclusively	O
4	that	O
5	phosphorylation	O
6	of	O
7	His	O
8	-	O
9	304	O
10	is	O
11	not	O
12	essential	O
13	for	O
14	any	O
15	of	O
16	the	O
17	known	O
18	functions	O
19	of	O
20	A	O
21	.	O
22	vinelandii	O
23	NifL	O
24	.	O

0	Deletion	O
1	analysis	O
2	was	O
3	carried	O
4	out	O
5	within	O
6	a	O
7	part	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	showing	O
15	homology	O
16	to	O
17	the	O
18	upstream	O
19	region	O
20	of	O
21	the	O
22	yeast	B
23	CYC1	I
24	gene	I
25	.	O

0	The	O
1	N	O
2	-	O
3	terminus	O
4	of	O
5	another	O
6	open	O
7	reading	O
8	frame	O
9	was	O
10	found	O
11	3	O
12	'	O
13	from	O
14	nifA	B
15	and	O
16	tentatively	O
17	identified	O
18	as	O
19	nifB	B
20	by	O
21	amino	O
22	acid	O
23	sequence	O
24	comparison	O
25	.	O

0	Stoichiometric	O
1	phosphorylation	O
2	of	O
3	human	B
4	p53	I
5	at	O
6	Ser315	O
7	stimulates	O
8	p53	B
9	-	O
10	dependent	O
11	transcription	O
12	.	O
13	p53	B
14	protein	I
15	activity	O
16	as	O
17	a	O
18	transcription	O
19	factor	O
20	can	O
21	be	O
22	activated	O
23	in	O
24	vivo	O
25	by	O
26	antibodies	O
27	that	O
28	target	O
29	its	O
30	C	O
31	-	O
32	terminal	O
33	negative	O
34	regulatory	O
35	domain	O
36	suggesting	O
37	that	O
38	cellular	O
39	enzymes	O
40	that	O
41	target	O
42	this	O
43	domain	O
44	may	O
45	play	O
46	a	O
47	role	O
48	in	O
49	stimulating	O
50	p53	B
51	-	O
52	dependent	O
53	gene	O
54	expression	O
55	.	O

0	TPO	B
1	by	O
2	itself	O
3	did	O
4	not	O
5	activate	O
6	ERK1	B
7	,	O
8	ERK2	B
9	and	O
10	protein	B
11	kinase	I
12	C	I
13	(	O
14	PKC	B
15	),	O
16	whereas	O
17	TPO	B
18	directly	O
19	enhanced	O
20	the	O
21	PKC	B
22	-	O
23	dependent	O
24	activation	O
25	of	O
26	ERKs	B
27	induced	O
28	by	O
29	other	O
30	agonists	O
31	including	O
32	thrombin	B
33	and	O
34	phorbol	O
35	esters	O
36	,	O
37	without	O
38	affecting	O
39	the	O
40	PKC	B
41	activation	O
42	by	O
43	those	O
44	agonists	O
45	.	O

0	Critical	O
1	evaluation	O
2	of	O
3	various	O
4	methods	O
5	of	O
6	determining	O
7	markers	O
8	of	O
9	fetal	O
10	maturity	O
11	in	O
12	amniotic	O
13	fluid	O

0	The	O
1	low	B
2	molecular	I
3	mass	I
4	polypeptide	I
5	complex	I
6	is	O
7	assumed	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	antigen	O
13	presentation	O
14	,	O
15	generating	O
16	peptides	O
17	from	O
18	cytosolic	B
19	protein	I
20	antigens	I
21	,	O
22	which	O
23	are	O
24	subsequently	O
25	presented	O
26	to	O
27	cytotoxic	O
28	T	O
29	-	O
30	lymphocytes	O
31	on	O
32	the	O
33	cell	O
34	surface	O
35	.	O

0	Dose	O
1	of	O
2	20	O
3	ig	O
4	were	O
5	administered	O
6	within	O
7	a	O
8	scheme	O
9	from	O
10	0	O
11	.	O
12	1	O
13	to	O
14	6	O
15	months	O
16	in	O
17	order	O
18	to	O
19	study	O
20	its	O
21	immunogenicity	O
22	,	O
23	which	O
24	was	O
25	evaluated	O
26	at	O
27	2	O
28	,	O
29	7	O
30	,	O
31	and	O
32	12	O
33	months	O
34	after	O
35	the	O
36	first	O
37	dose	O
38	.	O

0	Two	O
1	variant	O
2	PRP	B
3	-	I
4	precursor	I
5	alleles	I
6	occur	O
7	which	O
8	slightly	O
9	differ	O
10	in	O
11	the	O
12	number	O
13	of	O
14	repeats	O
15	in	O
16	domain	O
17	C	O
18	.	O

0	The	O
1	mei4	B
2	+	I
3	gene	I
4	of	O
5	the	O
6	fission	O
7	yeast	O
8	Schizosaccharomyces	O
9	pombe	I
10	was	O
11	cloned	O
12	by	O
13	functional	O
14	complementation	O
15	.	O

0	Abnormal	O
1	technetium	O
2	Tc	O
3	99m	O
4	medronate	O
5	scans	O
6	in	O
7	patients	O
8	with	O
9	previously	O
10	undiagnosed	O
11	polyarthralgias	O
12	suggested	O
13	inflammatory	O
14	arthropathy	O
15	and	O
16	influenced	O
17	management	O
18	decisions	O
19	with	O
20	favorable	O
21	therapeutic	O
22	outcomes	O
23	.	O

0	2	O
1	-	O
2	Chemical	O
3	occlusion	O
4	of	O
5	vas	O
6	is	O
7	quite	O
8	effective	O
9	in	O
10	producing	O
11	a	O
12	block	O
13	in	O
14	the	O
15	vas	O
16	deferens	O
17	of	O
18	dogs	O
19	.	O

0	Its	O
1	application	O
2	in	O
3	Madagascar	O
4	:	O
5	advantages	O
6	and	O
7	disadvantages	O

0	A	O
1	retrospective	O
2	study	O
3	of	O
4	banked	O
5	sera	O
6	from	O
7	19	O
8	cats	O
9	with	O
10	the	O
11	eosinophilic	O
12	granuloma	O
13	complex	O
14	revealed	O
15	that	O
16	68	O
17	%	O
18	of	O
19	affected	O
20	cats	O
21	had	O
22	circulating	O
23	antibodies	O
24	to	O
25	components	O
26	of	O
27	normal	O
28	cat	O
29	epithelium	O
30	.	O

0	We	O
1	report	O
2	here	O
3	on	O
4	the	O
5	molecular	O
6	nature	O
7	of	O
8	an	O
9	EMS	B
10	-	O
11	induced	O
12	mutant	O
13	,	O
14	mn1	B
15	-	I
16	89	I
17	,	O
18	a	O
19	leaky	O
20	semidominant	O
21	allele	O
22	of	O
23	the	O
24	Miniature1	B
25	(	O
26	Mn1	B
27	)	O
28	seed	O
29	locus	O
30	that	O
31	encodes	O
32	a	O
33	seed	B
34	-	I
35	specific	I
36	cell	I
37	wall	I
38	invertase	I
39	,	O
40	INCW2	B
41	.	O

0	Primer	O
1	extension	O
2	experiments	O
3	revealed	O
4	a	O
5	strong	O
6	transcription	O
7	initiation	O
8	site	O
9	102	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	translational	O
15	start	O
16	site	O
17	.	O

0	This	O
1	0	O
2	.	O
3	74	O
4	kb	O
5	cDNA	O
6	contains	O
7	an	O
8	open	O
9	reading	O
10	frame	O
11	(	O
12	ORF	O
13	)	O
14	of	O
15	477	O
16	bp	O
17	encoding	O
18	a	O
19	polypeptide	O
20	of	O
21	159	O
22	amino	O
23	acids	O
24	(	O
25	aa	O
26	)	O
27	which	O
28	differs	O
29	at	O
30	only	O
31	one	O
32	position	O
33	(	O
34	position	O
35	65	O
36	)	O
37	from	O
38	the	O
39	human	B
40	U1	I
41	-	I
42	C	I
43	protein	I
44	.	O

0	Although	O
1	large	O
2	epidemiologic	O
3	studies	O
4	are	O
5	best	O
6	able	O
7	to	O
8	identify	O
9	the	O
10	relative	O
11	contributions	O
12	of	O
13	specific	O
14	risk	O
15	factors	O
16	while	O
17	controlling	O
18	for	O
19	other	O
20	risk	O
21	factors	O
22	,	O
23	new	O
24	studies	O
25	need	O
26	to	O
27	focus	O
28	on	O
29	important	O
30	unresolved	O
31	questions	O
32	.	O

0	Gel	O
1	route	O
2	preparation	O
3	of	O
4	low	O
5	fusing	O
6	dental	O
7	porcelain	O
8	frit	O
9	.	O

0	Iodine	O
1	metabolism	O
2	in	O
3	chronic	O
4	thyroiditis	O
5	.	O

0	Deletion	O
1	of	O
2	the	O
3	POR2	B
4	gene	I
5	alone	O
6	had	O
7	no	O
8	detectable	O
9	phenotype	O
10	,	O
11	while	O
12	yeasts	O
13	with	O
14	deletions	O
15	of	O
16	both	O
17	the	O
18	POR1	B
19	and	O
20	POR2	B
21	genes	I
22	were	O
23	viable	O
24	and	O
25	able	O
26	to	O
27	grow	O
28	on	O
29	glycerol	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	,	O
35	albeit	O
36	more	O
37	slowly	O
38	than	O
39	delta	B
40	por1	I
41	single	O
42	mutants	O
43	.	O

0	Some	O
1	artificial	O
2	promoter	O
3	constructs	O
4	containing	O
5	multiple	O
6	Sp1	B
7	sites	I
8	were	O
9	highly	O
10	responsive	O
11	to	O
12	ethanol	O
13	,	O
14	but	O
15	others	O
16	were	O
17	not	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	organization	O
23	of	O
24	the	O
25	proximal	O
26	promoter	O
27	region	O
28	was	O
29	an	O
30	additional	O
31	factor	O
32	that	O
33	affected	O
34	the	O
35	ethanol	O
36	response	O
37	.	O

0	Invertases	B
1	are	O
2	responsible	O
3	for	O
4	the	O
5	breakdown	O
6	of	O
7	sucrose	O
8	to	O
9	fructose	O
10	and	O
11	glucose	O
12	.	O

0	The	O
1	effect	O
2	of	O
3	diffusion	O
4	limitation	O
5	was	O
6	quantified	O
7	in	O
8	terms	O
9	of	O
10	the	O
11	ratio	O
12	O2	O
13	uptake	O
14	/	O
15	O2	O
16	requirement	O
17	(=	O
18	fraction	O
19	of	O
20	cross	O
21	-	O
22	sectional	O
23	area	O
24	supplied	O
25	with	O
26	O2	O
27	),	O
28	assuming	O
29	local	O
30	O2	O
31	requirement	O
32	per	O
33	unit	O
34	volume	O
35	to	O
36	be	O
37	constant	O
38	and	O
39	independent	O
40	of	O
41	PO2	O
42	at	O
43	PO2	O
44	greater	O
45	than	O
46	0	O
47	.	O

0	Comparison	O
1	of	O
2	the	O
3	deduced	O
4	amino	O
5	acid	O
6	sequences	O
7	with	O
8	protein	O
9	sequences	O
10	of	O
11	T	B
12	.	I
13	pyriformis	I
14	H2As	I
15	showed	O
16	only	O
17	two	O
18	and	O
19	three	O
20	differences	O
21	respectively	O
22	,	O
23	in	O
24	a	O
25	total	O
26	of	O
27	137	O
28	amino	O
29	acids	O
30	for	O
31	H2A1	B
32	,	O
33	and	O
34	132	O
35	amino	O
36	acids	O
37	for	O
38	H2A2	B
39	,	O
40	indicating	O
41	the	O
42	two	O
43	genes	O
44	arose	O
45	before	O
46	the	O
47	divergence	O
48	of	O
49	these	O
50	two	O
51	species	O
52	.	O

0	Amikacin	O
1	concentrations	O
2	in	O
3	serum	O
4	and	O
5	blister	O
6	fluid	O
7	in	O
8	healthy	O
9	volunteers	O
10	and	O
11	in	O
12	patients	O
13	with	O
14	renal	O
15	impairment	O
16	.	O

0	The	O
1	present	O
2	study	O
3	investigated	O
4	dose	O
5	dependence	O
6	and	O
7	time	O
8	course	O
9	effects	O
10	of	O
11	the	O
12	benzodiazepine	O
13	(	O
14	BDZ	O
15	)	O
16	partial	O
17	inverse	O
18	agonist	O
19	,	O
20	RO19	O
21	-	O
22	4603	O
23	(	O
24	0	O
25	.	O
26	005	O
27	-	O
28	0	O
29	.	O
30	30	O
31	mg	O
32	/	O
33	kg	O
34	)	O
35	alone	O
36	,	O
37	and	O
38	in	O
39	combination	O
40	with	O
41	the	O
42	BDZ	B
43	receptor	I
44	antagonists	O
45	flumazenil	O
46	,	O
47	ZK	O
48	93426	O
49	,	O
50	and	O
51	CGS	O
52	8216	O
53	(	O
54	20	O
55	mg	O
56	/	O
57	kg	O
58	)	O
59	in	O
60	selectively	O
61	bred	O
62	alcohol	O
63	-	O
64	preferring	O
65	(	O
66	P	O
67	)	O
68	rats	O
69	provided	O
70	a	O
71	two	O
72	-	O
73	bottle	O
74	choice	O
75	test	O
76	between	O
77	ethanol	O
78	(	O
79	EtOH	O
80	)	O
81	(	O
82	10	O
83	%	O
84	v	O
85	/	O
86	v	O
87	),	O
88	and	O
89	a	O
90	palatable	O
91	saccharin	O
92	(	O
93	0	O
94	.	O
95	0125	O
96	%	O
97	g	O
98	/	O
99	v	O
100	)	O
101	solution	O
102	.	O

0	Interference	O
1	with	O
2	rheumatoid	B
3	factor	I
4	was	O
5	only	O
6	observed	O
7	in	O
8	the	O
9	ELISA	O
10	enzygnost	O
11	if	O
12	sera	O
13	were	O
14	not	O
15	pretreated	O
16	with	O
17	latex	O
18	adsorbents	O
19	.	O

0	Three	O
1	of	O
2	the	O
3	short	O
4	ORFs	O
5	in	O
6	the	O
7	central	O
8	region	O
9	of	O
10	BIV	O
11	have	O
12	been	O
13	identified	O
14	by	O
15	location	O
16	and	O
17	structural	O
18	similarity	O
19	to	O
20	the	O
21	nonstructural	O
22	/	O
23	regulatory	O
24	genes	O
25	(	O
26	vif	B
27	,	O
28	tat	B
29	,	O
30	and	O
31	rev	B
32	)	O
33	of	O
34	other	O
35	lentiviruses	O
36	;	O
37	we	O
38	also	O
39	discovered	O
40	two	O
41	unique	O
42	ORFs	O
43	,	O
44	termed	O
45	W	O
46	and	O
47	Y	O
48	,	O
49	which	O
50	may	O
51	serve	O
52	as	O
53	exons	O
54	for	O
55	novel	O
56	genes	O
57	.	O

0	From	O
1	250	O
2	g	O
3	of	O
4	cells	O
5	,	O
6	we	O
7	isolated	O
8	1	O
9	mg	O
10	of	O
11	PDH	B
12	complex	O
13	with	O
14	a	O
15	specific	O
16	activity	O
17	of	O
18	12	O
19	.	O
20	6	O
21	U	O
22	/	O
23	mg	O
24	of	O
25	protein	O
26	.	O

0	We	O
1	analyzed	O
2	an	O
3	EBV	O
4	B	O
5	-	O
6	cell	O
7	clone	O
8	,	O
9	E29	O
10	.	O
11	1	O
12	,	O
13	derived	O
14	from	O
15	an	O
16	11	O
17	week	O
18	-	O
19	old	O
20	embryo	O
21	,	O
22	and	O
23	secreting	O
24	both	O
25	IgM	B
26	kappa	I
27	and	O
28	IgM	B
29	lambda	I
30	.	O

0	Role	O
1	of	O
2	g2	O
3	in	O
4	relating	O
5	the	O
6	Schwinger	O
7	and	O
8	Gerasimov	O
9	-	O
10	Drell	O
11	-	O
12	Hearn	O
13	sum	O
14	rules	O
15	.	O

0	A	O
1	randomised	O
2	,	O
3	controlled	O
4	trial	O
5	was	O
6	undertaken	O
7	in	O
8	40	O
9	patients	O
10	with	O
11	active	O
12	Crohn	O
13	'	O
14	s	O
15	disease	O
16	to	O
17	evaluate	O
18	clinical	O
19	and	O
20	nutritional	O
21	outcomes	O
22	after	O
23	an	O
24	amino	O
25	acid	O
26	based	O
27	diet	O
28	containing	O
29	3	O
30	%	O
31	fat	O
32	was	O
33	given	O
34	by	O
35	a	O
36	feeding	O
37	tube	O
38	compared	O
39	with	O
40	a	O
41	peptide	O
42	based	O
43	diet	O
44	containing	O
45	33	O
46	%	O
47	fat	O
48	.	O

0	Our	O
1	study	O
2	differs	O
3	from	O
4	previous	O
5	studies	O
6	in	O
7	that	O
8	it	O
9	is	O
10	limited	O
11	to	O
12	one	O
13	diagnostic	O
14	entity	O
15	,	O
16	yet	O
17	at	O
18	the	O
19	same	O
20	time	O
21	evaluates	O
22	a	O
23	broad	O
24	range	O
25	of	O
26	social	O
27	and	O
28	work	O
29	-	O
30	related	O
31	factors	O
32	in	O
33	disability	O
34	.	O

0	Normal	O
1	baseline	O
2	(	O
3	day	O
4	-	O
5	8	O
6	)	O
7	PC	O
8	levels	O
9	(	O
10	86	O
11	and	O
12	89	O
13	%)	O
14	were	O
15	markedly	O
16	reduced	O
17	in	O
18	both	O
19	patients	O
20	at	O
21	the	O
22	time	O
23	of	O
24	VOD	O
25	manifestation	O
26	on	O
27	day	O
28	20	O
29	and	O
30	40	O
31	,	O
32	respectively	O
33	(	O
34	26	O
35	and	O
36	31	O
37	%).	O

0	This	O
1	GAP	O
2	activity	O
3	was	O
4	observed	O
5	in	O
6	3T3	O
7	-	O
8	L1	O
9	adipocyte	O
10	lysates	O
11	,	O
12	and	O
13	was	O
14	able	O
15	to	O
16	accelerate	O
17	the	O
18	hydrolysis	O
19	of	O
20	the	O
21	[	O
22	alpha	O
23	-	O
24	32P	O
25	]	O
26	GTP	O
27	bound	O
28	to	O
29	GST	B
30	-	I
31	Rab4	I
32	into	O
33	[	O
34	alpha	O
35	-	O
36	32P	O
37	]	O
38	GDP	O
39	.	O

0	The	O
1	alpha	B
2	2A	I
3	-	I
4	adrenergic	I
5	receptor	I
6	(	O
7	alpha	B
8	2AAR	I
9	)	O
10	is	O
11	coupled	O
12	to	O
13	a	O
14	variety	O
15	of	O
16	effectors	O
17	via	O
18	pertussis	B
19	toxin	I
20	-	I
21	sensitive	I
22	GTP	I
23	-	I
24	binding	I
25	proteins	I
26	.	O

0	Comparison	O
1	of	O
2	immunoassay	O
3	kits	O
4	for	O
5	detection	O
6	of	O
7	staphylococcal	O
8	enterotoxins	O
9	produced	O
10	by	O
11	Staphylococcus	O
12	aureus	O

0	Mutations	O
1	within	O
2	conserved	O
3	region	O
4	2	O
5	(	O
6	CR2	O
7	)	O
8	of	O
9	E1A	B
10	that	O
11	inhibit	O
12	the	O
13	binding	O
14	of	O
15	E1A	B
16	to	O
17	the	O
18	retinoblastoma	B
19	gene	I
20	product	I
21	(	O
22	pRb	B
23	)	O
24	further	O
25	enhanced	O
26	the	O
27	stimulation	O
28	of	O
29	transcription	O
30	from	O
31	the	O
32	PEPCK	B
33	promoter	I
34	by	O
35	2	O
36	3	O
37	-	O
38	fold	O
39	compared	O
40	with	O
41	wild	B
42	type	I
43	E1A	I
44	.	O

0	Many	O
1	canonical	O
2	TATA	O
3	sequences	O
4	are	O
5	present	O
6	upstream	O
7	from	O
8	these	O
9	VZV	O
10	transcriptional	O
11	start	O
12	sites	O
13	but	O
14	,	O
15	apparently	O
16	,	O
17	are	O
18	not	O
19	used	O
20	.	O

0	The	O
1	effects	O
2	of	O
3	loading	O
4	the	O
5	respiratory	O
6	pumps	O
7	on	O
8	the	O
9	oxygen	O
10	consumption	O
11	of	O
12	Callionymus	O
13	lyra	O
14	.	O

0	It	O
1	was	O
2	shown	O
3	that	O
4	estradiol	O
5	concentrations	O
6	obtained	O
7	after	O
8	estradiol	O
9	valerate	O
10	and	O
11	micronized	O
12	estradiol	O
13	ingestion	O
14	were	O
15	dependent	O
16	on	O
17	the	O
18	patient	O
19	'	O
20	s	O
21	age	O
22	as	O
23	well	O
24	as	O
25	on	O
26	the	O
27	constitutional	O
28	type	O
29	.	O

0	Immunologically	O
1	reactive	O
2	insulin	B
3	levels	O
4	were	O
5	determined	O
6	in	O
7	freely	O
8	-	O
9	moving	O
10	normal	O
11	rats	O
12	offered	O
13	three	O
14	different	O
15	test	O
16	-	O
17	meals	O
18	.	O

0	Examination	O
1	of	O
2	immediate	B
3	-	I
4	early	I
5	transcription	I
6	factor	I
7	expression	O
8	during	O
9	the	O
10	MDI	O
11	regimen	O
12	revealed	O
13	that	O
14	RA	B
15	mediated	O
16	an	O
17	elevated	O
18	,	O
19	prolonged	O
20	expression	O
21	of	O
22	c	B
23	-	I
24	Jun	I
25	mRNA	I
26	accompanied	O
27	by	O
28	diminished	O
29	expression	O
30	of	O
31	c	B
32	-	I
33	Fos	I
34	and	O
35	Jun	B
36	-	I
37	B	I
38	mRNAs	I
39	.	O

0	Taken	O
1	together	O
2	,	O
3	these	O
4	data	O
5	indicate	O
6	that	O
7	the	O
8	VirD2	B
9	omega	I
10	domain	I
11	is	O
12	important	O
13	for	O
14	efficient	O
15	T	O
16	-	O
17	DNA	O
18	integration	O
19	.	O

0	Notably	O
1	,	O
2	these	O
3	residues	O
4	are	O
5	located	O
6	in	O
7	different	O
8	domains	O
9	.	O

0	CONCLUSIONS	O
1	:	O
2	While	O
3	INR	O
4	correction	O
5	may	O
6	be	O
7	achieved	O
8	by	O
9	all	O
10	the	O
11	above	O
12	methods	O
13	,	O
14	that	O
15	relating	O
16	log	O
17	reference	O
18	INR	O
19	to	O
20	log	O
21	local	O
22	prothrombin	B
23	time	O
24	by	O
25	linear	O
26	regression	O
27	analysis	O
28	is	O
29	the	O
30	simplest	O
31	to	O
32	perform	O
33	.	O

0	The	O
1	Lp	B
2	mouse	I
3	mutant	I
4	provides	O
5	a	O
6	model	O
7	for	O
8	the	O
9	severe	O
10	human	O
11	neural	O
12	tube	O
13	defect	O
14	(	O
15	NTD	O
16	),	O
17	cranio	O
18	-	O
19	rachischisis	O
20	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	transcription	O
5	of	O
6	c	B
7	-	I
8	IAP2	I
9	promoter	I
10	was	O
11	strongly	O
12	up	O
13	-	O
14	regulated	O
15	when	O
16	CD40	B
17	or	O
18	Epstein	B
19	-	I
20	Barr	I
21	virus	I
22	latent	I
23	membrane	I
24	protein	I
25	1	I
26	was	O
27	overexpressed	O
28	.	O

0	1	O
1	.	O

0	Substitution	O
1	of	O
2	the	O
3	DR1	B
4	beta	I
5	chain	I
6	with	O
7	H	B
8	-	I
9	2E	I
10	beta	I
11	k	I
12	led	O
13	to	O
14	a	O
15	dramatic	O
16	loss	O
17	of	O
18	recognition	O
19	;	O
20	alpha	O
21	chain	O
22	substitution	O
23	had	O
24	a	O
25	less	O
26	marked	O
27	effect	O
28	.	O

0	Inclusion	O
1	of	O
2	the	O
3	extended	O
4	N	O
5	terminus	O
6	into	O
7	the	O
8	originally	O
9	reported	O
10	protein	O
11	resulted	O
12	in	O
13	a	O
14	striking	O
15	similarity	O
16	to	O
17	the	O
18	lymphoid	B
19	factor	I
20	Lef	I
21	-	I
22	1	I
23	.	O

0	No	O
1	consistent	O
2	correlation	O
3	between	O
4	blood	O
5	pressure	O
6	change	O
7	and	O
8	SCR	O
9	-	O
10	change	O
11	was	O
12	seen	O
13	.	O

0	The	O
1	history	O
2	of	O
3	exposure	O
4	and	O
5	carboxyhemoglobin	B
6	levels	O
7	should	O
8	alert	O
9	the	O
10	physician	O
11	to	O
12	this	O
13	diagnosis	O
14	.	O

0	The	O
1	amount	O
2	of	O
3	these	O
4	factors	O
5	was	O
6	reduced	O
7	in	O
8	GEO	O
9	cells	O
10	in	O
11	which	O
12	the	O
13	u	B
14	-	I
15	PAR	I
16	gene	I
17	is	O
18	only	O
19	weakly	O
20	transcriptionally	O
21	activated	O
22	.	O

0	Cerebrospinal	B
1	fluid	I
2	transferrin	I
3	II	I
4	studies	O
5	in	O
6	ischemic	O
7	disorders	O
8	of	O
9	the	O
10	central	O
11	nervous	O
12	system	O
13	.	O

0	Frog	O
1	type	O
2	I	O
3	(	O
4	Ft	O
5	I	O
6	)	O
7	and	O
8	frog	O
9	type	O
10	II	O
11	(	O
12	Ft	O
13	II	O
14	)	O
15	slowly	O
16	adapting	O
17	(	O
18	SA	O
19	)	O
20	units	O
21	produced	O
22	spikes	O
23	only	O
24	at	O
25	the	O
26	indentation	O
27	phase	O
28	,	O
29	and	O
30	the	O
31	threshold	O
32	response	O
33	phase	O
34	(	O
35	TRP	O
36	),	O
37	i	O
38	.	O
39	e	O
40	..	O
41	the	O
42	phase	O
43	of	O
44	the	O
45	first	O
46	spike	O
47	was	O
48	for	O
49	ca	O
50	.	O

0	We	O
1	have	O
2	partially	O
3	sequenced	O
4	the	O
5	RAP74	B
6	protein	I
7	from	O
8	purified	O
9	HeLa	O
10	cells	O
11	,	O
12	cloned	O
13	its	O
14	complementary	O
15	DNA	O
16	and	O
17	shown	O
18	that	O
19	its	O
20	translation	O
21	product	O
22	can	O
23	interact	O
24	with	O
25	RAP30	B
26	in	O
27	vitro	O
28	as	O
29	well	O
30	as	O
31	in	O
32	vivo	O
33	.	O

0	Until	O
1	such	O
2	investigations	O
3	are	O
4	performed	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	the	O
10	role	O
11	for	O
12	adjuvant	O
13	treatment	O
14	is	O
15	questionable	O
16	and	O
17	that	O
18	TME	O
19	surgery	O
20	is	O
21	preferred	O
22	as	O
23	the	O
24	treatment	O
25	option	O
26	for	O
27	Stage	O
28	T1	O
29	-	O
30	T3	O
31	rectal	O
32	cancers	O
33	.	O

0	Thus	O
1	,	O
2	the	O
3	bovine	B
4	PEDF	I
5	cDNA	I
6	isolated	O
7	here	O
8	codes	O
9	for	O
10	a	O
11	functional	O
12	soluble	O
13	secreted	O
14	PEDF	I
15	glycoprotein	I
16	.	O

0	HIV	O
1	infectiousness	O
2	and	O
3	the	O
4	AIDS	O
5	epidemic	O
6	.	O

0	For	O
1	SMX	O
2	at	O
3	pH	O
4	7	O
5	.	O
6	0	O
7	,	O
8	a	O
9	1	O
10	:	O
11	1	O
12	complex	O
13	is	O
14	formed	O
15	,	O
16	but	O
17	at	O
18	pH	O
19	7	O
20	.	O
21	5	O
22	HPCD	O
23	has	O
24	little	O
25	effect	O
26	on	O
27	the	O
28	solubility	O
29	of	O
30	the	O
31	highly	O
32	ionized	O
33	SMX	O
34	,	O
35	presumably	O
36	since	O
37	only	O
38	un	O
39	-	O
40	ionized	O
41	molecules	O
42	can	O
43	form	O
44	inclusion	O
45	complexes	O
46	with	O
47	the	O
48	HPCD	O
49	.	O

0	Vitrectomy	O
1	in	O
2	ocular	O
3	traumatology	O

0	EMBO	O
1	J	O
2	.	O

0	M	O
1	.	O
2	M	O
3	.	O
4	C	O
5	.	O
6	was	O
7	used	O
8	for	O
9	2	O
10	.	O
11	5	O
12	minutes	O
13	in	O
14	44	O
15	cases	O
16	(	O
17	20	O
18	HR	O
19	patients	O
20	,	O
21	24	O
22	LR	O
23	patients	O
24	),	O
25	and	O
26	for	O
27	5	O
28	minutes	O
29	in	O
30	66	O
31	cases	O
32	(	O
33	46	O
34	HR	O
35	patients	O
36	,	O
37	20	O
38	LR	O
39	patients	O
40	).	O

0	The	O
1	distribution	O
2	phase	O
3	is	O
4	followed	O
5	by	O
6	an	O
7	elimination	O
8	phase	O
9	with	O
10	a	O
11	much	O
12	longer	O
13	half	O
14	-	O
15	life	O
16	(	O
17	mean	O
18	value	O
19	375	O
20	min	O
21	)	O
22	and	O
23	a	O
24	volume	O
25	of	O
26	distribution	O
27	of	O
28	approximately	O
29	200	O
30	-	O
31	400	O
32	l	O
33	.	O

0	(	O
1	iii	O
2	)	O
3	In	O
4	these	O
5	cells	O
6	,	O
7	PKCbeta	B
8	plays	O
9	a	O
10	unique	O
11	Ras	B
12	-	O
13	independent	O
14	role	O
15	in	O
16	mediating	O
17	insulin	B
18	but	O
19	not	O
20	EGF	B
21	or	O
22	other	O
23	growth	O
24	factor	O
25	mitogenic	O
26	signals	O
27	.	O

0	A	O
1	developmentally	O
2	modulated	O
3	chromatin	O
4	structure	O
5	at	O
6	the	O
7	mouse	B
8	immunoglobulin	I
9	kappa	I
10	3	I
11	'	I
12	enhancer	I
13	.	O

0	Reconstitution	O
1	of	O
2	Raf	B
3	-	I
4	1	I
5	activity	O
6	was	O
7	observed	O
8	only	O
9	with	O
10	kinase	O
11	active	O
12	Jak1	B
13	in	O
14	both	O
15	cell	O
16	lines	O
17	.	O

0	The	O
1	remainder	O
2	(	O
3	18	O
4	.	O
5	4	O
6	%)	O
7	was	O
8	with	O
9	IgA	O
10	nephropathy	O
11	,	O
12	which	O
13	was	O
14	histologically	O
15	mild	O
16	.	O

0	Biologically	O
1	significant	O
2	amounts	O
3	of	O
4	platelet	B
5	activating	I
6	factor	I
7	were	O
8	eluted	O
9	from	O
10	the	O
11	sorbent	O
12	during	O
13	the	O
14	entire	O
15	treatment	O
16	time	O
17	.	O

0	At	O
1	both	O
2	water	O
3	temperatures	O
4	,	O
5	VO2	O
6	increased	O
7	linearly	O
8	with	O
9	increasing	O
10	swimming	O
11	velocity	O
12	.	O

0	The	O
1	trk	B
2	-	I
3	2h	I
4	oncogene	I
5	,	O
6	isolated	O
7	from	O
8	the	O
9	human	O
10	breast	O
11	carcinoma	O
12	cell	O
13	line	O
14	MDA	O
15	-	O
16	MB	O
17	231	O
18	by	O
19	genomic	O
20	DNA	O
21	-	O
22	transfection	O
23	into	O
24	NIH3T3	O
25	cells	O
26	,	O
27	consists	O
28	of	O
29	the	O
30	trk	B
31	proto	I
32	-	I
33	oncogene	I
34	receptor	I
35	kinase	I
36	domain	I
37	fused	O
38	to	O
39	a	O
40	N	O
41	-	O
42	terminal	O
43	41	O
44	amino	O
45	acid	O
46	activating	O
47	sequence	O
48	(	O
49	Kozma	O
50	,	O
51	S	O
52	.	O
53	C	O
54	.,	O
55	Redmond	O
56	,	O
57	S	O
58	.	O
59	M	O
60	.	O
61	S	O
62	.,	O
63	Xiao	O
64	-	O
65	Chang	O
66	,	O
67	F	O
68	.,	O
69	Saurer	O
70	,	O
71	S	O
72	.	O
73	M	O
74	.,	O
75	Groner	O
76	,	O
77	B	O
78	.	O
79	and	O
80	Hynes	O
81	,	O
82	N	O
83	.	O
84	E	O
85	.	O

0	Both	O
1	filters	O
2	equally	O
3	contributed	O
4	to	O
5	elevation	O
6	of	O
7	iliac	O
8	venous	O
9	pressure	O
10	(	O
11	median	O
12	,	O
13	9	O
14	.	O
15	3	O
16	and	O
17	7	O
18	.	O
19	2	O
20	mm	O
21	Hg	O
22	[	O
23	n	O
24	=	O
25	9	O
26	]	O
27	with	O
28	the	O
29	spring	O
30	filter	O
31	and	O
32	RF02	O
33	filter	O
34	,	O
35	respectively	O
36	).	O

0	Treatment	O
1	of	O
2	unstable	O
3	angina	O
4	:	O
5	role	O
6	of	O
7	antithrombotic	O
8	therapy	O
9	.	O

0	CONCLUSION	O
1	:	O
2	The	O
3	alpha2	O
4	-	O
5	adrenergic	O
6	antagonist	O
7	idazoxan	O
8	increases	O
9	glucose	O
10	-	O
11	induced	O
12	sympathetic	O
13	activity	O
14	but	O
15	not	O
16	energy	O
17	expenditure	O
18	in	O
19	obese	O
20	subjects	O
21	.	O

0	The	O
1	adeno	B
2	-	I
3	associated	I
4	virus	I
5	(	I
6	AAV	I
7	)	I
8	rep	I
9	gene	I
10	encodes	O
11	four	O
12	proteins	O
13	(	O
14	Rep78	B
15	,	O
16	Rep68	B
17	,	O
18	Rep52	B
19	,	O
20	and	O
21	Rep40	B
22	)	O
23	required	O
24	for	O
25	AAV	O
26	DNA	O
27	replication	O
28	and	O
29	AAV	O
30	gene	O
31	regulation	O
32	.	O

0	Cloning	O
1	and	O
2	sequencing	O
3	revealed	O
4	that	O
5	dMax	B
6	contains	O
7	a	O
8	deletion	O
9	spanning	O
10	the	O
11	basic	O
12	region	O
13	and	O
14	helix	O
15	1	O
16	and	O
17	the	O
18	loop	O
19	of	O
20	the	O
21	helix	O
22	-	O
23	loop	O
24	-	O
25	helix	O
26	region	O
27	,	O
28	presumably	O
29	as	O
30	a	O
31	result	O
32	of	O
33	alternative	O
34	splicing	O
35	of	O
36	max	B
37	RNA	I
38	.	O

0	Experiences	O
1	with	O
2	the	O
3	clinical	O
4	and	O
5	experimental	O
6	use	O
7	of	O
8	Urat	O
9	-	O
10	I	O
11	lithotriptor	O
12	.	O

0	Primary	O
1	invasive	O
2	Haemophilus	O
3	influenzae	O
4	type	O
5	b	O
6	disease	O
7	:	O
8	a	O
9	population	O
10	-	O
11	based	O
12	assessment	O
13	of	O
14	risk	O
15	factors	O
16	.	O

0	On	O
1	the	O
2	other	O
3	hand	O
4	,	O
5	neither	O
6	phosphate	O
7	buffered	O
8	saline	O
9	injection	O
10	into	O
11	the	O
12	ES	O
13	nor	O
14	primary	O
15	KLH	O
16	challenges	O
17	of	O
18	the	O
19	ES	O
20	were	O
21	capable	O
22	of	O
23	elevating	O
24	the	O
25	threshold	O
26	level	O
27	and	O
28	changing	O
29	the	O
30	latency	O
31	.	O

0	We	O
1	demonstrate	O
2	that	O
3	a	O
4	VT	B
5	+	I
6	peptide	I
7	was	O
8	specifically	O
9	phosphorylated	O
10	by	O
11	protein	B
12	kinase	I
13	C	I
14	(	O
15	PKC	B
16	)	O
17	in	O
18	vitro	O
19	,	O
20	but	O
21	not	O
22	by	O
23	protein	B
24	kinase	I
25	A	I
26	(	O
27	PKA	B
28	).	O

0	We	O
1	report	O
2	a	O
3	prevalence	O
4	study	O
5	of	O
6	the	O
7	best	O
8	visual	O
9	acuity	O
10	in	O
11	the	O
12	affected	O
13	eye	O
14	of	O
15	100	O
16	selected	O
17	patients	O
18	with	O
19	herpetic	O
20	keratitis	O
21	seen	O
22	during	O
23	a	O
24	two	O
25	-	O
26	year	O
27	period	O
28	.	O

0	Neutron	O
1	scattering	O
2	measurements	O
3	of	O
4	critical	O
5	exponents	O
6	in	O
7	CsMnBr3	O
8	:	O
9	A	O
10	Z2	O
11	&	O
12	gt	O
13	;=	O
14	1	O
15	antiferromagnet	O
16	.	O

0	Interspecific	O
1	backcross	O
2	analysis	O
3	using	O
4	progeny	O
5	derived	O
6	from	O
7	matings	O
8	of	O
9	(	O
10	C57BL	O
11	/	O
12	6J	O
13	x	O
14	Mus	O
15	spretus	O
16	)	O
17	F1	O
18	x	O
19	C57BL	O
20	/	O
21	6J	O
22	mice	O
23	indicates	O
24	that	O
25	the	O
26	thrombospondin	B
27	gene	I
28	is	O
29	tightly	O
30	linked	O
31	to	O
32	the	O
33	Fshb	B
34	,	O
35	Actcl	B
36	,	O
37	Ltk	B
38	,	O
39	and	O
40	B2M	B
41	loci	I
42	on	O
43	murine	O
44	chromosome	O
45	2	O
46	.	O

0	This	O
1	was	O
2	performed	O
3	in	O
4	a	O
5	double	O
6	blinded	O
7	,	O
8	randomized	O
9	,	O
10	placebo	O
11	-	O
12	controlled	O
13	study	O
14	.	O

0	The	O
1	pheromone	O
2	response	O
3	pathway	O
4	activates	O
5	transcription	O
6	of	O
7	Ty5	B
8	retrotransposons	I
9	located	O
10	within	O
11	silent	O
12	chromatin	O
13	of	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

0	Lengthy	O
1	and	O
2	repeated	O
3	hemodialyses	O
4	were	O
5	required	O
6	to	O
7	lower	O
8	lithemia	O
9	to	O
10	nontoxic	O
11	ranges	O
12	.	O

0	The	O
1	major	O
2	myosin	B
3	-	I
4	binding	I
5	domain	I
6	of	O
7	skeletal	B
8	muscle	I
9	MyBP	I
10	-	I
11	C	I
12	(	O
13	C	B
14	protein	I
15	)	O
16	resides	O
17	in	O
18	the	O
19	COOH	O
20	-	O
21	terminal	O
22	,	O
23	immunoglobulin	B
24	C2	I
25	motif	I
26	.	O

0	In	O
1	this	O
2	paper	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	binding	O
8	of	O
9	the	O
10	GA	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	GABP	B
16	)	O
17	to	O
18	ets	B
19	sequence	I
20	motifs	I
21	within	O
22	each	O
23	repeated	O
24	unit	O
25	is	O
26	required	O
27	for	O
28	transcriptional	O
29	activation	O
30	of	O
31	the	O
32	COXIV	B
33	promoter	I
34	.	O

0	PULSE	O
1	is	O
2	used	O
3	to	O
4	set	O
5	such	O
6	NMR	O
7	spectroscopic	O
8	parameters	O
9	as	O
10	the	O
11	delay	O
12	and	O
13	duration	O
14	of	O
15	rf	O
16	transmit	O
17	and	O
18	receive	O
19	gates	O
20	,	O
21	rf	O
22	phase	O
23	,	O
24	sampling	O
25	times	O
26	,	O
27	and	O
28	such	O
29	imaging	O
30	parameters	O
31	as	O
32	rf	O
33	pulse	O
34	shape	O
35	and	O
36	gradient	O
37	waveforms	O
38	.	O

0	Phosphorylation	O
1	analyses	O
2	indicated	O
3	that	O
4	inhibition	O
5	of	O
6	ERK	B
7	-	I
8	1	I
9	/	I
10	2	I
11	decreased	O
12	okadaic	O
13	acid	O
14	-	O
15	elevated	O
16	phosphorylation	O
17	of	O
18	JunD	B
19	and	O
20	FosB	B
21	.	O

0	Evoked	O
1	potential	O
2	and	O
3	single	O
4	unit	O
5	responses	O
6	to	O
7	olfactory	O
8	nerve	O
9	volleys	O
10	in	O
11	the	O
12	isolated	O
13	turtle	O
14	olfactory	O
15	bulb	O
16	.	O

0	This	O
1	report	O
2	substantiates	O
3	that	O
4	at	O
5	least	O
6	two	O
7	of	O
8	the	O
9	18	B
10	kDa	B
11	hsps	I
12	in	O
13	maize	O
14	are	O
15	products	O
16	of	O
17	different	O
18	but	O
19	related	O
20	genes	O
21	.	O

0	Using	O
1	one	O
2	of	O
3	the	O
4	six	O
5	fragments	O
6	(	O
7	CPK3	B
8	-	I
9	8	I
10	),	O
11	we	O
12	isolated	O
13	a	O
14	2022	O
15	bp	O
16	cDNA	O
17	(	O
18	VrCDPK	B
19	-	I
20	1	I
21	)	O
22	from	O
23	a	O
24	Vigna	O
25	radiata	O
26	lambda	O
27	gt11	O
28	library	O
29	.	O

0	Next	O
1	,	O
2	to	O
3	identify	O
4	regions	O
5	of	O
6	the	O
7	promoter	O
8	involved	O
9	,	O
10	we	O
11	examined	O
12	a	O
13	series	O
14	of	O
15	tenascin	B
16	-	I
17	C	I
18	promoter	I
19	constructs	I
20	with	O
21	5	O
22	'	O
23	deletions	O
24	and	O
25	showed	O
26	that	O
27	denatured	O
28	collagen	B
29	-	O
30	dependent	O
31	promoter	O
32	activity	O
33	was	O
34	retained	O
35	by	O
36	a	O
37	122	O
38	-	O
39	base	O
40	pair	O
41	element	O
42	,	O
43	located	O
44	-	O
45	43	O
46	to	O
47	-	O
48	165	O
49	bp	O
50	upstream	O
51	of	O
52	the	O
53	RNA	O
54	start	O
55	site	O
56	.	O

0	Serum	O
1	concentrations	O
2	of	O
3	bone	B
4	specific	I
5	alkaline	I
6	phosphatase	I
7	(	O
8	BALP	B
9	)	O
10	and	O
11	osteocalcin	B
12	(	O
13	bone	B
14	Gla	I
15	protein	I
16	,	O
17	BGP	B
18	),	O
19	urinary	O
20	levels	O
21	of	O
22	pyridinoline	O
23	(	O
24	Pyr	O
25	)	O
26	and	O
27	deoxypyridinoline	O
28	(	O
29	Dpyr	O
30	)	O
31	and	O
32	computed	O
33	tomography	O
34	(	O
35	CT	O
36	)	O
37	measurements	O
38	of	O
39	the	O
40	cross	O
41	-	O
42	sectional	O
43	areas	O
44	of	O
45	the	O
46	vertebrae	O
47	and	O
48	the	O
49	femurs	O
50	,	O
51	the	O
52	apparent	O
53	density	O
54	of	O
55	cancellous	O
56	bone	O
57	in	O
58	the	O
59	vertebrae	O
60	,	O
61	and	O
62	the	O
63	volume	O
64	and	O
65	the	O
66	material	O
67	density	O
68	of	O
69	cortical	O
70	bone	O
71	in	O
72	the	O
73	femurs	O
74	were	O
75	determined	O
76	in	O
77	126	O
78	boys	O
79	and	O
80	143	O
81	girls	O
82	,	O
83	ages	O
84	7	O
85	-	O
86	18	O
87	years	O
88	.	O

0	I	O
1	.	O

0	UDP	B
1	-	I
2	Gal	I
3	:	I
4	Gal	I
5	beta	I
6	1	I
7	----	I
8	4GlcNAc	I
9	alpha	I
10	1	I
11	----	I
12	3	I
13	-	I
14	galactosyltransferase	I
15	is	O
16	a	O
17	terminal	B
18	glycosyltransferase	I
19	that	O
20	is	O
21	widely	O
22	expressed	O
23	in	O
24	a	O
25	variety	O
26	of	O
27	mammalian	O
28	species	O
29	,	O
30	with	O
31	the	O
32	notable	O
33	exception	O
34	of	O
35	man	O
36	,	O
37	apes	O
38	,	O
39	and	O
40	Old	O
41	World	O
42	monkeys	O
43	.	O

0	This	O
1	fragment	O
2	contained	O
3	the	O
4	C	O
5	-	O
6	terminal	O
7	47	O
8	nucleotides	O
9	of	O
10	leuB	B
11	,	O
12	encoding	O
13	3	B
14	-	I
15	isopropylmalate	I
16	dehydrogenase	I
17	;	O
18	asd	B
19	,	O
20	encoding	O
21	aspartate	B
22	-	I
23	beta	I
24	-	I
25	semialdehyde	I
26	dehydrogenase	I
27	(	O
28	Asd	B
29	);	O
30	and	O
31	orfA	B
32	,	O
33	whose	O
34	product	O
35	showed	O
36	similarity	O
37	to	O
38	the	O
39	Asd	B
40	proteins	I
41	from	I
42	Vibrio	I
43	spp	O
44	.	O

0	Overall	O
1	prevalences	O
2	of	O
3	antibody	O
4	were	O
5	70	O
6	per	O
7	cent	O
8	in	O
9	cattle	O
10	,	O
11	67	O
12	per	O
13	cent	O
14	in	O
15	sheep	O
16	and	O
17	76	O
18	per	O
19	cent	O
20	in	O
21	goats	O
22	as	O
23	assessed	O
24	by	O
25	an	O
26	immunodiffusion	O
27	test	O
28	.	O

0	Artificial	O
1	ventilation	O
2	was	O
3	conducted	O
4	using	O
5	a	O
6	tidal	O
7	volume	O
8	of	O
9	10	O
10	ml	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	and	O
16	a	O
17	rate	O
18	of	O
19	10	O
20	to	O
21	12	O
22	c	O
23	X	O
24	min	O
25	-	O
26	1	O
27	.	O

0	Finally	O
1	,	O
2	we	O
3	show	O
4	that	O
5	PhLP	B
6	complexes	O
7	,	O
8	at	O
9	least	O
10	partially	O
11	,	O
12	with	O
13	Gbetagamma	B
14	in	O
15	vivo	O
16	.	O

0	Canine	O
1	reproduction	O
2	:	O
3	effects	O
4	of	O
5	a	O
6	single	O
7	injection	O
8	of	O
9	medroxyprogesterone	O
10	acetate	O
11	on	O
12	the	O
13	reproductive	O
14	organs	O
15	of	O
16	the	O
17	bitch	O
18	.	O

0	Here	O
1	,	O
2	it	O
3	is	O
4	shown	O
5	that	O
6	TAFII250	B
7	,	O
8	the	O
9	largest	O
10	subunit	O
11	of	O
12	TFIID	B
13	,	O
14	contains	O
15	two	O
16	tandem	O
17	bromodomain	O
18	modules	O
19	that	O
20	bind	O
21	selectively	O
22	to	O
23	multiply	O
24	acetylated	O
25	histone	B
26	H4	I
27	peptides	I
28	.	O

0	With	O
1	each	O
2	of	O
3	the	O
4	three	O
5	pairs	O
6	of	O
7	isolates	O
8	(	O
9	case	O
10	and	O
11	suspicious	O
12	case	O
13	),	O
14	identical	O
15	IS6110	B
16	banding	O
17	patterns	O
18	were	O
19	found	O
20	suggesting	O
21	identical	O
22	MTB	O
23	strains	O
24	.	O

0	Fgd3	B
1	and	O
2	FGD1	B
3	share	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	sequence	O
9	identity	O
10	that	O
11	spans	O
12	>	O
13	560	O
14	contiguous	O
15	amino	O
16	acid	O
17	residues	O
18	.	O

0	In	O
1	addition	O
2	,	O
3	a	O
4	noncanonical	O
5	C	B
6	/	I
7	EBP	I
8	-	I
9	binding	I
10	site	I
11	within	O
12	the	O
13	Gadd45gamma	B
14	promoter	I
15	where	O
16	C	B
17	/	I
18	EBPbeta	I
19	and	O
20	C	B
21	/	I
22	EBPdelta	I
23	could	O
24	bind	O
25	,	O
26	was	O
27	identified	O
28	by	O
29	electrophoretic	O
30	mobility	O
31	shift	O
32	assay	O
33	(	O
34	EMSA	O
35	)	O
36	and	O
37	reporter	O
38	gene	O
39	analysis	O
40	.	O

0	Patients	O
1	receiving	O
2	VPA	O
3	showed	O
4	differences	O
5	in	O
6	attention	O
7	,	O
8	visuomotor	O
9	performance	O
10	,	O
11	verbal	O
12	span	O
13	and	O
14	sensory	O
15	discrimination	O
16	tasks	O
17	at	O
18	T1	O
19	,	O
20	in	O
21	visuomotor	O
22	performance	O
23	at	O
24	T2	O
25	and	O
26	in	O
27	spatial	O
28	span	O
29	at	O
30	T3	O
31	,	O
32	whereas	O
33	no	O
34	differences	O
35	were	O
36	detected	O
37	at	O
38	T4	O
39	.	O

0	Expression	O
1	of	O
2	constitutively	O
3	active	O
4	MEK1	B
5	,	O
6	the	O
7	kinase	O
8	that	O
9	activates	O
10	ERKs	B
11	,	O
12	or	O
13	overexpression	O
14	of	O
15	ERK2	B
16	,	O
17	but	O
18	not	O
19	JNK1	B
20	,	O
21	inhibited	O
22	Stat3	B
23	activation	O
24	.	O

0	A	O
1	human	B
2	SPT3	I
3	-	O
4	TAFII31	B
5	-	O
6	GCN5	B
7	-	O
8	L	B
9	acetylase	I
10	complex	O
11	distinct	O
12	from	O
13	transcription	B
14	factor	I
15	IID	I
16	.	O

0	Point	O
1	mutations	O
2	in	O
3	the	O
4	third	O
5	SH3	B
6	domain	I
7	abolished	O
8	the	O
9	vinexin	B
10	-	O
11	Sos	B
12	interaction	O
13	.	O

0	After	O
1	2	O
2	min	O
3	of	O
4	dobutamine	O
5	injection	O
6	,	O
7	or	O
8	after	O
9	20	O
10	min	O
11	of	O
12	pimobendan	O
13	injection	O
14	,	O
15	the	O
16	myocardium	O
17	was	O
18	removed	O
19	,	O
20	and	O
21	used	O
22	for	O
23	determination	O
24	of	O
25	the	O
26	tissue	O
27	levels	O
28	of	O
29	metabolites	O
30	of	O
31	energy	O
32	and	O
33	carbohydrate	O
34	metabolism	O
35	.	O

0	In	O
1	a	O
2	PC12	O
3	cell	O
4	mutant	O
5	that	O
6	is	O
7	deficient	O
8	in	O
9	protein	B
10	kinase	I
11	A	I
12	activity	O
13	(	O
14	AB	O
15	.	O
16	11	O
17	),	O
18	all	O
19	three	O
20	differentiating	O
21	agents	O
22	were	O
23	unable	O
24	to	O
25	down	O
26	-	O
27	regulate	O
28	nrg	B
29	-	I
30	1	I
31	mRNA	I
32	.	O

0	This	O
1	repression	O
2	was	O
3	mediated	O
4	through	O
5	binding	O
6	to	O
7	the	O
8	E2	B
9	DNA	I
10	-	I
11	binding	I
12	site	I
13	immediately	O
14	upstream	O
15	of	O
16	the	O
17	P105	B
18	promoter	I
19	TATA	O
20	box	O
21	and	O
22	could	O
23	be	O
24	abrogated	O
25	by	O
26	preincubation	O
27	of	O
28	the	O
29	HPV	B
30	-	I
31	18	I
32	P105	I
33	promoter	I
34	template	I
35	with	O
36	the	O
37	nuclear	O
38	extract	O
39	allowing	O
40	the	O
41	formation	O
42	of	O
43	the	O
44	preinitiation	O
45	complex	O
46	.	O

0	We	O
1	also	O
2	identified	O
3	an	O
4	alternative	O
5	spliced	O
6	form	O
7	of	O
8	Lyp	B
9	RNA	I
10	,	O
11	Lyp2	B
12	.	O

0	RT	O
1	-	O
2	PCR	O
3	was	O
4	performed	O
5	using	O
6	previously	O
7	reported	O
8	degenerate	O
9	oligonucleotide	O
10	primers	O
11	to	O
12	the	O
13	ligand	O
14	binding	O
15	domain	O
16	(	O
17	LBD	O
18	)	O
19	of	O
20	known	O
21	beta	B
22	integrin	I
23	subunits	I
24	and	O
25	Bge	B
26	cDNA	I
27	.	O

0	Both	O
1	mutations	O
2	completely	O
3	abolished	O
4	binding	O
5	of	O
6	the	O
7	Abl	B
8	SH3	I
9	domain	I
10	to	O
11	proline	O
12	-	O
13	rich	O
14	target	O
15	proteins	O
16	in	O
17	a	O
18	filter	O
19	-	O
20	binding	O
21	assay	O
22	.	O

0	(	O
1	3	O
2	).	O

0	Oncogenic	O
1	activation	O
2	of	O
3	the	O
4	tyrosine	B
5	kinase	I
6	domain	I
7	of	O
8	the	O
9	human	B
10	trk	I
11	proto	I
12	-	I
13	oncogene	I
14	by	O
15	fusion	O
16	to	O
17	a	O
18	cell	O
19	adhesion	O
20	molecule	O
21	.	O

0	The	O
1	elevations	O
2	achieved	O
3	by	O
4	LDEE	O
5	given	O
6	s	O
7	.	O
8	c	O
9	.	O
10	were	O
11	higher	O
12	than	O
13	those	O
14	achieved	O
15	after	O
16	i	O
17	.	O
18	p	O
19	.	O
20	administration	O
21	and	O
22	lasted	O
23	for	O
24	longer	O
25	periods	O
26	.	O

0	When	O
1	combined	O
2	with	O
3	independent	O
4	activating	O
5	mutations	O
6	in	O
7	the	O
8	c	B
9	-	I
10	abl	I
11	kinase	I
12	domain	I
13	or	O
14	NH2	O
15	-	O
16	terminus	O
17	,	O
18	the	O
19	G128R	B
20	mutation	I
21	blocked	O
22	transformation	O
23	by	O
24	the	O
25	double	O
26	mutant	O
27	,	O
28	suggesting	O
29	that	O
30	the	O
31	G128R	B
32	mutant	I
33	was	O
34	unable	O
35	to	O
36	transform	O
37	cells	O
38	for	O
39	trivial	O
40	reasons	O
41	.	O

0	Primary	O
1	adrenal	O
2	hypersensitivity	O
3	to	O
4	ACTH	B
5	drive	O
6	in	O
7	obesity	O
8	has	O
9	also	O
10	been	O
11	suggested	O
12	.	O

0	Antivitamin	B
1	K	I
2	agents	O

0	ECM	O
1	disruption	O
2	in	O
3	Lytechinus	O
4	embryos	O
5	caused	O
6	a	O
7	relative	O
8	drop	O
9	in	O
10	USF	B
11	RNA	I
12	accumulation	O
13	levels	O
14	to	O
15	approximately	O
16	60	O
17	%	O
18	of	O
19	control	O
20	embryos	O
21	,	O
22	while	O
23	LpS1	B
24	RNA	I
25	accumulation	O
26	levels	O
27	dropped	O
28	to	O
29	less	O
30	than	O
31	5	O
32	%.	O

0	The	O
1	5	O
2	'-	O
3	flanking	O
4	region	O
5	,	O
6	from	O
7	nucleotide	O
8	-	O
9	837	O
10	to	O
11	-	O
12	336	O
13	,	O
14	contains	O
15	TATA	O
16	and	O
17	inverted	O
18	CAAT	O
19	boxes	O
20	as	O
21	well	O
22	as	O
23	GATA	B
24	-	I
25	1	I
26	/	O
27	SP1	B
28	erythroid	O
29	-	O
30	specific	O
31	cis	O
32	-	O
33	acting	O
34	regulatory	O
35	elements	O
36	.	O

0	Jerseys	O
1	had	O
2	higher	O
3	hepatic	O
4	Cu	O
5	concentrations	O
6	than	O
7	did	O
8	Holsteins	O
9	on	O
10	d	O
11	60	O
12	(	O
13	346	O
14	vs	O
15	.	O

0	PKC	B
1	-	I
2	gamma	I
3	,	O
4	which	O
5	is	O
6	not	O
7	present	O
8	in	O
9	keratinocytes	O
10	,	O
11	also	O
12	induces	O
13	involucrin	B
14	gene	I
15	expression	O
16	in	O
17	a	O
18	TPA	O
19	-	O
20	independent	O
21	manner	O
22	,	O
23	when	O
24	introduced	O
25	into	O
26	SVHK	O
27	cells	O
28	.	O

0	To	O
1	test	O
2	the	O
3	role	O
4	of	O
5	ML	B
6	in	O
7	human	O
8	reproductive	O
9	axis	O
10	,	O
11	128	O
12	healthy	O
13	children	O
14	,	O
15	68	O
16	boys	O
17	and	O
18	60	O
19	girls	O
20	,	O
21	were	O
22	studied	O
23	.	O

0	nos	B
1	-	I
2	1	I
3	and	O
4	nos	B
5	-	I
6	2	I
7	,	O
8	two	O
9	genes	O
10	related	O
11	to	O
12	Drosophila	B
13	nanos	I
14	,	O
15	regulate	O
16	primordial	O
17	germ	O
18	cell	O
19	development	O
20	and	O
21	survival	O
22	in	O
23	Caenorhabditis	O
24	elegans	O
25	.	O

0	Regulation	O
1	of	O
2	embryonic	O
3	growth	O
4	and	O
5	lysosomal	O
6	targeting	O
7	by	O
8	the	O
9	imprinted	O
10	Igf2	B
11	/	O
12	Mpr	B
13	gene	I
14	.	O

0	Thus	O
1	,	O
2	the	O
3	P	B
4	.	I
5	aeruginosa	I
6	orfX	I
7	and	O
8	vfr	B
9	promoters	I
10	are	O
11	arranged	O
12	in	O
13	a	O
14	back	O
15	-	O
16	to	O
17	-	O
18	back	O
19	orientation	O
20	rather	O
21	than	O
22	the	O
23	face	O
24	-	O
25	to	O
26	-	O
27	face	O
28	orientation	O
29	of	O
30	the	O
31	dorf	B
32	and	O
33	crp	B
34	promoters	I
35	.	O

0	PURPOSE	O
1	:	O
2	To	O
3	introduce	O
4	an	O
5	image	O
6	analysis	O
7	of	O
8	the	O
9	cornea	O
10	in	O
11	photorefractive	O
12	keratectomy	O
13	(	O
14	PRK	O
15	)	O
16	for	O
17	preoperative	O
18	and	O
19	early	O
20	postoperative	O
21	determination	O
22	of	O
23	changes	O
24	in	O
25	the	O
26	condition	O
27	of	O
28	the	O
29	cornea	O
30	.	O

0	These	O
1	consisted	O
2	of	O
3	beading	O
4	and	O
5	strictures	O
6	mainly	O
7	of	O
8	the	O
9	intrahepatic	O
10	biliary	O
11	tree	O
12	(	O
13	IHB	O
14	).	O

0	Commonly	O
1	observed	O
2	systemic	O
3	toxic	O
4	effects	O
5	(	O
6	bone	O
7	marrow	O
8	,	O
9	gastrointestinal	O
10	tract	O
11	,	O
12	and	O
13	heart	O
14	)	O
15	were	O
16	not	O
17	seen	O
18	in	O
19	this	O
20	study	O
21	.	O

0	Comparative	O
1	study	O
2	on	O
3	acute	O
4	oral	O
5	overload	O
6	using	O
7	tolbutamide	O
8	and	O
9	tolazamide	O
10	in	O
11	normal	O
12	and	O
13	diabetic	O
14	subjects	O
15	.	O

0	Increasing	O
1	the	O
2	RH	O
3	beyond	O
4	32	O
5	%	O
6	resulted	O
7	in	O
8	solvation	O
9	of	O
10	the	O
11	peroxy	O
12	radical	O
13	,	O
14	sterically	O
15	hindering	O
16	the	O
17	radical	O
18	from	O
19	entering	O
20	the	O
21	propagation	O
22	transition	O
23	state	O
24	.	O

0	Transcription	O
1	of	O
2	the	O
3	gene	O
4	for	O
5	ivanolysin	B
6	O	I
7	and	O
8	expression	O
9	of	O
10	other	O
11	genes	O
12	of	O
13	the	O
14	virulence	O
15	gene	O
16	cluster	O
17	in	O
18	L	O
19	.	O
20	ivanovii	O
21	were	O
22	dependent	O
23	on	O
24	PrfA	B
25	.	O

0	Takayasu	O
1	'	O
2	s	O
3	disease	O
4	:	O
5	association	O
6	with	O
7	HLA	B
8	-	I
9	B5	I
10	.	O

0	This	O
1	motif	O
2	,	O
3	first	O
4	described	O
5	for	O
6	the	O
7	Drosophila	B
8	homeobox	I
9	activator	I
10	DEAF	I
11	-	I
12	1	I
13	,	O
14	identifies	O
15	an	O
16	emerging	O
17	group	O
18	of	O
19	metazoan	O
20	transcriptional	O
21	modulators	O
22	.	O

0	Furthermore	O
1	,	O
2	this	O
3	element	O
4	confers	O
5	p53	B
6	induction	O
7	to	O
8	the	O
9	otherwise	O
10	nonresponsive	O
11	adenovirus	B
12	major	I
13	late	I
14	promoter	I
15	.	O

0	However	O
1	,	O
2	Cbf5p	B
3	was	O
4	found	O
5	to	O
6	be	O
7	nucleolar	O
8	and	O
9	is	O
10	highly	O
11	homologous	O
12	to	O
13	the	O
14	rat	B
15	nucleolar	I
16	protein	I
17	NAP57	I
18	,	O
19	which	O
20	coimmunoprecipitates	O
21	with	O
22	Nopp140	B
23	and	O
24	which	O
25	is	O
26	postulated	O
27	to	O
28	be	O
29	involved	O
30	in	O
31	nucleolar	O
32	-	O
33	cytoplasmic	O
34	shuttling	O
35	(	O
36	U	O
37	.	O

0	The	O
1	terminator	O
2	region	O
3	supported	O
4	termination	O
5	of	O
6	transcripts	O
7	initiated	O
8	by	O
9	RNA	B
10	polymerase	I
11	I	I
12	in	O
13	vivo	O
14	.	O

0	The	O
1	final	O
2	predicted	O
3	structure	O
4	has	O
5	an	O
6	overall	O
7	backbone	O
8	deviation	O
9	of	O
10	0	O
11	.	O
12	7	O
13	A	O
14	from	O
15	that	O
16	of	O
17	ras	B
18	-	I
19	p21	I
20	.	O

0	E2	O
1	treatments	O
2	elevated	O
3	hen	O
4	plasma	O
5	TG	O
6	7	O
7	.	O
8	2X	O
9	,	O
10	PL	O
11	5	O
12	.	O
13	1X	O
14	,	O
15	and	O
16	C	O
17	7	O
18	.	O
19	2X	O
20	;	O
21	and	O
22	pullet	O
23	plasma	O
24	TG	O
25	6	O
26	.	O
27	8X	O
28	,	O
29	PL	O
30	3	O
31	.	O
32	7X	O
33	,	O
34	and	O
35	C	O
36	2	O
37	.	O
38	5X	O
39	.	O

0	In	O
1	rubella	O
2	patients	O
3	with	O
4	serologic	O
5	confirmation	O
6	by	O
7	HI	O
8	,	O
9	the	O
10	IF	O
11	test	O
12	detected	O
13	significant	O
14	rises	O
15	in	O
16	219	O
17	(	O
18	99	O
19	.	O
20	1	O
21	%)	O
22	of	O
23	221	O
24	patients	O
25	and	O
26	the	O
27	PHA	O
28	test	O
29	detected	O
30	antibody	O
31	conversion	O
32	in	O
33	68	O
34	(	O
35	93	O
36	%)	O
37	of	O
38	73	O
39	patients	O
40	.	O

0	After	O
1	i	O
2	.	O
3	v	O
4	.	O
5	administration	O
6	of	O
7	500	O
8	mg	O
9	acetazolamide	O
10	and	O
11	disinfection	O
12	of	O
13	the	O
14	conjunctiva	O
15	,	O
16	50	O
17	micrograms	O
18	rt	O
19	-	O
20	PA	O
21	in	O
22	0	O
23	.	O
24	1	O
25	ml	O
26	(	O
27	BSS	O
28	)	O
29	and	O
30	0	O
31	.	O
32	5	O
33	ml	O
34	SF6	O
35	were	O
36	injected	O
37	intravitreally	O
38	.	O

0	The	O
1	binding	O
2	of	O
3	transcription	B
4	factor	I
5	AP	I
6	-	I
7	1	I
8	and	O
9	vitamin	B
10	D	I
11	receptor	I
12	(	O
13	VDR	B
14	)	O
15	to	O
16	the	O
17	composite	O
18	AP	B
19	-	I
20	1	I
21	plus	O
22	vitamin	O
23	-	O
24	D	O
25	-	O
26	responsive	O
27	promoter	O
28	region	O
29	(	O
30	AP	B
31	-	I
32	1	I
33	+	O
34	VDRE	B
35	)	O
36	of	O
37	the	O
38	human	B
39	osteocalcin	I
40	gene	I
41	was	O
42	characterized	O
43	in	O
44	osteocalcin	O
45	-	O
46	producing	O
47	(	O
48	MG	O
49	-	O
50	63	O
51	)	O
52	and	O
53	non	O
54	-	O
55	producing	O
56	(	O
57	U2	O
58	-	O
59	Os	O
60	,	O
61	SaOs	O
62	-	O
63	2	O
64	)	O
65	human	O
66	osteosarcoma	O
67	cell	O
68	lines	O
69	.	O

0	Lowering	O
1	of	O
2	the	O
3	renal	O
4	blood	O
5	flow	O
6	alters	O
7	the	O
8	glomerular	O
9	and	O
10	tubular	O
11	excretion	O
12	processes	O
13	.	O

0	RNA	O
1	transcripts	O
2	that	O
3	hybridize	O
4	to	O
5	the	O
6	introduced	O
7	foreign	O
8	gene	O
9	have	O
10	been	O
11	identified	O
12	.	O

0	Its	O
1	potential	O
2	as	O
3	a	O
4	diagnostic	O
5	tool	O
6	for	O
7	epidemiological	O
8	surveillance	O
9	was	O
10	assessed	O
11	in	O
12	comparison	O
13	with	O
14	three	O
15	other	O
16	diagnostic	O
17	tests	O
18	:	O
19	stool	O
20	examination	O
21	,	O
22	ELISA	O
23	with	O
24	soluble	B
25	egg	I
26	antigen	I
27	(	O
28	SEA	B
29	)	O
30	and	O
31	the	O
32	circumoval	O
33	precipitin	I
34	test	O
35	(	O
36	COPT	O
37	).	O

0	The	O
1	FinO	B
2	protein	I
3	of	O
4	IncF	O
5	plasmids	O
6	binds	O
7	FinP	B
8	antisense	O
9	RNA	O
10	and	O
11	its	O
12	target	O
13	,	O
14	traJ	B
15	mRNA	I
16	,	O
17	and	O
18	promotes	O
19	duplex	O
20	formation	O
21	.	O

0	Induction	O
1	of	O
2	AtP5CS1	B
3	mRNA	I
4	accumulation	O
5	in	O
6	salt	O
7	-	O
8	treated	O
9	seedlings	O
10	involves	O
11	an	O
12	immediate	O
13	early	O
14	transcriptional	O
15	response	O
16	regulated	O
17	by	O
18	ABA	B
19	signalling	O
20	that	O
21	is	O
22	not	O
23	inhibited	O
24	by	O
25	cycloheximide	O
26	,	O
27	but	O
28	abolished	O
29	by	O
30	the	O
31	deficiency	O
32	of	O
33	ABA	O
34	biosynthesis	O
35	in	O
36	the	O
37	aba1	B
38	Arabidopsis	I
39	mutant	I
40	.	O

0	Selective	O
1	activation	O
2	of	O
3	adrenaline	O
4	secretion	O
5	by	O
6	the	O
7	rat	O
8	adrenal	O
9	in	O
10	neuroglycopenia	O
11	detected	O
12	via	O
13	microdialysis	O

0	QBMDs	O
1	for	O
2	a	O
3	5	O
4	%	O
5	change	O
6	in	O
7	response	O
8	(	O
9	QBMD05	O
10	)	O
11	were	O
12	6	O
13	-	O
14	fold	O
15	lower	O
16	,	O
17	on	O
18	average	O
19	,	O
20	than	O
21	the	O
22	corresponding	O
23	NOAEL	O
24	.	O

0	Self	O
1	or	O
2	foreign	O
3	cellular	O
4	proteins	O
5	provide	O
6	peptides	O
7	for	O
8	presentation	O
9	by	O
10	major	B
11	histocompatibility	I
12	complex	I
13	(	O
14	MHC	B
15	)	O
16	class	O
17	I	O
18	molecules	O
19	on	O
20	the	O
21	surface	O
22	of	O
23	antigen	O
24	presenting	O
25	cells	O
26	(	O
27	APC	O
28	).	O

0	The	O
1	domains	O
2	involved	O
3	in	O
4	superactivation	O
5	appear	O
6	to	O
7	be	O
8	a	O
9	subset	O
10	of	O
11	those	O
12	necessary	O
13	to	O
14	achieve	O
15	synergistic	O
16	activation	O
17	.	O

0	NuA4	B
1	has	O
2	an	O
3	apparent	O
4	molecular	O
5	mass	O
6	of	O
7	1	O
8	.	O
9	3	O
10	MDa	O
11	.	O

0	A	O
1	single	O
2	exon	O
3	encodes	O
4	the	O
5	carboxyl	O
6	-	O
7	terminal	O
8	26	O
9	amino	O
10	acids	O
11	of	O
12	the	O
13	ssd	B
14	chain	I
15	and	O
16	the	O
17	3	O
18	'	O
19	untranslated	O
20	region	O
21	of	O
22	its	O
23	mRNA	O
24	,	O
25	ending	O
26	with	O
27	a	O
28	poly	O
29	(	O
30	A	O
31	)-	O
32	addition	O
33	site	O
34	.	O

0	The	O
1	RI	B
2	alpha	I
3	gene	I
4	is	O
5	composed	O
6	of	O
7	nine	O
8	coding	O
9	exons	O
10	of	O
11	varying	O
12	lengths	O
13	,	O
14	separated	O
15	by	O
16	introns	O
17	,	O
18	giving	O
19	the	O
20	gene	O
21	a	O
22	total	O
23	length	O
24	of	O
25	at	O
26	least	O
27	21	O
28	kb	O
